var title_f15_47_16112="Traction tracheomegaly";
var content_f15_47_16112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Traction tracheomegaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph from a patient with post-primary tuberculosis demonstrates tracheomegaly, upper lobe fibrosis with volume loss, bronchiectasis, emphysema, and bibasilar pleural scarring.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_47_16112=[""].join("\n");
var outline_f15_47_16112=null;
var title_f15_47_16113="Toxocariasis eye findings";
var content_f15_47_16113=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Toxocariasis eye findings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 217px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADZAgIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3n4ofEDSvhxoFvq+uW99PbTXS2irZojOHZHYEhmUYwh7+leYf8NV+CP8AoFeJP/AeD/49R+2r/wAks0r/ALDMX/oievKfgN8HvC3jr4f6p4i8TajqtmbK8lhY2ssaRrEkUbliGjY5+du/QDigD1b/AIar8Ef9ArxJ/wCA8H/x6j/hqvwR/wBArxL/AOA8H/x6uK+F3wd+FvxJ0y8vdB1LxhCLSYQyw3ctskgyuVbCxsNp5xz/AAnivmCgD7U/4ar8D/8AQK8Sf+A8H/x6j/hqvwP/ANArxJ/4Dwf/AB6viqigD7V/4ar8D/8AQK8Sf+A8H/x6j/hqvwP/ANArxJ/4Dwf/AB6viqnKpZgqgljwAOc0Afaf/DVfgf8A6BXiT/wHg/8Aj1H/AA1X4I/6BXiX/wAB4P8A49XydaeEdQZY5L5PscbjIEg+cj12/wCNdr4b8F2aqk8kHmL2abkt746Cuari6VJXbue1g8hxeJ1a5V5/5bn0Tp/7S3hbUXC2Ph/xXOTxlLSEj8/OxWx/wvHS9oJ8MeJl74ZLQH8jcV4/BbeTHthVVjAHCjFSlFxlmBJ715cs1qPWMUl5/wBI+gp8K4dL95OTflZfoz1sfHLSiuR4a8SkH0W0/wDkij/heOlYz/wjPiTH+7af/JFePPuRD5QwB2HeoyxJGB9az/tat2X4/wCZp/qrhP5pfev8j2U/HHSgMnwz4l/75tP/AJIqKf486NAm+Xw34lC+oS1P8p68g57Dr3pGQt97HPFCzer1S/H/ADD/AFVwn80vvX+R7BF8edFlXdH4d8RsPULaf/JFOb47aOoJPhrxKQPRLU/yuK8MmsZYHeSyIAP3oz0NXLZ47uAvGNpXh1PUGrea1d0lb5/5h/qrhP5pfev8j1K+/aV8LWOftfh/xXEB/E1pDj8/OxVL/hqvwR/0CvEn/gPB/wDHq8x1JIoIDI+0L3Dcg+2K4q48N2etzO8doLYH+OL5cf0NddDMlNXmrLuefiuFnHXDzv5P/Nf5I+g/+Gq/BH/QK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer5V1zwVf6eWe2xdwj+4PmA9xXLMpViGBBHBB7V6FOpCorwdz5rE4OvhJclaLT/rZn2n/w1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1fFVFWcx9q/8NV+CP8AoFeJP/AeD/49R/w1X4H/AOgV4k/8B4P/AI9XxVRTsB9q/wDDVfgf/oFeJP8AwHg/+PUf8NV+B/8AoFeJP/AeD/49XxXRSA/SPQ/iBpWs/DSTxxa298mkx2txdmKREE+yEuHG0MVyfLOPm9OleYf8NVeCP+gV4k/8B4P/AI9R8NP+TNrz/sC6t/6HcV89/s9fD/SviP40vdI1y4voLaHT3u1azdFcuskagEsrDGHPb0oA+hP+Gq/BH/QK8S/+A8H/AMeo/wCGqvBH/QK8Sf8AgPB/8erzTw58N/hdrt3osUQ8f2tvrFzLaWV1cS2XlySx/eUhAzr9SoFeV/GXwrY+CPiVrHh7Spbmays/J8t7llaQ74Uc5KgDqx7dMUAfT/8Aw1X4I/6BXiX/AMB4P/j1H/DVfgj/AKBXiX/wHg/+PV8V1t+HNEbU5DLMSlnGcMw6sf7o/wA8VM5xhHmlsaUqUq0lCC1Psaz/AGlvCl5EZbbRPEzxg43GC3Az+M1WB+0V4bIyNB8SED0jtv8A4/XzMsSRKqQIEiUYCjoBVmCN8gY49K86WNlukj6ClklNpczd/wCvI+kl/aH8OtnboHiU4/6Z23/x+lT9oTw+8vlr4f8AEpfrjy7b/wCP188wQOpGBz7+lWbi2zEJUXEq/MvbI9KyeYzTtZHXHh6g/tS/D/I+gv8Ahf2hYyfDviUfVLX/AOP0D4+6Genh3xL/AN8Wv/x+vCLY/aI15JP07VdtYlE43AYI28jGKxlmtWO6X4/5mq4cw3WUvvX+R7aPj1opOB4c8Sn/AIBa/wDx+h/jzoyEBvDniUE/7Fp/8frxm4gUKVX7tQFPMWM7QMEYJNZrOKr6L8f8ylw1hX9qX3r/ACPb1+O2jtjb4b8SnP8AsWn/AMfqf/hdenbd3/CMeJMeuLP/AOSK8diiSALtA+p6CoLlmlJCuVBPPvWf9tV29Evx/wAx/wCrWFe0pfev8j2NvjrpCsVPhvxJkc/dtP8A5IoPx10gYJ8NeJcf7tp/8kV4lNbhUyfmKjNPlIWDzJCBtGTx+lX/AGxW0sl+P+Y/9WcL/NL71/keyH4+6GJTH/wjviXeOwS1P/tenj486MRn/hHPEuP9y1/+P14ZZ2zkG4kI3yHJGO1Xjb7drRjg5zVTzipF2SX4/wCYPhrCr7UvvX+R7P8A8L30faD/AMI34lwenyWn/wAkUh+PGjAAnw54kweny2n/AMkV4n5OC+0kjttPQ1JEhdSuOgxj3pf2xV7L8f8AMj/VvC/zS+9f5Hs3/C+9Exn/AIR3xJj12Wn/AMfqNv2gdBTaG8PeJQW6Dy7X/wCP14tNAtnEzzkccqn949qyRCzuXl5kbk/4VtTzSpLWyt8/8x/6t4X+aX3r/I98P7Qvh4H/AJF/xL/37tf/AI/TX/aI8OJ97QPEv/fu2/8Aj9eAvCVYdMe1VbmIFG4749zW8cfNvZEy4bwy+1L71/kfQbftH+GFHzaF4lH/AGytv/j9If2kvC466H4l/wC/Nt/8fr5suIgiMM5qq0YBx14rpjiG1c555BRWzf4f5H0y37THhNfvaL4lH/bG3/8Aj1Mb9p3wgOujeJf+/Fv/APHq+XpYfbP1qhcQDsK1VVs4qmUQjs3/AF8j6pk/am8FRth9J8Sg/wDXvB/8epv/AA1V4I/6BXiT/wAB4P8A49XyRc24kQq4+h9KxZYzFIVbt39a1jK55OIw7ovyPtH/AIaq8Ef9ArxJ/wCA8H/x6j/hqrwR/wBArxJ/4Dwf/Hq+K6Ko5j7U/wCGq/BH/QK8S/8AgPB/8ersPhf8a/DnxI1+40jQ7LV4LmG1a7ZryKNUKB0UgFZGOcuO3rX5917/APsVf8lT1T/sCy/+j4KAPtSiiigDwD9tb/klmlf9hqL/ANET1x/wE0HWfFH7OHifQ/DtzaWt3f6xJBJNcsyqsJht/MxtUkkrlce55rsP21f+SWaV/wBhqL/0RPXxXQB9/eBPhlqHgf4hS6lpWqLd+H7vTIrO6iutiTiWEBYmVYo1QqEAXnnkk5r4AoooAWjFFdd4Q8MxXlxFcayWjs+ojHDP9fQVFSpGnHmkdWDwdXGVFSpLX8F6lPwn4Q1TxNIxsodtsn+suHGFX2HqfYV6FbeHNP8ADC288CGeZHHmTOOT9PSuz0/UbCKKO2tGS3gjAVEjIUAVh+LLhb+7ht7HDoOW2j+KvGq4qVdpJ2XVH32X5NRwK5rc0+/+Xb8yrY2z6vqktzdN+63fgfQV2BSFYQq8EcciqVhY/ZbBYl4wMEjqTUoJwD+H1ry6tXmem3Q9qMbEm8qNhJH1pyoBtDggHocVm3upW9oCrnMuMbByaiTWLry13WUm09DUKnKWthmrKoGV5PpUAIC8n8Kgs9SW7Z0mjMTg8Bupqw67cjHOaiSadmNEe4BuNxB/SlJ464Pbmqd5cLaFWkJIOQqjuaz/ACdQ1Bt7yfZ4j91R1NaRp3V27IGzZMkca/NIq465NYuoXy296tzpshZ/+WigfKwqaz0pDG5ndi6HkZ4NWkgigz5MKjtk1ceSD7iabM6KOTWnNzdMBErYWNegNa0SLFCFRQox0FZ2ya0uTNbJuiP+sjH9KmtbxLwFYshwMsh61VS8tvh/IS0HvgsSATmsLXfDNhq8ZaWMRTY4mTg/j610KqQ4HUUu0KMkjrxShVlTd4OxFajTrQcKkbrszw7xB4evdElxOu+An5Zk+6f8DWNXvupRxz2zxTKJFkG3YwyDXlvijwtJY77mzUtAD86dSnv7ivewmNVZcs9GfD5tw/LDp1sNrHquq/zX4nKUtJRXoHzAtFFFOwH2p8NP+TNrz/sC6t/6HcV5V+xV/wAlT1T/ALAsv/o+CvVfhp/yZtef9gXVv/Q7iviukB9o+Dfgxr2jyeHFlTw/YT6ZqrahcavYTSNd3cRYn7OQYU+QggHLsOOnavA/2o/+S7eJv+3X/wBJYq8qqW1t5bu5jt7eMyTSMFVR1JNDdtWNJt2RoeHdHl1i98pCUhjG6WT+6v8Aie1eiLCtrDHDZgJAg2hOuB6/jVrTNOh0jSY9PtsNIPnmkH8bnqfp2FSCFTkYz6CvBr4r20r/AGVt/mfYZbgFQheXxPcrQDc64XB9OlXo4cMBgjd6ClS2BCnnd1DDtVmEs42OOV61yznfY9unSJre2MT7WAx0yKnkjDNjqM5xUlosG1lujNkcqYwDn8zVxY7Ta2xrouem5UAz+dc7TfvXNk+V2s/uMq1iEUzQtwr5ZCOx7irckDBNwLbh60+5i3IJEwJF+YcVct3EqqQRtIyPWsJ1G/eN7W1KwRiFyeetPVNsPcY9atGEwuyHjPK5HanRLvWRCvYj/CsHMoqkkuMHIHrTlQ8ZxjpVhYgQFxnAqxFCRGzsMDHFS52G9EQGEJbkuMfLgc1S1OFfJgiUkk4J+lX7x/MRQnArPt8yzu7H5V+VRj86qm2veBLqWreMGPbjnp9Kkt41XO/GDxmmqgVsjjPXFSvmTYIwB2qGxOJUeEqTj7vTrxUEs6WqsV++vJPpV2RsDaO+RWIym7kGARApzn++f8K2prm1lsLlI2Ml5KZpNzf3RTxEgB7sp4HarSRBVHAyPTsKnWAdenGeK2dW2i2EYUyujEhc/TvVeaMxrjbg554rphZqyg8jH60l9apFbtIqjzCMDnpWkcUrpWJk1scVdxkttx8qnn6+lVXtyBuYbU/n9K6BrYIUigXzG65I4FVL23jgw11MA3p1P4V6NOvskYzic9KhycVTmAUc8ke1asjkq4hG1W4LMOfwqg8QB6fjXo03fc4K1PsY9xGW5xgelUZYFbhlBx0zW/LHmqM0WK2UjyMRhk9znrqBUUsoxjtVSte+jLQvtGT/AErIreLuj53FU1CdkFe//sVf8lT1T/sCy/8Ao+CvAK9//Yq/5Kpqv/YFl/8AR8FUcx9qUUUUAeAftrf8ks0r/sNRf+iJ6+K6+1P21f8Aklmlf9hqL/0RPXxVTQBS0ld98LPB/wDb+ofb9QjJ0q1Ybgf+Wzdl+nrWdSahHmZ0YXDTxVVUqe7/AKuXPh34GN7AurauhFswzbwnrJ/tH29PWu7GiWaOWdpAvoWwBXVaxPZRxBlkWIKuBk4AHpXC6xqMmoTiztAFjY4yT97/AOtXg4mVSrV0lp5bI/S8vwdLBUVCC9X1bILlYHl8nTvNkcnk9RVqPRb202TQyJ5o52jtW7pNhHYW6KgDOeWcjBJq1IRv4x71xzxDWkdvPqd6Xcx4dVuI/wB1dwNv/i28Co5b28uzssIWQnrI/AFbKDEh3JnI6jtTsAcAVh7SK1USrGXp+lRWriWUme6JyXb19q0WA3c5JqQp05qNsj3rOU3N3kxryK91Aky4xh+zDqKzS2pWgChI50zw2ea1h8x96Vlxj1HarjPl0eoMzLbTJ57gXOoOrMOka9FrSZPmzwe1PzwO1IQTnH86Upymw2ISAJfQlTn6U0rvHenBgspJ5LLjPpSnkfKP/r0ARMuznGBWbfxFW+2W4CzR8/7wrVYHtjpUMiAoVOOQQa0py5XcT1EgdJYo5VPEgzj0NOPQjGe9UNIcNaeWTl4mK7R1xV7kg4OSaJx5ZNCRA7Dzc4zgcVDNGkoIYDPTpVsgbiW78VGV+bP6VUXYDy3xr4Vax3X1gha2zmRAPue/0ri6+grtVkhdDgqw+YYzkV5D4w0H+yrlZrYE2Ux+X/YP90172AxbqLknufD5/kypXxVBe71XbzXl+RzdFLSV6Z8ofavw0/5M2vP+wLq3/odxXxXX2p8NP+TNrz/sC6t/6HcV8V0gCvRPh/o4tLI6vcr+9mBS3UjkJ0Z/x6D2zXIeGNIk1vW7exTIRjulcfwIOWP5frivYLtF2pFaqEgiUIiD+FQMAflXl5liOW1Fdd/T/gnt5NhfaT9rLZbepURd3IByBVmGPcT7frTIV2HP6VoRopXK4z6Yrx5ysfYU4hDF0A+960+SEbd65LgdPUVNGucZGMdcVZjjyc5GPWuWVSzOuKsQpGGjXHfoanTkdAO2PSlRdrHAG09fanldr5U5HQ8VjKVzVII1I5IzSWyCOZlx8rHIqeFe2OP51aFqzJmNcsDkZ/lWbnbQL23GzKVjjY9uPwpYdpSQjk+/eppmSWEKmOmee1VoFJ3KDkis76CWw62K5AOcDpUs7mROvAHSokXDMMdDnrTwny89cUm9Ru17lK5JW339wMAUtlCEhC9Gxz9afMvmPHGD7mrCRY7cVfN7th30GEYHuMU1nIHHB9qnfGMDByOKqzcAKp+Y+3QUo6iRSuj5z7FOFBw2D+lKqhEKjgCp/L2LxUeGJz1HqK2vpZBfoKqH5d2AfSlD4OD/AA8UiuojOeTn8jUDTYlITAPfPQfU07XExtxdSBf3fAJ/Gsu7cNNmeQ4UZ5OKlvdQtYFP71ZJh1ANZUY+0EzSncTzjPSu6hSsuZqxOhcN05UpbptH97HWs6eJpZd8xLv0ye1XPMCjAFMLLnLH5e2a6Ie7siHYy5oSd2xTiqU0TckA+lbNxeRKCACx9Kzbi6lkyANi+wxXZRlN9DCaVig8DjJYBQOfmOKo3CJk5cY9uauygknOSe9V2TsRXar9WedVjfQyJk54GMdzWHew+VLkDCtyPaunnQ5PpWXfwb0ZO/UH3reErHhY7Dc0dNzDr3/9ir/kqeq/9gWX/wBHwV4AeDgjFe//ALFX/JU9V/7A0v8A6PgrY+fPtSiiigDwD9tb/klmlf8AYai/9ET18VV9q/trf8ks0r/sNRf+iJ6+KxQBq+FtEufEWu2mmWgw8zYZ8ZCL3Y/QV9JXkOl+FNJt9PsSvlxptjXP3j3Y/jya5H4O6Knh/wAK3Gv3oVbm+QiLcOViHT6bj+mK09EtZNZuJLvUkYwM+UVun/6q8vG10o2td9P68/y9T73IMv8AYUfbT3l+XRf1+hkLaajrMrXEoKwk5DN0A/2R/WujttNtILARRRBicFnPJJrpp7ZEt1VAoXAC46VUt4FhJ8xTzzXkVudNRex9BGomroxAZrYDDeZEOqsMkVZjMc67ovlPdfWr1zbjAbHuPes6S3ZSJIm2P/OuSStuaqSkORMkjoe9O2ADkc4qq1zco+HhDE/xIaBctJlfKZZD/f4FQ0ytSdsfdHSoZMDBJx7+lOaNgMO5Bx0XgVD5SEHKnI75zSQwXJkAbuemetT+WBw3JHFUirhvvn8atSBiNwbnGD9abGDEKOc4o7UkgYxKTyPpS9EU9eOaQiFhiXcTgdKc3tyTTyA2PSo9hUnbytO4EbZG7aAKiEZkcBmwvOQOtTEnuKjCkA+/etEwMq9Q2N/FdRDETfLIPb1rTYgk4OV7EVBdKbm2ljYfJjg+9VtH2S2Khy25SQTurZ+9Dme6Fsy7Kdo5Pao+dpPQUrwlfmDnPQAmmKT359eaS20AQKdpXjdjjBrMv7CLUbGa0nX5XyPoexFaqg4zkVBOvzFgBmtIScXdEygppxkrpnhup2Uun301rOMPG2M+o7GqleifEXS/Ptk1CNCJYvlk919fwrzuvpqFX2sFI/Ls1wLwOJlS6br0/rQ+1fhp/wAmbXn/AGBdW/8AQ7iviuvtT4af8mbXn/YF1b/0O4r4ysLWS9vre1gGZZ5FjQe5OBWraSuzz0m3ZHpvwy0tbLQLjVJQfPvGMUftGp5/Nv8A0Gt913OxXIGccVoXUMdlDDZW+BDbRiJD6hRj9etVogGOR39TXyM67rTlVfX8uh9vgKPsaaihixMAdykj1AzVy3Xn5eePpUsCkY9D+tStAuzIBU5zxWMqnRnsUhyqeT1NWY+TyB6VEPMwAy7h61LkHBGAfSueTudKQ9VHIOOe4poDDg8rUsYIqeOIscD8qzcrF7DrOIMB6jitJ5PJiCRNtYj5iO1U5GaFU2oFOOTjrTA5Jxtw3pWb11M2uYrYKTlSeH+YZ9aeARccAAN60+eMsAw+8ORUgAYKwHTpQ2NyEVMzE/7NSFMIw9qVeX4IyR07VLtyNo/WouQ5Fe3jyxdskmphEQASOOlW44QF247ZqWKFfvHG0DuKL3IdQzpICq7ivA4AqJbbYDu5kIyTWk+JJN2CEU/IPX3qJgP4s8dqLsftGZc6bQFAwCaYNpTaeCPwqXVbqK2h3zHJz8qjqawLg3F8pe4xbWw525wzV0U4OSu9EXe6DUdQgi3RxHzZR2UcVkG0vL4jzmZIv7o6mti3EEIBhgaQ46qvH5moZnu5sgbLdfbk13U5cmkF82JyexnNp1vDHyAD6seazZ1W3Ym2lZj3UL8taU1ovmsZ3eTHQMaimA2EAYArsp1O7uS2Z0V00pI3BD79TVpYsqWZmKn1qCS3Tg7QW6j2qGQShDtkwoP0rotGXw6Epk8kQPMS4H9KiMcZ3D5gR2IqJpp1XAIwec1EZXf765OOuMVpGnLuQ2Rzxgfd71UZD3qxJLgkAHb71C0xJ7flXVBSSOSpZspTjisu4B3HPetqc5U5C/yrMuEbPyoOfQVrBnl4mNznr+PbNuHRufx717t+xV/yVPVf+wNL/wCj4K8Wv4WeFjj7vNe0/sVf8lT1T/sCy/8Ao+CumLuj5fFU+So/M+1KKKKo5zwD9tb/AJJZpX/Yai/9ET18g+FNHk17xDY6bED+/kAcj+FByx/IGvr79tX/AJJZpX/Yai/9ET183fCRk06TUdXcjzY4/s8C+rNyT+AA/Osa9T2dNyR35ZhfrWJhS6dfRas9O1+5F7cWuj2qslpbFY1wOMgcg/QV1INvZ2yW6qqkKMAf4Vy3gywubsy3UjMGZiQx7Z6mupaykijdXXGf+WmM187KpNzbWttD9Mlyq0RrShEQcg5BGTVrcLgFXClh1wOadbQsBukjH7xflJ5//VToQ4BcDay/eyOKPesrmMpLoUZkEa7Rzjv71nN80vJ4Hc1duGbd2z9OtU3YK4+dVz6kVw1OyOmmtCJwEkHBz/OmyIsiEdP6U+Xrjnp371GcAHJrJ6GyKzTBP3c/4OB/Om8AN0wecioZ7uPzWCK7gDDMo4FQIVuHBhcqMHGOgOep9a0UdLsouRhmHz4Unkj2qWEleDgqTyO+MVH5hA/eDB/vDkVIrR7Mhxu9c1DAsQuiNtkXcvXBNEsAQRkEbXGeveo1IeQKvzMRTwQy7edwNQyRjKMjB4pNhZDtA5OM1L5akqFyeOfrUzQFI8dvWlcLlCSEof7x9qgZVRMuwGferxTkqDgn1rNjtRcyyzSDeAxjUEZAA7/nWsX3YyC4uA5+z2qh5COT/Cg96h0yD7MGtpcCQMWyOje9aaQpCpCIFX2GKguYRMB/C4+63etlUVuVbCJOMc/eP6VBNGExg8dMUtvclmCSjy5F656N7ipHkDAhUYk8ZxU6xYyo7AZqu7570sgO5j17VAVHVe/HFdMUIbcxxXFtLBLg+apQgj1rxO/tnsr2a2l+/G5U+/vXtEh2jJ5/WvPfiLaCPUYLtFws6Ybj+If5/SvVy6fLJw7nzPE+F9rh1XW8H+D/AODY+p/hp/yZtef9gXVv/Q7ivl/4UWAufE32t1zFZRmX/gZ+Vf1Ofwr6g+Gn/Jm15/2BdW/9DuK+fPhPE0Gi6ncsuBNKiIcfe2gk/h8wrpzKo4YaVt3p9/8AwD47L6ftK8V21OruX3Oc/Nk+maLZeVwBiqzPumXHQVfi24Hf1xXzTXLGx91ShZFqPgADpirKEkev17VFGAe44qzGgA6/WuWTOyESSNVB+bp6HmkdY2xzzUu35CAR7UgTLdRntWVzdEcayA/Kd1WEfaBngdqQRc55x7VPLCWh3H7o4zUt3G2OB3rz0780mwABWBwehqoBJGTsPv61ZSXIw6kHue1SyXpsPQleG59DToBwyt0zkYpybSMZyB0OakSLYc8fz5pGTkJF1PTNX7a2ABYkE+vpUmn6VNcvvWMkDnmt3+zDEmZPv46YrSNGcle2hy1cRFO1zEIEQy3PU1XlnMmAOFzU+qq0eePl+lYcr3Bcqmfrjis2mtC6a5tTQnmUKOR+FUpp5ScRISe1SWtqxbdMQ3t71r28CJj5R6Ur2NG1E5WWwup5vMlU7vXAzS/Zo4HzLGd2PvN81dlHaJkAdR1PrVa6sSV3bQc9gKr2r2ZPtk9DkZ9pBOcn61myN27VtajaqnKZWQH/ADxWBdysjESRHPTIGQa66HvbFp3KdwxySAOcde1UZJQdw9KmnlSTJ3D6Vk3kg3YUgjFenShcxqT5SwzqfmJy2OSKgmIZWAbHrVKSUg9TgUwz5HUe1dkKb3RkqyLhcBRkYOOtQSPlcL/KqwlOCfel38e9dMadi/aJiOM1C6jpxn3qVmHWoW7461tG5hNkMiA5/wAapzhgDgsavnJ9MVXlj6/0qzjqwutDMbBXDda9f/YvTy/ivq6H+HR5h/5HgryS4j6kV7F+x0m34taqf72iyn/yPBW0GfPZhTsk+x9l0UUVoeSeAftq/wDJLNK/7DUX/oievA/h7pkZsLIT4WN/3jHHUk8Cvff20wW+F2kqBydaiA/78T15JJYvpNpbWsBDQui7Wz0IWvOzGbUFBPVn1fClBSq1Kr6JL7/+GPSNPCQQrHbAD1OP88VrQSYUwzpwf4hyDXE6Rb3WqWFvLc37RxEAFIeD+JrpoNNu9LdZLV5by0/5aROctj1FeNRnNfCtj6ivCN7N6/11NxbSJUGFcjb94DioZViWAgA7u9TJq1utu4XeSRjYcgr74rAvPtl5M0dvEygHLSuMYHoBXdWnGMFyK78jipU5yfv6IxdTumaf7Laj58ZdsZIFVotNDQbpCxz827Nb1rpcMCyDBklf78h71Tu4hGPLjkwo/hHNeROnKK5pbHrQqxfuxMGZbu1JES+fGOxOCPpUTNc3a+XHA0CnhmkPPvitVsL36epqu7DueKwU/I6UyIRRwxJFEgAAwff3rLikSymeKUbYmO5HxwM9j6VrPgJnrnkYqKVEdSXXcD1GKcZW36gLE4ZSV2tgdQaqXl1axECZgCegAyT+AqFtNgaQBVeMEE/u3Iq7a2ENvkxoCx6k8k/jVe5HW4ENvqMZJMcVy2O4iNXI72JhxHcMf+uZ4qzAMKTzk81csVwwBGc9c1jKUeiIlKyuVYZgWB8icAc/cqzKyz20XlOC8jhBkdDXQ21udgdVLd2x2FVo7aws9bguLsM+nynLqnVGH8R9qHGxyvEJt2WxTbQQke6SaV2xnhsA04WIs4fKiRdmMHI6V3NzBZXNo39nvHIvaTcKpG3gYBJJIlbpkODW/sk9mcMMwcviRw0tnHKxzwD3z0rFngEF0wLHy+gOOtdh4hhitLgQ25WaduQoxge59BXOS6eHLNcO7SN2BIArL4G4s9SjU54qXczbvaRE20fI45Poakl+ZSOPSqupbrRSJGZo8jDnt7GrEMgdSAMk9K0s+VM3KEkYJI4/Cqlw207Exk1euD5e4tz9P5VTKnBZ/vHniumD6gV5FO0YXIA/OuZ8d2hl0Bpf4oXD/geD/Ouqk+6M9Ky9bgNzol+h5zC2wD1xXXh58tSL8zkx1H22GqU+6f5Hufw0/wCTNrz/ALAurf8AodxXifha2Wy8HaaiHmVDO5zkFmP+G0V7Z8NP+TNrz/sC6t/6HcV5L5YgtIYFwVihWMe+1cV15xL3YQ7u/wB3/Dn5/ksE6kpdismWkJPTvWjADt+bAx3FUo1O/OB7Y71fhXK5HHbgV4lRn2cFoXImHb86sJn2P0qtH8q9jnqKmVc45wMdK5JHVEtodyjHFWIQFUHuarQqSFFaVvEW4Az/AIVhIcnZCRxruy3T09akmYuoVVwueBWjb6cZAMA8885rVttEMgXAOM9qqFGdT4UctTEwhuzk2hPHBxQlvLnOTtPqK72Pw6TzsBGMkjnFXYvC5cH5ORg5Irpjl9aWyOaWZU47s84EDZwAfTAFdT4a8P3F5OrOrCP6dK7Kw8JR7kLLwOTn2rsLG1htLYRwxgYGDxivQweTylLmrPRHl43OoqPLS1Zl22j29raIqhVYDGCK53VIPLJC/dXOWPcV1t7KxGFyEH8NcxqZAye57HjAzXrYmlBQstLHmYSpOUryd7nH6haiZvmPTniq40+MjkDpgcVsztvbGFHJ6CoXKKuQe3pXztanBts96FWVrHMXFu0EgyMr60se4EbXx35rQu5EdSr55PQelZr4U/uywHQZFeZKyeh6FOTktTUsJGU/vFyM9RWlIEeHcmCCOQTWDb3JUY5OKuNexbd2XUjuFNRd7Gc4Nu6MnWIBlmI4/SuTv1A3Z/Poa6vULpDuDEnPtXL6lPCqsS34EV04a9ytUchqibW3hSD6+1Y08vygkitnVJkkPzPk9MAVy19Oisu3I9QK+kw8XJWZyYipbVjp5epB9jzUC3GevWqVxcBiSKrmX5gc16MKdkebLE2ehtRSErnPXtUwIPSs2GXdV2M5rRI7qVTmRN196TtSdqSnY3bA1DLkjg1J047UxhkfWixlLUzpxnNeyfsgAD4p6h6/2NN/6Pt68euQcE17D+yBn/hauo5H/MGm/wDR9vVw3PBzFWpv+up9i0UUVseAeF/tex+d4C8OxAbi/iC3XHrmKavH7YRSXMVtK37tSQw5GwZxjHYk17X+1PG8nhXwmsalm/4SS1OAO3lTE14sI0TxNO25HgklZSAegPf868jM9beSPuOFF+5qPzX5HQ+CdKvv+EwudP0zbPbuAxDcqvevYP7A1G3kVZpVUgc7E4/OuT+EUNtb61c3EMp+xco59T6Z+or1a+VVMTWk0jBSSY2PGPStcuw0ZU3Unvf8gzjGzhiFSja1u3U5TWbKWCxivUkDPCwDK6DBB9eK5/WJdQ8r54oQoGNytgc9K7/xHHbr4fuJJTgtgYPY54rh9aLvauAAVwuMn7ox0oxsXG/K3sZZdW9ok5LZ2/L/ADOd+3JCBHcqUOfmJBIP4isnULuCWQmI8dCQMZq7fFyApA2jg8/yrJlcAqO1fOVasmuR7H1FGnG/MQGRDkZ57buKYxGfrxT5MPnt25qqyjcBkjA45rnR1JEm4BsrQQrHg7TUAHzcliKewK9AST0OelOwAcJJ8w4AyMVJFIJOhwKrx7zMu9WK9M5qxDEyMMj5SetEgNC2i8xPer9lGu9U6Nkc1TglMKYHBPFWtOfddo3PqRWOlzlqN6neQ6LNJpXmWas0oGTGOrj0rkLS3uJ79YBG0K5yzFecc8Y7V3uj6sbS3QBCzkDAHBrqLTSoriSS9lgVLiUcZ7j3ruq0VJpI+ZeZTwnOqiunszzZtBS5Yy+QgdPmYDgMK24PDulvFDE9hAztk5C8/nXZQaKpim8wAM+RgdAKzLyNbO1g4BO3d16VnGk10OWWZzrPlhJ6HM6ppFtp1m0cUEUYJ3AqOvsTXB6l97MfHvjtXpXie8SSxiVU3MByOwrznUOQzEgD2p4jpZHt5TOco809zmdShWZfJkyQ3LD2rLigms3kK/PBn5R3A9vWt55AryFcE+9ZzEbiWZs+1KnNpW6HvFIzQTDMjEy5+VDxj8Khk4BOOnard0kUwG0AH+93rPiJWRo5G+dTnn+IV0ws1oMjbJHK59KguP8AUSr6q38qnbhiQfpVWfCoxJ4wTXRDcTPbPhsMfscXo9NG1b/0O4ryeQ/LvGBx6V6z8OcH9ju+I6f2Pq//AKHcV5LIB5YwDnAyAK7M43p/P9D86yRe/P5fqRQD5RtzzV+3HAx1NQW0ZbAwPQk1q2kI9fwrwqk7H10ZJIIYjwT6VcgtycZq5bwhQeuSOf8A61WgqqOwrklNs0VQht7b2/8Ar1tWNrgqSMHHT1qkkiqBjH0zUy3uzjIFSrXuyJuUtEdNYxouOemB04Fb9k0SHkKMDpXny6qwAwQQBkGpIteZf4ue3NejQxsKXQ86tg51D1S2kiVRnbuHX0rTs2TIx6d/515RZ+IsPjewGefyrq9E1vz9sbHAPr7162HzKnVaieRicuqQTZ3cRGNuQM8k47Ve8tSFxkAVn2V3EIQeh9AKivdXWNT5XYd69lSSV2eC6c5SskVtWlERKgZ561x+pzPIQWBx6j+dWda1YZZw3zHnjkH/AArBnv1kB+YD29q8XG4qCbjc9/B4WUUm0RtIB1yVHrVG8mAOFGP61BPqMYOAc5J5quLtXck5OehI6c183Vrc2iPbp0WtWie3tfOXc/BJ5zTriBYhu4wB0p0rFoMxMFx2qvfXCi3ClwzYwTSnTilZfeXHmbIDKIx8pyCOh7VWmvEUEggexqrLJ8hOcDNYd5IZGI3cD0rKnS5nqdaiWtR1FADyMevauS1bUx8wJ+U1PqDAIcMWHpXJX8oDEDoK9zBYSLdzOolFXG3t5kN8x696567nDNk/hUt7N1Aasx2zXv0aSgeBi693ZDXf5jQnJpmCWqxBHuIz0ro2OCCcmWLfJPetGLpVeFNvarC/rUHr0I8qJgccGkJGOaQdOlIetUdN9ALYzUZf1FOY+v6VBIx5x+VSZzlYjnOVz0r1/wDZBOfirqPto03/AKPt68bmbK8mvYv2Pf8Akquo/wDYGm/9H29XDc8XMpXps+xqKKK2PnzxD9rSaeDwR4cktSwmGvwAbevMM4P6ZrxTTVllvk0+3iDNKcyt3Ar2D9sqeS1+GujTwsVkj1uFlI7EQT15X4Cuo/7QeQjcZ4lZWx615WZLRSZ9rwrV/dVYLdNP8P8AgHo3gq7Wx0wrGuzy3PmHsSOprsNE1jUZ9tyLFp7UHICP8+31xXCzaeod2N5JbQy8SKuMGuj8Oa5JZWskcWXf7kbEc47E++KwwlZwlGlOVl8j0MdQjUjKcI8zfe5a8d+IV1iSzsdM+aCNt8pIx83TH4VHcNm1kWbliOAO/pWYLSbz5LmBNsh5cN/HVe5kvmmBUIhznOck06lSfPKpNN30XoTSw9OEI0qbso/fcjuoOG+8uBxkdK568jCPt4Pqa27u9ZGkhu1xJjIbs1c6zSzlmhRNg7s2Pyrx8Uo81kevhlJK7I3GB+GahOT/APqqxuRzhSVfHKt/SoZgI0ZmfjsDXKjsJIs8ZVSAc9KnQNJKQ8S7n4J6YqnDNvIKZAHUEYq2buOTJVBkHqehqZJkseIgofcMY60m0yBigVcDuetMCn+9wxyan5SNQcFT+dQyWVJm2qrN8pPQZq3pEyu5DuMk4560rwJImW+771BbWyxTblBA7YpOzRhON9Udz4dvRDOsRcv027v8a9Gs9UlFu+x1dT2PUH0rxi2eSNQVIzWquq3AjEfmsq9ODXVha6pq0jxMdlqxEuZHqM2tzPGYQEWQ5yx4A/WsiaaIhRK+dgGR2NcgdS8mAlS7PgDJbpWZe6q7bsMQe5zXdLFwirpHLQylp2jobGu6wkpZFOQOATXH3sm9Wx93rTpZdzbnyfU1n3ErSNsQ8da8+pVlVldn0WGw0aKtErqCCT8pJP1pjQAODuXB5IHalfdhcEZFOeMYAywz1pbHaUbhUXg5YnnpVC4gSfmQcjoR1FaN5FsXIbOOuazWI5IOWNdNJ9UBRl8+L5docDo2cH8aqXW9reRpSFXaeB9K0JGHRunWsTxBL5GlXsmcYiYA+5HFd9Fc0kjKtNQpym9kmz3r4a/8mcXn/YG1b/0O4ry9UBSNtuAUVufcV6h8NP8Akza8/wCwLq3/AKHcV5bFcpcafa3MalY5YUdVIxgFR1Fb50n+7t5/ofnuR/FNen6lmEBcDritS2ZQB244rEhlGcA1bW6AQEHP1NfPzg2fWQg2bwmCrzjI6+9RSXTZIDZPX6Vk/aTjIB+bpRzsBLYJrP2dtzqhTSL7Xcmcb17YzURnmI4YD3A4qvjIC9/WpE5GTjBo5UjXRClp2JPmfpVi3tpCNzSEg9gBSwxgnPQetX4wdp2AY9TWcpdiGxYUK4A9OlbGl3JhdclsHH5/WsuIKvr61YDADjjIrNNp3RhUXMrM9Ct9cVbc8nOAMjtVK+1j5TiQHHfPWuL+0y4AVsAcfWqrTuDtLH2r0JZnVascMcugnc1NQ1Ys5CnOOmeayvt0kmQWIGelVpDkn0NNU4PfH1rhlNz1kehClGKskWgCxqRQQMISCB07VXSXaOMH39BThMF56/WosVysna8uAChIZaryXhI/eZX3I4qNpD6n1qvM52mrir6Fqmuwl1choztbOf51jXk/Oc81ZulRwcgg+qnFYt2JAoYPkDsw6V3YemmxuNijfzZDc5981y95JyxPWtbUHYMwYfjWFdDIIr6HDU+VXODFy00Mi6clutVcFjVuaMljxTorf5huHHWvQTsj5yVOU5EUMJODjircSYAFTxxADjFPUACle52UqCiEainYpQPypQOgxQdSQueBQfagHjpzQSBVFEUhGMVE57+1SygkcCq0zEcCpOeo7EM5+U17H+x7/wAlV1H/ALA03/o+3rxaR+or2n9j05+Kmo/9gWb/ANH29aQ3PFx8uamz7HooorU8Q8A/bV/5JZpX/YZi/wDRE9eI/C26NzHp2HCOFMOfQjpn8hXt37av/JLNK/7DUX/oievmb4Y3xjkubZTh1InT+R/pXHj6fPRdj6Dhqv7PGcj+0mvnuvyPoyII8kM1y58pf3bA8+W3+Brq4bGCKJZoyOVHI7GuN0mRri2iu0TzIZk2zp646HHrWubmOzjiS3lMliR82eqH/CuTBKNvaSWn4/L9ex9ViqcpNRi/6/r7zblQI+S64I6jvWfKynHl4bsXzVG8uZpE8tHMauc8d/eqI3RkgysjKc4P3Wq6+IUXZIzpYZ2u2F7bJIcSr5pH3c9TWfdhY18pIlQD25NaL3zzOf3QZl4+V8D61lXDTrcs5jUkjA+YV42IlB35T0aKltIqzxjYSVGPeqzIgwQCcdC3NWpEmILEoPcnNRMrgHO056GvPeh2JmfcxlmBVsSevtT4JsgKy7Cp6HvUjhc8n5u5qsxxKW5Ixj6VS1Viy4h39yPb1qdGbG3tVWIhmBBycZq0PvNxwKzkiWTxt2J496U/L8y8Y561FE26Q7BnnApbptp8vB3njAqbEW1NKOWNF+Zvm7UjT7CWx9QaoJ8gxxSGQlOaDP2SuOnvZGbaCdtQfaScc5x2qGWOR8gDaB3qrExjJ5BOfXrVqNzVRS2JLq5dOVyfr2qrFdmWYFuOe3ei7fduYZHbisuLeLpSPvg/nXTTppxZZ04YmJc7SAcjHU0u6ENgrKAR2NVVBJ9DTkUGQAtz14rC1hWK9/uaHg7hnvwRWK0W9CfmB6Vuav8AuIhhgc+1YqSMckNn0FdVG/LdAV3tlbOcn8a5Dx7MtvpHkrkGZwBz2HNdm/QgHA6V5j8QrwT6ytupytumD/vHk/0r1cBFzqq/Q8fPsQqGCm+stPv3/C59V/DT/kza8/7Aurf+h3FeEaDf/a/C2msGJeOLyWH+6SB+gFe7/DT/AJM2vP8AsC6t/wCh3FfMvgSfzNLuYN5Bikzj/ZYf4iu7MKSnTUuzPjciqKOJ5X1X5anWpcbmPIGPSrUFwwChT8ves1BGCCMnHOT3qdXGCCc+lePKEXoj7iDRrQ3GMgn5vY9K0IXzkkVhQMRjnB+laVvIAcZLN3weK5K1K2xu9i/vwwIGR25qaIdduXb0B4FU4sup3njPQdKuxBsdMewrkmrCsXoVww8xtxHOAMLV53wgxj61VtF5BIHPtVqQKQMcY61yyJa1GK2Fp3mcYB603bjIPGahY5fYOvUipsHLcvIP3ZJPPX1qrOMf07VZYbYMrnn9agkAPGTSQoorg7sk96Yz7WweT2z3pLgNH86cjv8ASmlhKmQB9RVpdTVRJRgn+VPX2qtHIUbbJjPY1Yz2796LWG4ikLx378VA5BJz0FWC2Meo9KgIJJPTjvTiCKNwvzfWsjUkKAkDI7+xrckHzfN1rNvuUZQAR3rtoStJEs5O/AI4NZE0fbFbl3ES/TC59aqPASele/Rmoo5q1HmMX7MNx4pxiHpWi8QxwKiZK7YzTOV4ZRKezHtQBU5T0ppT8K0TRDp2IsYpCuR0qXFI2BTJ5LETcUwnHT8alNRuKDOSI2PBxmqU2S2c1afAzkc1WlH4UjkraopSnmvbP2Omz8VNS9f7Fm/9HwV4lMOte0/sbHPxZ1Uf3dFlH/keCtYng412jY+zaKKK0PLPAP21v+SWaV/2Gov/AERPXx54f1A6ZrFtdAkKrYf3U8GvsP8AbW/5JZpX/Yai/wDRE9fFYpSSkmmaUqsqM41Ibp3+4+qvBN3vtzDHJ8gbcp6jB5FdzBHGbYsyo7dW4rw34Ga6twjWFww82FQBu7r2/L+le2TzRRxBpGBYjp049a4sCo0eeFTWzP0SdaOKhCtT2kr/AOa+RAlpLbs5LE5GdjchB7U2QuXw/UcAY/St3TbQS2vnzTgAr8nOfwxUcsmnvMDKxjcDDN6+9bV8IlBSva+xisReTVr27HM3NlG9wyplJD1K9B+FQXlvs+VJAW9SuPwrQvnDXTGIgY5DA8kdjVaQ4VlfknBIz1/GvDqU4XloehCctGY12xUlZNu7Gciq55UDOR6+tajxx7csNxPTHIFZ0sZRjhgfQDtXmVYcup2wlfQrSKDwaj2fN3H0qVgQ/HX09KYx+me9YmqZGMZ5+Vh3p8YZizEnB7YxTFG6Q56AcVOFZeMHn9aGMliXDDacHqOaS5zE8TEchsMT2BqeJVHzkBmB4FV5y0l0UbG1cMT6mpSIvdlgEbSSAQOKsfYG+zxTMSqSZ4+neqysMAcknmrqXzokYViNoK47HI6U4pdTOfMvhOWvL6e2uvKbBJOBmrn2RWC5Jz3A9ahvl+2X+YEGYz8xPTPpU5S4J+adVH+wn+Nau1lbQ2KV2m9vIhx5ufmY9EHqfemxWBgkEkc8hZhznBq9GiQIwGSx5LHkk+9RqSeRyR2qlNpWWwDUtickSyF+2TQtjIZvNaVyTx1xinoHZzsyT3H+FLf3Xl2+GBDDgY5xSvJuyBmNqiAu255SF7lqy9u1SyyuCPWrMsu8njrVYtljn7oFehTi0rEsivNQS3s5J5RsESliMda8du53urqWeQ5eRix/Gux8f6nwlhE3J+eXH6D+tcRXt4KjyQ5u58HxLjvbV1Qi9Ib+v/A/zPtX4af8mbXn/YF1b/0O4r5J8G3Rg1fyicJcIY8e/Ufyx+NfW3w0/wCTNrz/ALAurf8AodxXxdDI0UqSIcOhDD6iuqpDni4ngYas6FWNRdGeoLIBJ3x9atQOWPygkds8CqlkqXUUFwn+qlUMPx7Vswxqg3Egnpt9K8GrJR06n6JSlzK6HQKQMtyCO3Sr9qu4/KTjtmoYk3tnPPXArYs4cDLgnHSuCtUsjtirLUlgjOCccetX4oskZAPao41+UYGFFXIR3OP8a82ciyaNBsBQ4470A8/NyB2pm4ZO3pmpw0RiJcFWH61iyWiCWQIpJOeOBTLWPqWOSeee1IyFzucYPQD096vW0YC47jFDdkEtESuAVjB4BPX1qMxkk8CnkL52MdBnmrLIu0bcc9hWbZjexnNFhcke1YvksLmVUYqAeBXQy8cHn+lZONt22erCtKcrXN4MpSM6sqTjA7HHBqSFzGVLEtGeM+lXbiITRlNufQ1RW1lgG5MtEc5X0rZSUkWncvxuJVGMHH60/Zkdvaq8UJVRJDyp5K1ItzFuC5xnjntWduxLXYilj4wP4qzruIKvHX3rZmG4kggAflWbc4zhhgeta0pajRz9zbrMpYD2HHesmRSR2z0NdJeKi/cx6DjrWH5TtJIUAABwe/Nexh6l1qNq5lyLg/XtUTDrWgYsN8wyarumeelejGoYSiU2XiomFWHHrUZXiumMjnlErnrTTUrDnimEVqmc8kREUxhyTUppjirMZIqTKQ1VX6c1clOTVO59jUnDWVtSjM2Msfqa9k/Ytbd8VdWY9To0x/8AI8FeJ6hJtiI7txXtf7FX/JU9V/7A0v8A6PgreC0PmsbO8uU+1KKKKo4jwD9tb/klmlf9hqL/ANET18VV9q/tq/8AJLNK/wCwzF/6Inr4roA0/DurzaJq9vfW7EGM/MB/EvcV9L+GPENpq1nG4k3SyKCoY9R7V8qV1vgfXXs7hbGWYxxO2YpM48t/6A1x4qi3+9h8S/FH0mQZjGjL6tWfuy2fZ/5M+qYWjtyP3kqxkbQobHPt6VoW728UBkx5rjnnqfY15Xpfi6YJ9i1FCJwcCQdz/jXS6fr8YkVbhWRegxyPqa5aONhTfLUVrn1lTCSkro6CdjduJgoWFDwmMYNQTxbXAI684FTrPFbFiJhMpGcKOo9arX0+FEkKjY45BOSDW1WnBqUpP3v62M4XukloZ1/II5ghA56+lZc3XI6t+v0rQNu5Uzy4Eec5/wA96oTLl/rzivnq6bd2tD0aVloiBuQcCq+8vuVRgjqatSLtiLLnIqMK0UKjI3sMt+NcqNkyA/KMA/jjrUqOXGO47VE5GMgcUiSeUjSMcAA0WuUX55k8wzRoRFt6bs845qGItks4IZhk8dBVCJ3ZQ8oKp1VD1PuatyXSiBTIw6Y460OJNrE5lzwCMelMdvkypwR8w/CqgeViCoCA9N3U1TupLoRFnfGTtVQMZJqo07sdizpcgeGWQ53PKxNWmk3cZFUrWAxQRx7gf7xHc1Ko52+vHTrTkk22gHtnJ2nJqPq2Bwf51I0QiH7wHI4I9BVeZwnTAKnOaa12Amc+T8wOSOeDWLf3PmzgDOCSSPSrV3cjyzIpCqB+FZO8yv5n3BjABrpoU/tMTHcgfN+nesrWNQj02wluJTyPuD+83YVo3NwkULyysqIgyzE8V5V4m1qTWLzIytshxGn9T716WEoOrK72PIzfM44GjdfG9l+vyMu5nkuZ5JpmLSOck1DS0le4j80lJyd3ufavw0/5M2vP+wLq3/odxXxWK+1Php/yZtef9gXVv/Q7iviugR3HgO+MtpLYtgvEfMTP909fyP8AOu1t1G0cEk8Zrx7SL59N1GG6j5KH5l/vL0I/KvYLKRZkimgIaKRQ6t6g14uYUuSXMtmfaZFi/bUfZyesfy6f5GzYQBfvYAxnNacYyfYfrWbAc5JY+uAKuxSEkZ/AZr5+rdu59HF3L6nOD2FPDMQSCf8AGokbI3E9KcjKgLNwP5VzNGqJkBABc4HpSozzOCfuqeB6+9V1bzzzxH/OtBNqqAoOR1qJaA9C3bwC4lzwHHQepqVk2n0x1zUFkzRSAsMHr9KsXcm5nK/dzWTOaV+axWBzISO9Tq3Unk+5p1vDkjBwD0J9aspbnJxk44HvUsmUkihNwfrWZKhFwp56V0L2ygDI5Jzms/yVF/CGIAIJNOMrGlOaIUhZcE9OtTRxNLMUUcMflFa/kocMR6YpsKJHcLJtLFsnjt3ouZutdGRc2L2pZ4eUPVQehrIkC7sr0b7wI6GuouSWc8YGfzrLuLJJ42K/I+cZHetIT11NqVTT3igLcmPdGzKMdM5FUZ450PRZVPXBwasSSTWrFJkyqnG5RSJcxyr8jAkdh1rePMtdzYyL+YRRZVGDemKyt6pEdwOTycit29Hn3CoFyinceMCoboI0eAuW6mu6lUUUlYdzm2dAOuT9Kqysu08jJ7VtXMYwMAegzVC6t8DlRnqTXpUqkWRJGXjvTDViWLaeOKgYEdcfhXbCSexzyREwqJxk1MeaYa3izCSISO9RsOM1I2M1HIeOlao5porydD61RuDx75q87DnPArK1SYW8LMPvNwv19aEtTzcVJQg5PYxdQk8y4IH3U4/xr3b9ir/kqmq/9gaX/wBHwV4BXv8A+xV/yVTVf+wNL/6PgroWh8hObnJyfU+1KKKKCTwD9tX/AJJZpX/YZi/9ET18V19qftq/8ks0r/sNRf8AoieviugBKKWkoA9C8H6/BqFsul6o4jvVwLW5Y8P6Rv7+h/CvX/DU8F9pz2l6yfaYxj5urf8A1xXy/Xa+FPF0lvLFHfSkSIQEuCc/g3+NediMJr7SCvbofY5NnicVh8U7PpL9H/me5aFevp9/LZTSFh2brx2rXcx25Moid0Y4wD0+lckZ/wC17RLuxH+lQ8lQevt/hXSaL4i057dYpXEdygw0cny81w4az/dzdo7q/Rn1VaNveSv3L9xue2WTGFJ3GMHj8TWbOoA84D5uhGelT3N3EshkjmjZGOCgYHA9azr67iibMTct93HUVhjJKT5b7f1f/gCpRaHXGJHVR8oI3H6VTuZo0BLyImOvPepkt1ePzLmRzI4wEXgGqht4VXKRDr1Iya87ltqzojYqtctLgW6F2P8AEeFFMktxIn75zKR74UfSrm3A3ZxisiczajceRbDEQ6ns3v8ASrgr7aFk9zNZqqLNcjjj75NFvcWpwLeWNseh5P50radaqoVkWRgeXfuaqXWl2zZEabGHQof6VolB6XYtTXEpbaG4HfAqrcOTqUCtypBIHvishZb6wBXImj/vHJ2/1rQ08xuHuGmE8rDBI4A9gKTpcnvboE7mg0hXHA4pvnbX3NwR0qLzOmeo7elQzT5BIy2eM1ChcZclnyxZnBA43Hv3rOnlMmNgzjpUWC3G5gPTtVe4le3DYHzHgEetbwpWegtiEYkklDklEPyjsKY8ibTkgIMktngUy9nhsbUyXEgWNeWY15x4l8RyakTBbborMHp0L/X29q9Ghh5VnpseXmOZ0sBC89ZPZdX/AMDzJPFuv/b3NpZki0U/M3/PQ/4VzNFFezCCpx5Yn5xi8XUxdV1ar1f4eSCkpaKs5j7U+Gn/ACZtef8AYF1b/wBDuK+K+9fanw0/5M2vP+wLq3/odxXxXQAV3nw61cEnS5255eAk/mv9R+NcHT4ZXgmSWJikiMGVh1BHQ1lXpKtBwZ14LFSwlZVF8/NHv9s4wN5HAq2hBPXpXIeHNdXVrBZiR9oQhZox2b1HsetdHbXICh3OT0C18pWoSg2nufo2HqxqwU4O6ZrJJtUNLwMce9WoYHmXfIpCdgKrafH5zCWbp2HpW+WRIwOB/npXm1Jcrstzoc7bEVnCuzf1HT6Ve2JJKoHypjJ/Cq9kPlJfIBqzagPOZEGVHQGuaT1M5y3ZMsAdgcHavrUcyjeiqOeW9K0/LAhK5wcZJ9Kz4EM0zOSSoOAfWpuYxne7LFuVYocHngCr+xURdowduD7n2qJYRGA7AZ+6ADU3msi4cEEcjtj3NBzzd3oVJSVk+cY4/KsmeNhfxLyCy9PSta4jlliEgIVCeGbqaxpi6XcJJYkkgMaDoonTW0IYDaAMDaBnqfWo79BDGqKQGLZPrUumxSeQJcgRj3qDUSGkUkkAnI+nqab2OSLbqWuZly7YYAAHJ6Gs9SVmx2HPJrRliDDevHOcGq10iqh7kjqKSZ305LYzrgKZA3Y8H3qld2MbqeCpHIZeDWvd26iFQPr+NUzkxAyKdvfHtW8Jtao3jK60OfCvYB/My0b/AMZ7H3pspjeLdE49yO9a9xF5owCAvUD6Vn6jpUDIrx5V26lT/SuyFSLa5ty+YotCrDbnJI4+tZd23J3H86vvYTqw2TuW6A1lX9vLbS/vzvT1FehQ5XKylclsrXDK/wBzJPoKqSZ44IrRVoxGdmMEcYqq6luvRq76crGckUXBxnGKiIyfWrLjGRUDdTiuyDuc00QN0qGQ8GpWNQSPjP5VujiqMrzMPp61y2pXP2m4JB/drwv+NaOu3m3MEZ+Y/fPoPSsOtIR6nyuaYrnl7KPTcK9//Yq/5Knqn/YFl/8AR8FeAV7/APsVf8lT1X/sCy/+j4K0PIPtSiiigDwD9tX/AJJZpX/Yai/9ET18V19qftq/8ks0r/sNRf8AoieviugAooopgJRS0UgOk8JeLr7w7do0ZM1uODGx7egr2TSdV0LxTCJ7WVPPC5eJvlkQ/wBfrXzvUkM0kEqyQu8ci9GU4Irlr4SNXVaM93Lc+r4O0J+9Dt1Xo/0/I+g7i0idyloJHY9+gqzp2kXtpuvZSZFUcjrXmnhb4oXmnJHBq1sl7Ap/1q/LKB/I/pXqmi+MdA16BYbTUljkY/6ic+W4+mev4V5n1Jxuqj08v8z7LDZxhsXb2Utez0f/AAflcVtTtrliJD5RXhVPGKZcXsEed80Zz028k1cvtKj5E0SuvTdn+tZyaRAJRFGNu7BUk9a4qlN395HqJq2hTuJp7z93ChWLvngt/gK0rSNbW3KR/wCsJyzVeNrFZqEXiXHXHf3qhN0CkkFuTis6lOUVZ6DTUtiN8gZH41WJyWJHPYippM7T8xz6g1W4yAMnnNZxRQdue9ZNzA9nKLi0zgfeStUsVHIwD6moTIGwB3raDaE1cW2uBeoHjURgfeBPelZvMyMYHase4LafdebGdsTdcnArM1PxnptmhSNzcyf3Y+g/HpW0cNKb/dq6OetiqWHjzVpKPqdEflOeM1zXiXxHZ6e3l7xNOnPloc8+57Vx2teLtQ1HKRsLaA/wRnk/Vq53OTyetenQwFveqHy2YcTxs4YRX83+i/z+4v6vq93qs2+5f5B92MfdWs+iivSUVFWR8fVqzrTc6ju2FFFFMzCiiimB9qfDT/kza8/7Aurf+h3FfFlfafw0/wCTNrz/ALA2rf8AodxXxZSASiiimBf0XU59Jvlubc57Oh6Ovoa9e8P3EN9bxXkLCSFz/wB8nuCPWvEq3PC3iG40G6Ypl7WXiWL19x6EVw43CutG8PiPbyjNPqkvZ1Pgf4f8Due9W1wFYAdewH9a17VCx3zNluoFc/oN1aXVhDc2cwmhlG4yD26qfQ+1b0E4kbCc56e1fF14uMmrH2qqqSvHYvt8wwOpGfoKv6YoUAA5OMnNZ+VRG+b5m4yRSTXYgUBSWbpiuRpvRDs5KyLuoXgKSBOCxCjHpTbOQJhc8AYGO5rJHLIzk5Lc+wrQikEWJCBu/hU9qHGxTglGyNSWcqIugfP3fSgSCWYg/cT7xJ6msOSRw259xdjkA9BVmO4ClUiDSHq3uff2pNMh0bLQ1Z50WEoQGYngZrL1UjzYWcjCyAfKP61Kdxlxw0zcgAcJUeo2p+ysVJYr8xP9KS3CnFRkjft5/wB2m/8A1ZGFTPX3NVLtTI4jdiSTn0yPWoLKcPDGSMgjJ54FXZyRaySbfnYZPso7UX6HPy8kineAJKqRgnPA5rOuWyVGD12/WrqODI1w6sFPyxiqluPOuC0g+VOcepoR00/dWvQZIW80D0PAquOE4BPzEY9q0jGDOxJJ2L37mqEa/vth+7u/pVRZpGV0UZ4lYOcYcnAxVbDrETkN22ngj8a1r6IIzbeo7CsySPPy9ycAfzreDui1K6MuSdScEFXBzg8VFqcCygbuSVq7cBWkKMAUxjFZl6NlumCVyOBnI/Ku2lq1YdzmpYCCSjY/lVeSQqpVhye9aDEqcOoGe5P8qpXmGkwGAzXuU5XdmZS8ik7jnmoXbOcU9yR/jVaQjGRXoQSOOpOw126+tZWq34tY+DmVvuj+pqXUb9LSPc/zM33Vzyf/AK1cpcTPcStJKcsa3jG58/mWYKkuSD95/gMdi7FmJLE5JNJRRWp8ve4V7/8AsVf8lT1T/sCy/wDo+CvAK9//AGKv+Sp6r/2BZf8A0fBQB9qUUUUAcB8a/h1/ws3wta6N/an9meRepeed9n87dtSRNu3cuP8AWZznt0rxX/hkf/qdv/KT/wDbq+qaKAPlb/hkb/qdv/KT/wDbqP8Ahkb/AKnb/wApP/26vqmigD5W/wCGR/8Aqdv/ACk//bqP+GR/+p2/8pP/ANur6pooA+Vf+GRv+p2/8pP/ANuo/wCGRv8Aqdv/ACk//bq+qqKAPlX/AIZG/wCp2/8AKT/9uo/4ZG/6nb/yk/8A26vqqigD5v0v9m/W9LAWy+JFyif3Dpm5fyMxFdDbfBfXogRL4ysLgEY/e6IePfi4Fe30VlKhTk7uKO2lmOKorlhUaXqeKD4Oa7sKHxbpzDOQTo0mR7f8fNRN8FdZYn/irNOAPb+xn/8AkmvcKKl4alLeJr/bGNX/AC9Z4W/wO1hwQfF1h+GjP/8AJNR/8KJ1bj/ir7L/AMEz/wDyTXvFFT9Uo/yof9s47/n6zwVvgPqrDH/CXWI/7gz/APyTVW4/Z81mYDb46ihI6GPRuf1nNfQlFUsNSW0UKWcY6Ss6r+8+X7z9le7vWLXfj6WUk5+bSyR+XnVV/wCGRv8Aqdv/ACk//bq+qqK2SS0R585ym+abu/M+Vf8Ahkb/AKnb/wApP/26j/hkb/qdv/KT/wDbq+qqKZJ8q/8ADI3/AFO3/lJ/+3Uf8Mjf9Tt/5Sf/ALdX1VRQB8q/8Mjf9Tt/5Sf/ALdS/wDDI/8A1O3/AJSf/t1fVNFAHyr/AMMjf9Tt/wCUn/7dS/8ADI//AFO3/lJ/+3V9U0UAcB4a+HX9ifBubwF/ann+ZZXdn9u+z7ceeZDu8vcfu+Z03c46jNeK/wDDI/8A1O3/AJSf/t1fVNFAHyt/wyP/ANTt/wCUn/7dR/wyP/1O3/lJ/wDt1fVNFAHyt/wyP/1O3/lJ/wDt1H/DI/8A1O3/AJSf/t1fVNFAHzf4c/Zr1Dw+8v2HxyjRSj54ZdIJRj2OBOMH3FdDbfBbW7cEJ4u0857nRX/+Sa9vornqYSjVfNOKbOqnjcRSjyQm0jxWT4O684H/ABV2nDBzxor/APyTUf8AwpbWu/i3TjznnRnP/tzXt1FZf2dhv5EbLNcWtqjPFl+DuuKykeK9M+XoP7Fk/wDkmnyfCHXpPveLNN/DRZP/AJJr2ail/ZuF/kQf2rjP+fjPF3+D2vNnPi3TeRj/AJAr/wDyTU0Pwm16EAR+KdKGP+oLJz/5NV7FRR/ZmFf/AC7QPNcY9PaM8ej+FHiBHZ18VaVubqf7Fk/+Sqe3ws8RNGyHxXpWG6/8SWT/AOSq9eopf2XhP+faF/amLf8Ay8Z45a/CbxBbReWnizTChOSG0WTn/wAmqsz/AAx8RzRGM+KdIVSMHbokn/yVXrVFH9mYT/n2geZ4tu7qM8kPww8ReUsY8U6QFUYAGiSf/JVRQfCrxBCoCeKtK65ydFk5/wDJqvYKKP7Mwn/PtC/tPF7e0Z5C/wALfET78+KtJAY5IGiSf/JVQH4R6+ZRIfFemZHb+xZMf+lNey0U/wCzML/z7Q1mmLW1RnjMnwi16TO7xXpg+miv/wDJNQN8GNbLEjxbpwJGONFf/wCSa9toprLsKtoIf9q4z/n4zwo/A7WCpX/hL7Hnqf7Gf/5JpLn4F6rcKA/izTwAMDboz8f+TNe7UVawOHTuoIP7Vxn/AD8Z8+y/s96jLEY38X2ZH/YHbI/8mKrH9nC+OM+Mrc4/6hDf/JFfRdFaxoU47ITzTFv/AJeM+cH/AGa7xjk+MoOf+oQf/j9Rn9mW6PXxlD/4KD/8fr6Toq1CK6EPMMS95s+Wrj9k17iVpJfHGWP/AFCen/kao/8Ahkf/AKnb/wApP/26vqmiqOSTcndnyt/wyP8A9Tt/5Sf/ALdR/wAMj/8AU7f+Un/7dX1TRQI+Vv8Ahkf/AKnb/wApP/26u/8Agp8DP+FZeKrrWf8AhIv7T8+yez8n7F5O3c8b7t3mNn7mMY79a9qooAKKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Twelve-year-old boy who noted poor vision in the left eye over the preceding two months. His visual acuity measured 20/20 RE and 20/100 LE. Toxocara serum titer (ELISA) was positive at 1:4. Ophthalmoscopic photograph, left eye. Note the deep, subretinal white mass with surrounding hemorrhage, lipid, and retinal edema.",
"    <br/>",
"    (B) Eight-year-old girl with a Toxocara lesion adjacent to the optic disk with overlying vitreal inflammation. Visual acuity measured 20/25 RE and 20/100 LE. Ophthalmoscopic photograph, left eye. There is a white mass over the optic nerve head. Also, note the significant vitritis associated with the mass. White, fingerlike projections from the white mass extend into the peripheral retina.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gold DH, Weingeist TA. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_47_16113=[""].join("\n");
var outline_f15_47_16113=null;
var title_f15_47_16114="Pneumatic compression boots";
var content_f15_47_16114=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pneumatic compression boots",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Intermittent pneumatic compression devices are applied before draping, and the power units placed well out of the way of the surgeons and assistants.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_47_16114=[""].join("\n");
var outline_f15_47_16114=null;
var title_f15_47_16115="Three dimensional LV blood pool";
var content_f15_47_16115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Real-time 3-D images using IV contrast injection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The slices are obtained from a data set obtained during contrast opacification of the left ventricular blood pool. The data set were obtained from a single cardiac cycle at the peak of contrast effect. The left panel shows long and short axis and C- scans and the right, a volume rendered three dimensional depiction of the contrast blood pool.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_47_16115=[""].join("\n");
var outline_f15_47_16115=null;
var title_f15_47_16116="Porokeratosis histopathology 3";
var content_f15_47_16116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Porokeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 491px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A column of parakeratosis consistent with a cornoid lamella is present in the center of this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_47_16116=[""].join("\n");
var outline_f15_47_16116=null;
var title_f15_47_16117="Zanamivir: Pediatric drug information";
var content_f15_47_16117=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Zanamivir: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"    see \"Zanamivir: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/44/16068?source=see_link\">",
"    see \"Zanamivir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Relenza&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F235669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Relenza&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1042836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Neuraminidase Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1042868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"      see \"Zanamivir: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral inhalation:",
"     <b>",
"      Note:",
"     </b>",
"     10 mg dose is provided by 2 inhalations (one 5 mg blister per inhalation):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of influenza: Children &ge;7 yrs and Adults: 10 mg twice daily (12 hours apart) for 5 days. Longer treatment may be considered for patients who remain severely ill after 5 days.",
"     <b>",
"      Note:",
"     </b>",
"     Two doses should be taken on the first day of treatment, if possible, provided doses can be spaced at least 2 hours apart.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prophylaxis of influenza:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;5 yrs and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Household setting: 10 mg once daily for 10 days; initiate within 1.5 days following onset of signs or symptoms in the index case",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Institutional outbreak, CDC recommendations: Treatment should continue for &ge;2 weeks or until ~10 days after illness onset in the last patient. Zanamivir is to be used to control institutional outbreaks of influenza when circulating strains are suspected of being resistant to oseltamivir.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents and Adults: Community outbreaks: 10 mg once daily for 28 days; initiate within 5 days of outbreak",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for renal impairment:",
"     </b>",
"     Adjustment not necessary following a 5-day course of treatment due to low systemic absorption; however, the potential for drug accumulation should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F235648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Relenza&reg;: 5 mg/blister (20s) [contains lactose 20 mg/blister; 4 blisters per Rotadisk&reg; foil pack, 5 Rotadisk&reg; per package; packaged with Diskhaler&reg; inhalation device]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F235634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11217378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zanamivir",
"     <i>",
"      aqueous solution",
"     </i>",
"     intended for nebulization or intravenous (I.V.) administration is",
"     <b>",
"      not",
"     </b>",
"     currently approved for use. Data on safety and efficacy via these routes of administration are limited. However, limited supplies of zanamivir aqueous solution may be made available through the Zanamivir Compassionate Use Program for qualifying patients for the treatment of serious influenza illness.  For information, contact the GlaxoSmithKline Clinical Support Help Desk at 1-866-341-9160 or gskclinicalsupportHD@gsk.com.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1042872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral Inhalation:",
"     <b>",
"      Inhalation powder not for use via nebulizer:",
"     </b>",
"     Use a Diskhaler&reg; (special breath-activated plastic inhaler) to deliver dose. Load Relenza Rotadisk into the diskhaler; 10 mg dose is provided by 2 inhalations (one 5 mg blister per inhalation). A blister that contains medication is pierced and the drug is dispersed into the air stream created when the patient inhales through the mouthpiece. Patients scheduled to take inhaled bronchodilators at the same time as zanamivir should be advised to use their bronchodilator before taking zanamivir.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1042857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F). Excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not puncture Rotadisk blister until taking a dose using the Diskhaler.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1042837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of influenza A or B infection in patients who have been symptomatic for no more than 2 days (FDA approved in children &ge;7 years and adults); prophylaxis of influenza A or B infection (FDA approved in children &ge;5 years and adults); has also been used for treatment of patients symptomatic for &gt;2 days with severe illness (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends that antiviral",
"     <b>",
"      treatment",
"     </b>",
"     be considered for the following (see specific antiviral product monograph for appropriate patient selection):",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     &bull; Persons with severe, complicated or progressive illness",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     &bull; Hospitalized persons",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     &bull; Persons at higher risk for influenza complications:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     - Children &lt;2 years of age (highest risk in children &lt;6 months of age)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     - Adults &ge;65 years of age",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     - Persons with chronic disorders of the pulmonary (including asthma) or cardiovascular systems (except hypertension)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     - Persons with chronic metabolic diseases (including diabetes mellitus), hepatic disease, renal dysfunction, hematologic disorders (including sickle cell disease), or immunosuppression (including immunosuppression caused by medications or HIV)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     - Persons with neurologic/neuromuscular conditions (including conditions such as spinal cord injuries, seizure disorders, cerebral palsy, stroke, mental retardation, moderate-to-severe developmental delay, or muscular dystrophy) which may compromise respiratory function, the handling of respiratory secretions, or that can increase the risk of aspiration",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     - Pregnant or postpartum women (&le;2 weeks after delivery)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     - Persons &lt;19 years of age on long-term aspirin therapy",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     - American Indians and Alaskan Natives",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     - Persons who are morbidly obese (BMI &ge;40)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     - Residents of nursing homes or other chronic care facilities",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     &bull; Use may also be considered for previously healthy, nonhigh risk outpatients with confirmed or suspected influenza based on clinical judgment when treatment can be started within 48 hours of illness onset.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The ACIP recommends that",
"     <b>",
"      prophylaxis",
"     </b>",
"     be considered for the following (see specific antiviral product monograph for appropriate patient selection):",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     &bull; Postexposure prophylaxis may be considered for family or close contacts of suspected or confirmed cases, who are at higher risk of influenza complications, and who have not been vaccinated against the circulating strain at the time of the exposure or if exposure occurred within 2 weeks of vaccination.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     &bull; Postexposure prophylaxis may be considered for unvaccinated healthcare workers who had occupational exposure without protective equipment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     &bull; Pre-exposure prophylaxis should only be used for persons at very high risk of influenza complications and who cannot be otherwise protected at times of high risk for exposure. Prophylaxis should also be administered to all eligible residents of institutions that house patients at high risk when needed to control outbreaks.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7731023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Relenza&reg; may be confused with Albenza&reg;, Aplenzin&trade;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F235703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, fever/chills, headache, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite decreased, diarrhea, nausea, throat/tonsil discomfort/pain, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, articular rheumatism, muscle pain, musculoskeletal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, infection, nasal inflammation, nasal signs and symptoms, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic or allergic-like reaction (including oropharyngeal edema), arrhythmia, bronchospasm, consciousness altered, delusions, dyspnea, hallucinations, neuropsychiatric events (self-injury, confusion, delirium), nightmares, rash (including serious cutaneous reactions [eg, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis]), seizure, syncope",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1042843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to zanamivir, lactose, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F7290843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for use in patients with underlying airway disease (eg, asthma or chronic obstructive pulmonary disease) due to risk of bronchospasm. Zanamivir is not a substitute for annual influenza vaccination. Not recommended for prevention of influenza in nursing homes (per manufacturer). The CDC recommends zanamivir be used to control institutional outbreaks of influenza when circulating strains are suspected of being resistant to oseltamivir (refer to current guidelines). Antiviral treatment should begin within 48 hours of symptom onset; however, the CDC recommends that treatment may still be beneficial and should be started in hospitalized patients with severe, complicated, or progressive illness if &gt;48 hours. Nonhospitalized persons who are not at high risk for developing severe or complicated illness and who have a mild disease are not likely to benefit if treatment is started &gt;48 hours after symptom onset. Nonhospitalized persons who are already beginning to recover do not need treatment.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1042844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cases of serious, sometimes fatal, bronchospasm have been reported. Discontinue zanamivir if bronchospasm, decline in respiratory function, or allergic reaction occurs. If a medical decision is made to prescribe zanamivir for a patient with an underlying airway disease, a fast-acting bronchodilator should be made available and used prior to each dose, along with close monitoring of respiratory function. Pediatric patients with influenza may be at increased risk of seizures, confusion, or abnormal behavior early in their illness (monitor for abnormal behavior). Relenza&reg; inhalation powder should only be administered via inhalation using the provided Diskhaler&reg; delivery device. The commercially available formulation is a lactose-containing powder and is",
"     <b>",
"      not",
"     </b>",
"     intended to be solubilized or administered via any nebulizer/mechanical ventilator; inappropriate administration has resulted in death.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F235643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F235645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F235656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Influenza infection may be more severe in pregnant women. Untreated influenza infection is associated with an increased risk of adverse events to the fetus and an increased risk of complications or death to the mother. Oseltamivir and zanamivir are currently recommended for the treatment or prophylaxis of influenza in pregnant women and women up to 2 weeks postpartum. Oseltamivir and zanamivir are currently recommended as an adjunct to vaccination and should not be used as a substitute for vaccination in pregnant women (consult current CDC guidelines).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7290897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for abnormal behavior, respiratory function",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1042859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zanamivir inhibits influenza virus neuraminidase enzymes, altering virus particle aggregation and release.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1042861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Systemic: 4% to 17%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;10%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 2.5-5.1 hours; mild-to-moderate renal impairment: 4.7 hours; severe renal impairment: 18.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Renally excreted as unchanged drug; unabsorbed drug is excreted in the feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1042876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/44/16068?source=see_link\">",
"      see \"Zanamivir: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contact physician if wheezing worsens, if shortness of breath or bronchospasm occurs, or if unusual behavior occurs. Zanamivir does not reduce the risk of transmission of influenza to others.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F9775238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children ages 2-4 years have a higher rate of influenza-related complications compared to older children.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Infectious Diseases, \"Antiviral Therapy and Prophylaxis for Influenza in Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 119(4):852-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16117/abstract-text/17403862/pubmed\" id=\"17403862\" target=\"_blank\">",
"        17403862",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16117/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, \"Interim Guidance on the Use of Influenza Antiviral Agents During the 2010-2011 Influenza Season,\" December 15 2010. Available at",
"      <a href=\"file://www.cdc.gov/flu/professionals/antivirals/index.htm\" target=\"_blank\">",
"       file://www.cdc.gov/flu/professionals/antivirals/index.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harper SA, Bradley JS, Englund JA, et al, \"Seasonal Influenza in Adults and Children - Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(8):1003-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16117/abstract-text/19281331/pubmed\" id=\"19281331\" target=\"_blank\">",
"        19281331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13079 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-A6750C7309-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_47_16117=[""].join("\n");
var outline_f15_47_16117=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235668\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235669\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042836\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042868\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235648\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235634\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217378\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042872\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042857\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042837\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7731023\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235703\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042843\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7290843\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042844\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300233\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235643\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235645\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235656\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7290897\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042859\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042861\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042876\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9775238\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13079\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13079|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=related_link\">",
"      Zanamivir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/44/16068?source=related_link\">",
"      Zanamivir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_47_16118="Proctalgia fugax";
var content_f15_47_16118=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Proctalgia fugax",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/47/16118/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/47/16118/contributors\">",
"     Amy Barto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/47/16118/contributors\">",
"     Kristen Robson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/47/16118/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/47/16118/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/47/16118/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/47/16118/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/47/16118/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proctalgia fugax is a benign condition that is characterized by intermittent, recurrent, self-limited rectal pain that is severe. It is one of several functional gastrointestinal disorders and its diagnosis requires exclusion of other causes of rectal or anal pain.",
"   </p>",
"   <p>",
"    This topic will review proctalgia fugax. Functional gastrointestinal disorders as well as other disorders that affect the anus or rectum are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=see_link\">",
"     \"Clinical manifestations and diagnosis of irritable bowel syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26246?source=see_link\">",
"     \"Perianal abscess: Clinical manifestations, diagnosis, treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34181?source=see_link\">",
"     \"Anal fissure: Clinical manifestations, diagnosis, prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5348?source=see_link\">",
"     \"Overview of hemorrhoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=see_link\">",
"     \"Perianal complications of Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38762?source=see_link\">",
"     \"Clinical features, staging, and treatment of anal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proctalgia fugax is largely under-reported. It is estimated that it affects 4 to 18 percent of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/1-5\">",
"     1-5",
"    </a>",
"    ], with only 17 to 20 percent of patients reporting their symptoms to their physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/2,6,7\">",
"     2,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early reports had suggested a male predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/4,8,9\">",
"     4,8,9",
"    </a>",
"    ], but more recent studies have found that a majority of patients (58 to 84 percent) are female [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/1,5,6,10-13\">",
"     1,5,6,10-13",
"    </a>",
"    ]. Studies report a mean age at diagnosis of 46 to 58 years, though the ages of patients included in the studies ranged from 10 to 87 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/1,9,11-15\">",
"     1,9,11-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older studies suggested that the prevalence may be higher in patients with irritable bowel syndrome (IBS) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, in a more recent study of 148 patients with irritable bowel syndrome, peptic ulcer disease, or inflammatory bowel disease, proctalgia fugax was not more common in patients with IBS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sporadic, fleeting, and infrequent nature of this disorder has limited efforts to study the physiologic mechanism. In the available small case series, the underlying mechanisms appear to be heterogeneous. The pathology of proctalgia fugax previously was thought to be located either in the external anal sphincter or the voluntary striated muscles of the anorectum [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/10,17\">",
"     10,17",
"    </a>",
"    ], but newer theories have focused on the smooth muscle of the internal anal sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/11,18\">",
"     11,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3384790\">",
"    <span class=\"h2\">",
"     Muscle spasm/hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spasm of the anal sphincter is commonly cited as a cause of proctalgia fugax [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/9,11,16,18\">",
"     9,11,16,18",
"    </a>",
"    ]. In one study, anorectal manometry in 18 patients showed slightly increased resting anal pressures, but no differences in squeeze pressure, sphincter relaxation, rectal compliance, or internal and external anal sphincter thickness [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/11\">",
"     11",
"    </a>",
"    ]. During the study, two of the patients experienced symptoms while undergoing anorectal manometry. Their anorectal manometry studies showed that with increasing pain duration, anal resting tone and slow wave amplitude increased continuously.",
"   </p>",
"   <p>",
"    An inherited form of proctalgia fugax has also been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. An autosomal dominant inherited myopathy of the internal anal sphincter was found in a study of a family with several affected members [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/19\">",
"     19",
"    </a>",
"    ]. Histologically, the internal anal sphincter showed hypertrophy, disarrangement, and vacuolization of fibers, with the presence of polyglycosan bodies in many fibers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3384844\">",
"    <span class=\"h2\">",
"     Nerve compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pudendal nerve compression or neuralgia may also cause proctalgia fugax [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/12,21\">",
"     12,21",
"    </a>",
"    ]. In a study of 68 patients, 55 had tenderness along the pudendal nerve during rectal digital examination. The location, character, and degree of pain elicited by digital examination were similar to the pain experienced during spontaneous paroxysms of pain. Treatment with a nerve block was associated with resolution of symptoms in 65 percent of the patients and a decrease in symptoms in an additional 25 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Psychologic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some believe that those who seek medical attention for proctalgia fugax exhibit certain personality traits that may contribute to the development of the disorder. Two uncontrolled studies that used psychiatric and personality testing found these patients to be more \"perfectionist, anxious, tense, hypochondriacal, and neurotic\" [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/15\">",
"     15",
"    </a>",
"    ]. However, another study comparing three proctalgia fugax patients with controls showed no statistically significant differences regarding somatization, depression, or anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/22\">",
"     22",
"    </a>",
"    ]. These characteristics have been reported in patients with irritable bowel syndrome who seek medical care, while those who do not seek care have psychological profiles similar to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25442501\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with proctalgia fugax describe attacks of severe anorectal pain that may last from a few seconds to two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/12,24\">",
"     12,24",
"    </a>",
"    ]. Patients are asymptomatic between episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/7,24\">",
"     7,24",
"    </a>",
"    ]. The attacks are generally infrequent, occurring less than five times per year in about one-half of patients, though wide ranges have been reported (1 to 180 attacks per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/6,14\">",
"     6,14",
"    </a>",
"    ]. The discomfort can occur during the day or night, although it is not typically associated with bowel movements [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/25\">",
"     25",
"    </a>",
"    ]. In many cases there is no obvious trigger for the pain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of proctalgia fugax is based upon clinical grounds in the absence of anorectal disease that could cause rectal pain. There are no specific findings on physical examination or laboratory tests that support this diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/7,26\">",
"     7,26",
"    </a>",
"    ]. Anorectal manometry in these patients is usually normal, though it may demonstrate increased internal anal sphincter pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proposed diagnostic criteria for proctalgia fugax (Rome III) include all of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recurrent episodes of pain localized to the anus or lower rectum",
"     </li>",
"     <li>",
"      Episodes last from seconds to minutes",
"     </li>",
"     <li>",
"      There is no anorectal pain between episodes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis is based upon these characteristics and exclusion of anorectal and pelvic pathology. Conditions that need to be excluded prior to making a diagnosis of proctalgia fugax include pain related to hemorrhoids, cryptitis, ischemia, intramuscular abscess, anal fissures, rectoceles, malignancy, and inflammation. Some urogenital abnormalities and chronic benign prostatitis can produce similar symptoms.",
"   </p>",
"   <p>",
"    Testing to exclude other conditions generally includes colonoscopy or flexible sigmoidoscopy. Other testing that may be considered includes endoanal ultrasound, magnetic resonance imaging, gynecologic examination, and urologic examination. Additional testing is particularly important in patients who do not fulfill the Rome III criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Distinction from chronic proctalgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of functional anorectal pain also need to be considered. The Rome III criteria define proctalgia fugax as a separate disorder from chronic proctalgia (also referred to as levator ani syndrome, levator spasm, puborectalis syndrome, piriformis syndrome, or pelvic tension myalgia) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients with chronic proctalgia describe a vague, dull ache or pressure sensation high in the rectum, often worse with sitting than with standing or lying down. The typical pain is elicited during puborectalis palpation with predominantly left-sided pain.",
"   </p>",
"   <p>",
"    Diagnostic criteria for chronic proctalgia include all of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic or recurrent rectal pain or aching",
"     </li>",
"     <li>",
"      Episodes last at least 20 minutes",
"     </li>",
"     <li>",
"      Exclusion of other causes of rectal pain such as ischemia, inflammatory bowel disease, cryptitis, intramuscular abscess and fissure, hemorrhoids, prostatitis, and coccygodynia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria should be fulfilled for the past three months with symptom onset at least six months prior to diagnosis. Diagnostic testing is similar to proctalgia fugax.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients, symptomatic episodes are brief and infrequent, requiring no specific treatment other than reassurance and explanation of the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/7,27\">",
"     7,27",
"    </a>",
"    ]. On the other hand, a small percentage of patients have more frequent and troubling symptoms. There are limited data to guide treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3385389\">",
"    <span class=\"h2\">",
"     Warm water",
"    </span>",
"    &nbsp;&mdash;&nbsp;Water at 40 degrees celsius reduces resting anal canal pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/29\">",
"     29",
"    </a>",
"    ], so hot baths and warm water enemas have been employed in patients requiring therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/25,30,31\">",
"     25,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3384977\">",
"    <span class=\"h2\">",
"     Topical treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/9,32,33\">",
"     9,32,33",
"    </a>",
"    ] or antispasmodics [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/9,34\">",
"     9,34",
"    </a>",
"    ] has been used. In one report, a female patient was instructed to apply a small amount of nitroglycerine to the external anal region as needed for rectal pain. At two weeks, three months, and six months, she reported 100 percent relief. However, she experienced one near-syncopal episode.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3385076\">",
"    <span class=\"h2\">",
"     Oral and intravenous treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral treatments that have been tried include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/18,20\">",
"     18,20",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/35\">",
"     35",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/36\">",
"     36",
"    </a>",
"    ]. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    has also been tried. In a case report, a single dose of low-dose of intravenous lidocaine brought lasting relief to a 28-year-old man who had previously had recurrent symptoms for eight months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3385084\">",
"    <span class=\"h2\">",
"     Inhaled treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled beta agonists have also been studied for proctalgia fugax. In a randomized trial, 18 patients were randomly assigned (in a crossover design) to inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/38\">",
"     38",
"    </a>",
"    ]. Albuterol treatment was associated with a significant reduction in the duration of severe pain. The effect was most pronounced in patients who had prolonged attacks. However, the mechanism of benefit was unclear since albuterol had no significant effect on anal resting tone, sphincter relaxation, or rectal compliance while patients were asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3385092\">",
"    <span class=\"h2\">",
"     Invasive treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive treatments that have been tried for severe proctalgia fugax include botulinum toxin injection, pudendal nerve blocks, and superior hypogastric plexus blocks. There is little evidence to support the use of internal anal sphincterotomy, except as a treatment for constipation (but not pain) in patients with the inherited form of proctalgia fugax [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/19,39\">",
"     19,39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3384790\">",
"     'Muscle spasm/hypertrophy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an uncontrolled study, symptoms resolved in 55 of 68 patients following pudendal nerve block [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38633?source=see_link&amp;anchor=H24#H24\">",
"       \"Pharmacologic management of pain during labor and delivery\", section on 'Pudendal nerve block'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a case report, a female patient with a one-year history of severe anal pain was treated with 5 units (0.2 mL) of botulinum toxin injected into four sites [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/40\">",
"       40",
"      </a>",
"      ]. At one-week, one-month, and two-month re-evaluations she reported 100 percent relief of anal pain and denied incontinence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3385224\">",
"    <span class=\"h2\">",
"     Psychologic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of concomitant psychological dysfunction may also be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Approach to management",
"    </strong>",
"    &mdash; One set of authors has proposed the following approach to managing patients with suspected proctalgia fugax [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most patients with mild symptoms, reassurance and explanation are sufficient",
"     </li>",
"     <li>",
"      For patients who require treatment, warm baths can be tried as a first step",
"     </li>",
"     <li>",
"      If after three months symptoms persist, attempt topical treatment with nitroglycerine (0.2%) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      (2%) as needed",
"     </li>",
"     <li>",
"      Patients failing topical treatment can try inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      200 mcg as needed",
"     </li>",
"     <li>",
"      Warm water enemas, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      (150 mcg twice daily), local anesthetic blocks, or botulinum toxin injection can be attempted in patients failing other treatments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proctalgia fugax is a sudden, severe pain in the anorectal region that lasts several seconds or minutes, and then resolves completely. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathology of proctalgia fugax previously was thought to be located either in the external anal sphincter or the voluntary striated muscles of the anorectum [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16118/abstract/10,17\">",
"       10,17",
"      </a>",
"      ], but newer theories have focused on the smooth muscle of the internal anal sphincter. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of proctalgia fugax is based upon clinical grounds in the absence of anorectal disease that could cause rectal pain. Diagnostic clinical criteria are recurrent episodes of anal or lower rectal pain, lasting from seconds to minutes, without anorectal pain between episodes. Alternative diagnoses need to be excluded with colonoscopy or flexible sigmoidoscopy and in some cases, other testing. (See",
"      <a class=\"local\" href=\"#H25442501\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic proctalgia is a separate disorder and presents with a vague, dull ache or pressure sensation high in the rectum, often worse with sitting than with standing or lying down. Pain episodes last at least 20 minutes and the typical pain is elicited during puborectalis palpation with predominantly left-sided pain. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients require no specific treatment other than reassurance and explanation of the disorder. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients requiring treatment there are limited data. Warm baths are a nonpharmacologic intervention that may be helpful. Inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      has been shown to relieve pain in a controlled study. Other possible treatments reported include: pudendal nerve block, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      , botulinum toxin injection, intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      , and psychotherapy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We gratefully acknowledge the generous contribution of the Carter Charitable Trust Foundation, which made preparation of this manuscript possible.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/1\">",
"      Thompson WG, Heaton KW. Proctalgia fugax. J R Coll Physicians Lond 1980; 14:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/2\">",
"      Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/3\">",
"      Whitehead WE, Wald A, Diamant NE, et al. Functional disorders of the anus and rectum. Gut 1999; 45 Suppl 2:II55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/4\">",
"      IBRAHIM H. Proctalgia fugax. Gut 1961; 2:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/5\">",
"      Boyce PM, Talley NJ, Burke C, Koloski NA. Epidemiology of the functional gastrointestinal disorders diagnosed according to Rome II criteria: an Australian population-based study. Intern Med J 2006; 36:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/6\">",
"      Thompson WG. Proctalgia fugax in patients with the irritable bowel, peptic ulcer, or inflammatory bowel disease. Am J Gastroenterol 1984; 79:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/7\">",
"      Bharucha AE, Wald A, Enck P, Rao S. Functional anorectal disorders. Gastroenterology 2006; 130:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/8\">",
"      EWING MR. Proctalgia fugax. Br Med J 1953; 1:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/9\">",
"      KARRAS JD, ANGELO G. Proctalgia fugax. Am J Surg 1951; 82:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/10\">",
"      DOUTHWAITE AH. Proctalgia fugax. Br Med J 1962; 2:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/11\">",
"      Eckardt VF, Dodt O, Kanzler G, Bernhard G. Anorectal function and morphology in patients with sporadic proctalgia fugax. Dis Colon Rectum 1996; 39:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/12\">",
"      Takano M. Proctalgia fugax: caused by pudendal neuropathy? Dis Colon Rectum 2005; 48:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/13\">",
"      Gracia Solanas JA, Ram&iacute;rez Rodr&iacute;guez JM, El&iacute;a Guedea M, et al. Sequential treatment for proctalgia fugax. Mid-term follow-up. Rev Esp Enferm Dig 2005; 97:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/14\">",
"      de Parades V, Etienney I, Bauer P, et al. Proctalgia fugax: demographic and clinical characteristics. What every doctor should know from a prospective study of 54 patients. Dis Colon Rectum 2007; 50:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/15\">",
"      Pilling LF, Swenson WM, Hill JR. The psychologic aspects of proctalgia fugax. Dis Colon Rectum 1965; 8:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/16\">",
"      Harvey RF. Colonic motility in proctalgia fugax. Lancet 1979; 2:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/17\">",
"      Smith RN. Proctalgia fugax. Lancet 1935; 2:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/18\">",
"      Rao SS, Hatfield RA. Paroxysmal anal hyperkinesis: a characteristic feature of proctalgia fugax. Gut 1996; 39:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/19\">",
"      Kamm MA, Hoyle CH, Burleigh DE, et al. Hereditary internal anal sphincter myopathy causing proctalgia fugax and constipation. A newly identified condition. Gastroenterology 1991; 100:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/20\">",
"      Celik AF, Katsinelos P, Read NW, et al. Hereditary proctalgia fugax and constipation: report of a second family. Gut 1995; 36:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/21\">",
"      Shafik A. Pudendal canal syndrome and proctalgia fugax. Dis Colon Rectum 1997; 40:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/22\">",
"      Salas LR, Whitehead WE, Schuster MM. Psychological symptoms in patients with levator ani and proctalgia fugax (abstract). Gastroenterology 1992; 102:508A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/23\">",
"      Whitehead WE, Bosmajian L, Zonderman AB, et al. Symptoms of psychologic distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples. Gastroenterology 1988; 95:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/24\">",
"      Thompson WG. Proctalgia fugax. Dig Dis Sci 1981; 26:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/25\">",
"      Potter MA, Bartolo DC. Proctalgia fugax. Eur J Gastroenterol Hepatol 2001; 13:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/26\">",
"      Wald A. Functional anorectal and pelvic pain. Gastroenterol Clin North Am 2001; 30:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/27\">",
"      Atkin GK, Suliman A, Vaizey CJ. Patient characteristics and treatment outcome in functional anorectal pain. Dis Colon Rectum 2011; 54:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/28\">",
"      Lacy BE, Weiser K. Common anorectal disorders: diagnosis and treatment. Curr Gastroenterol Rep 2009; 11:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/29\">",
"      Dodi G, Bogoni F, Infantino A, et al. Hot or cold in anal pain? A study of the changes in internal anal sphincter pressure profiles. Dis Colon Rectum 1986; 29:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/30\">",
"      Olsen B. Proctalgia fugax--a nightmare drowned in enema. Colorectal Dis 2008; 10:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/31\">",
"      Penny RW. The doctor's disease--proctalgia fugax. Practitioner 1970; 204:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/32\">",
"      Lowenstein B, Cataldo PA. Treatment of proctalgia fugax with topical nitroglycerin: report of a case. Dis Colon Rectum 1998; 41:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/33\">",
"      Clayton MR. Therapy for proctodynia. Med J Aust 1985; 143:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/34\">",
"      Schuster MM. Constipation and anorectal disorders. Clin Gastroenterol 1977; 6:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/35\">",
"      Boquet J, Moore N, Lhuintre JP, Boismare F. Diltiazem for proctalgia fugax. Lancet 1986; 1:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/36\">",
"      Swain R. Oral clonidine for proctalgia fugax. Gut 1987; 28:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/37\">",
"      Peleg R, Shvartzman P. Low-dose intravenous lidocaine as treatment for proctalgia fugax. Reg Anesth Pain Med 2002; 27:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/38\">",
"      Eckardt VF, Dodt O, Kanzler G, Bernhard G. Treatment of proctalgia fugax with salbutamol inhalation. Am J Gastroenterol 1996; 91:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/39\">",
"      Guy RJ, Kamm MA, Martin JE. Internal anal sphincter myopathy causing proctalgia fugax and constipation: further clinical and radiological characterization in a patient. Eur J Gastroenterol Hepatol 1997; 9:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/40\">",
"      Katsinelos P, Kalomenopoulou M, Christodoulou K, et al. Treatment of proctalgia fugax with botulinum A toxin. Eur J Gastroenterol Hepatol 2001; 13:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16118/abstract/41\">",
"      Jeyarajah S, Chow A, Ziprin P, et al. Proctalgia fugax, an evidence-based management pathway. Int J Colorectal Dis 2010; 25:1037.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2590 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-93025ABAAB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_47_16118=[""].join("\n");
var outline_f15_47_16118=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3384790\">",
"      Muscle spasm/hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3384844\">",
"      Nerve compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Psychologic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25442501\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Distinction from chronic proctalgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3385389\">",
"      Warm water",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3384977\">",
"      Topical treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3385076\">",
"      Oral and intravenous treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3385084\">",
"      Inhaled treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3385092\">",
"      Invasive treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3385224\">",
"      Psychologic treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34181?source=related_link\">",
"      Anal fissure: Clinical manifestations, diagnosis, prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38762?source=related_link\">",
"      Clinical features, staging, and treatment of anal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=related_link\">",
"      Clinical manifestations and diagnosis of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=related_link\">",
"      Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5348?source=related_link\">",
"      Overview of hemorrhoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26246?source=related_link\">",
"      Perianal abscess: Clinical manifestations, diagnosis, treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=related_link\">",
"      Perianal complications of Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38633?source=related_link\">",
"      Pharmacologic management of pain during labor and delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_47_16119="Arsenic trioxide: Drug information";
var content_f15_47_16119=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Arsenic trioxide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/32/25092?source=see_link\">",
"    see \"Arsenic trioxide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/1/24598?source=see_link\">",
"    see \"Arsenic trioxide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F136731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Trisenox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F136750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F136733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      APL, relapsed or refractory:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Induction:",
"     </i>",
"     0.15 mg/kg/day; administer daily until bone marrow remission; maximum induction: 60 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Consolidation:",
"     </i>",
"     0.15 mg/kg/day starting 3-6 weeks after completion of induction therapy; maximum consolidation: 25 doses over a period of up to 5 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      APL initial treatment (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Induction, consolidation, and maintenance (Mathews, 2006):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Induction: 10 mg/day; administer daily until bone marrow remission; maximum induction: 60 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Consolidation: 10 mg/day for 4 weeks, starting 4 weeks after completion of induction therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance: 10 mg/dose administered 10 days per month for 6 months, starting 4 weeks after completion of consolidation therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Consolidation therapy after remission induction with tretinoin, daunorubicin and cytarabine (Powell, 2007; Powell, 2010):",
"     </i>",
"     Two consolidation courses (2 weeks apart): 0.15 mg/kg/day 5 days/week for 5 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      In combination with tretinoin (Estey, 2006; Ravandi, 2009):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Induction (beginning 10 days after initiation of tretinoin): 0.15 mg/kg/day until bone marrow remission; maximum induction: 75 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Consolidation: 0.15 mg/kg/day Monday through Friday for 4 weeks every 8 weeks for 4 cycles (weeks 1 to 4, 9 to 12, 17 to 20, and 25 to 28)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      MDS (unlabeled uses):",
"     </b>",
"     I.V.: 0.25 mg/kg/day 5 consecutive days/week for 2 weeks, followed by a 2-week rest period (Schiller, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F136746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/1/24598?source=see_link\">",
"      see \"Arsenic trioxide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      APL, relapsed or refractory:",
"     </b>",
"     I.V.: Children &ge;4 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      APL initial treatment (unlabeled use):",
"     </b>",
"     I.V.:",
"     <i>",
"      Induction, consolidation, and maintenance (Mathews, 2006):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Induction: 0.15 mg/kg/day (maximum dose: 10 mg); administer daily until bone marrow remission; maximum induction: 60 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Consolidation: 0.15 mg/kg/day (maximum dose: 10 mg) for 4 weeks, starting 4 weeks after completion of induction therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: 0.15 mg/kg/dose (maximum dose: 10 mg) administered 10 days per month for 6 months, starting 4 weeks after completion of consolidation therapy",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F136735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): Use with caution (systemic exposure to metabolites may be higher); may require dosage reduction; monitor closely for toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dialysis patients: Has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F136736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic impairment: Use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe hepatic impairment (Child-Pugh class C): Monitor closely for toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F136716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trisenox&reg;: 1 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F136702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F136718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer as I.V. infusion over 1-2 hours. If acute vasomotor reactions occur, infuse over a maximum of 4 hours. Does not require administration via a central venous catheter.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F136717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Remission induction and consolidation in patients with relapsed or refractory acute promyelocytic leukemia (APL) characterized by t(15;17) translocation or PML/RAR-alpha gene expression",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5132459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial treatment of APL, treatment of myelodysplastic syndrome (MDS)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F136748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia (55%), edema (40%), QT interval &gt;500 msec (40%), chest pain (25%; grades 3/4: 5%), hypotension (25%; grades 3/4: 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (63%), fever (63%), headache (60%), insomnia (43%), anxiety (30%), dizziness (23%), depression (20%), pain (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dermatitis (43%), pruritus (33%), bruising (20%), dry skin (15%), erythema (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia (50%; grades 3/4: 13%), hyperglycemia (45%; grades 3/4: 13%), hypomagnesemia (45%; grades 3/4: 13%), hyperkalemia (18%; grades 3/4: 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (75%), abdominal pain (58%), vomiting (58%), diarrhea (53%), sore throat (35%), constipation (28%), anorexia (23%), appetite decreased (15%), weight gain (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginal hemorrhage (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukocytosis (50%; grades 3/4: 3%), APL differentiation syndrome (23%; grades 3/4: 8%), anemia (20%; grades 3/4: 5%), thrombocytopenia (18%; grades 3/4: 13%), febrile neutropenia (13%; grades 3/4: 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (20%; grades 3/4: 5%), AST increased (13%; grades 3/4: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site: Pain (20%), erythema (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Rigors (38%), arthralgia (33%), paresthesia (33%), myalgia (25%), bone pain (23%), back pain (18%), limb pain (13%), neck pain (13%), tremor (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (65%), dyspnea (53%; grades 3/4: 10%), epistaxis (25%), hypoxia (23%), pleural effusion (20%), sinusitis (20%), postnasal drip (13%), upper respiratory tract infection (13%), wheezing (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Herpes simplex (13%), diaphoresis (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (10%), flushing (10%), pallor (10%), palpitation (10%), facial edema (8%), abnormal ECG (not QT prolongation) (8%), atrial dysrhythmia (5%), torsade de pointes (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Seizure (8%; grades 3/4: 5%), somnolence (8%), agitation (5%), coma (5%), confusion (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Hyperpigmentation (8%), petechia (8%), skin lesions (8%), urticaria (8%), local exfoliation (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypocalcemia (10%), hypoglycemia (8%), intermenstrual bleeding (8%), acidosis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (10%), loose stools (10%), abdominal distension (8%), abdominal tenderness (8%), caecitis (children: 8%), fecal incontinence (8%), gastrointestinal hemorrhage (8%), hemorrhagic diarrhea (8%), oral blistering (8%), weight loss (8%), xerostomia (8%), oral candidiasis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Incontinence (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (10%; grades 3/4: 10%), DIC (8%), hemorrhage (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site edema (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (10%), eye irritation (10%), dry eye (8%), eyelid edema (5%), painful red eye (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Earache (8%), tinnitus (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal failure (8%; grades 3/4: 3%), renal impairment (8%), oliguria (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Breath sounds decreased (10%), crepitations (10%), rales (10%), hemoptysis (8%), pulmonary edema (children: 8%), rhonchi (8%), tachypnea (8%), nasopharyngitis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Bacterial infection (8%), herpes zoster (8%), lymphadenopathy (8%), night sweats (8%), hypersensitivity (5%), sepsis (5%; grades 3/4: 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute respiratory distress syndrome, AV block, capillary leak syndrome, CHF, heart block, hypoalbuminemia, hyponatremia, hypophosphatemia, lipase increased, mitochondrial myopathy, pancytopenia, peripheral neuropathy, pneumonitis, pulmonary infiltrate, respiratory distress, stomatitis, ventricular extrasystoles, ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F136721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to arsenic or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F136706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; APL differentiation syndrome:",
"     <b>",
"      [U.S. Boxed Warning]: May cause APL differentiation syndrome (formerly called retinoic-acid-APL [RA-APL] syndrome) in patients with APL,",
"     </b>",
"     which is characterized by dyspnea, fever, weight gain, pulmonary infiltrates, and pleural or pericardial effusions. May be fatal. High-dose steroids (dexamethasone 10 mg I.V. twice daily for &ge;3 days; begin at initial presentation) have been used for treatment; in general, most patients may continue arsenic trioxide during treatment of APL differentiation syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperleukocytosis: May lead to the development of hyperleukocytosis (leukocytes &ge;10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ). Hyperleukocytosis did not correlate with baseline WBC counts In general, WBC counts were not as high during consolidation as observed during induction treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolongation:",
"     <b>",
"      [U.S. Boxed Warning]: May prolong the QT interval. May lead to torsade de pointes or complete AV block.",
"     </b>",
"     Risk factors for torsade de pointes include extent of prolongation, HF, a history of torsade de pointes, pre-existing QT interval prolongation, patients taking medications know to prolong the QT interval or potassium-wasting diuretics, and conditions which cause hypokalemia or hypomagnesemia. If possible, discontinue all medications known to prolong the QT interval. If baseline QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;500 msec, correct prior to treatment. If QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;500 msec during treatment, reassess, correct contributing factors, and consider temporarily withholding treatment. If syncope or irregular heartbeat develop during therapy, hospitalize patient and do not reinitiate until QT",
"     <sub>",
"      c",
"     </sub>",
"     &lt;460 msec, electrolyte abnormalities are corrected and syncope/irregular heartbeat has resolved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalances: Correct electrolyte abnormalities prior to treatment and monitor potassium and magnesium levels during therapy (maintain potassium &gt;4 mEq/dL and magnesium &gt;1.8 mg/dL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; in patients with severe hepatic impairment, monitor closely for toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment; systemic exposure to metabolites may be higher. Has not been studied in dialysis patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring recommendations:",
"     <b>",
"      [U.S. Boxed Warning]: A baseline 12-lead ECG, serum electrolytes (potassium, calcium, magnesium), and creatinine should be obtained prior to treatment.",
"     </b>",
"     Monitor ECG weekly; more frequently if clinically indicated. Monitor electrolytes, CBC with differential, and coagulation parameters at least twice a week during induction and weekly during consolidation; more frequently if clinically indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of a physician experienced in acute leukemia management.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F136710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F136728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid homeopathic products (arsenic is present in some homeopathic medications). Avoid hypoglycemic herbs, including alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng, gymnema, marshmallow, and stinging nettle (may enhance the hypoglycemic effect of arsenic trioxide).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F136712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F136723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increased resorptions, neural-tube defects, and ophthalmic abnormalities have been observed in animal studies. Arsenic crosses the human placenta. In studies of women exposed to high levels of arsenic from drinking water, cord blood levels were similar to maternal serum levels. Dimethylarsinic acid (DMA) was the form of arsenic found in the fetus. An increased risk of low birth weight and still births were observed in women who ingested high levels of dietary arsenic. Women of childbearing potential should avoid pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F136741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5132460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Arsenic is naturally found in breast milk; concentrations range from 0.2-6 mcg/kg. In studies of women exposed to high levels of arsenic from drinking water, breast milk concentrations were low (~3.1 mcg/kg) and did not correlate with maternal serum levels. The possible effect of maternal arsenic trioxide therapy on breast milk concentrations is not known. Due to the potential for serious adverse reactions in a nursing infant, breast-feeding during therapy is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Trisenox Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/10 mL (10 mL): $564.48",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F136714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline then weekly 12-lead ECG; monitor electrolytes, CBC with differential, and coagulation at baseline then at least twice weekly during induction and at least weekly during consolidation; more frequent monitoring may be necessary in unstable patients",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Asadin (TW);",
"     </li>",
"     <li>",
"      Trisenox (AT, BE, BG, CH, CZ, DE, DK, ES, FI, FR, GB, GR, HN, IE, IL, IT, JP, NL, NO, PT, RU, SE, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F136705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induces apoptosis in APL cells via morphological changes and DNA fragmentation; also damages or degrades the fusion protein PML-RAR alpha",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F136720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : As",
"     <sup>",
"      III",
"     </sup>",
"     : 562 L; widely distributed throughout body tissues; orally administered arsenic trioxide distributes into the CNS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Arsenic trioxide is immediately hydrolyzed to the active form, arsenious acid (As",
"     <sup>",
"      III",
"     </sup>",
"     ) which is methylated (hepatically) to the less active pentavalent metabolites, monomethylarsonic acid (MMA",
"     <sup>",
"      v",
"     </sup>",
"     ) and dimethylarsinic acid (DMA",
"     <sup>",
"      v",
"     </sup>",
"     ) by methyltransferases; As",
"     <sup>",
"      III",
"     </sup>",
"     is also oxidized to the minor metabolite, arsenic acid (As",
"     <sup>",
"      v",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: AS",
"     <sup>",
"      III",
"     </sup>",
"     : 10-14 hours; MMA",
"     <sup>",
"      v",
"     </sup>",
"     : ~32 hours; DMA",
"     <sup>",
"      v",
"     </sup>",
"     : ~72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: As",
"     <sup>",
"      III",
"     </sup>",
"     : At the end of infusion; MMA",
"     <sup>",
"      v",
"     </sup>",
"     and DMA",
"     <sup>",
"      v",
"     </sup>",
"     ; ~10-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (MMA",
"     <sup>",
"      v",
"     </sup>",
"     ,  DMA",
"     <sup>",
"      v",
"     </sup>",
"     , and 15% of a dose as unchanged As",
"     <sup>",
"      III",
"     </sup>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Au WY, Tam S, Fong BM, et al, &ldquo;Determinants of Cerebrospinal Fluid Arsenic Concentration in Patients With Acute Promyelocytic Leukemia on Oral Arsenic Trioxide Therapy,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(9):3587-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16119/abstract-text/18703707/pubmed\" id=\"18703707\" target=\"_blank\">",
"        18703707",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Concha G, Vogler G, Lezcano D, et al, &ldquo;Exposure to Inorganic Arsenic Metabolites During Early Human Development,&rdquo;",
"      <i>",
"       Toxicol Sci",
"      </i>",
"      , 1998, 44(2):185-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16119/abstract-text/9742656/pubmed\" id=\"9742656\" target=\"_blank\">",
"        9742656",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Echaniz-Laguna A, Benoilid A, Vinzio S, et al, \"Mitochondrial Myopathy Caused by Arsenic Trioxide Therapy,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2012, 119(18):4272-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16119/abstract-text/22427206/pubmed\" id=\"22427206\" target=\"_blank\">",
"        22427206",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Estey E, Garcia-Manero G, Ferrajoli A, et al, &ldquo;Use of All-Trans Retinoic Acid Plus Arsenic Trioxide as an Alternative to Chemotherapy in Untreated Acute Promyelocytic Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 107(9):3469-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16119/abstract-text/16373661/pubmed\" id=\"16373661\" target=\"_blank\">",
"        16373661",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fox E, Razzouk BI, Widemann BC, et al, &ldquo;Phase 1 Trial and Pharmacokinetic Study of Arsenic Trioxide in Children and Adolescents With Refractory or Relapsed Acute Leukemia, Including Acute Promyelocytic Leukemia or Lymphoma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(2):566-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16119/abstract-text/17959855/pubmed\" id=\"17959855\" target=\"_blank\">",
"        17959855",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gore SD, Gojo I, Sekeres MA, et al, &ldquo;Single Cycle of Arsenic Trioxide-Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      ,  2010, 28(6):1047-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16119/abstract-text/20085935/pubmed\" id=\"20085935\" target=\"_blank\">",
"        20085935",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of  Medicine),",
"      <i>",
"       Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc",
"      </i>",
"      , Washington, DC: National Academy Press, 2001, 162-84.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mathews V, George B, Chendamarai E, et al, &ldquo;Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(24):3866-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16119/abstract-text/20644086/pubmed\" id=\"20644086\" target=\"_blank\">",
"        20644086",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mathews V, George B, Lakshmi KM, et al, &ldquo;Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Durable Remissions With Minimal Toxicity,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 107(7):2627-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16119/abstract-text/16352810/pubmed\" id=\"16352810\" target=\"_blank\">",
"        16352810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 3, 2010.&rdquo; Available at file://www.nccn.org/professionals/physician_gls/PDF/aml.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Powell BL, Moser B, Stock W, et al, &ldquo;Arsenic Trioxide Improves Event-Free and Over-All Survival for Adults With Acute Promyelocytic Leukemia: North American Leukemia Intergroup Study C9710,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(19):3751-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16119/abstract-text/20705755/pubmed\" id=\"20705755\" target=\"_blank\">",
"        20705755",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Powell BL, Moser B, Stock W, et al, &ldquo;Effect of Consolidation With Arsenic Trioxide (As2O3) on Event-Free Survival (EFS) and Overall Survival (OS) Among Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL): North American Intergroup Protocol C9710,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(18s):2 [abstract 2 from 2007 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ravandi F, Estey E, Jones D, et al, &ldquo;Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(4):504-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16119/abstract-text/19075265/pubmed\" id=\"19075265\" target=\"_blank\">",
"        19075265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schiller GJ, Slack J, Hainsworth JD, et al, &ldquo;Phase II Multicenter Study of Arsenic Trioxide in Patients With Myelodysplastic Syndromes,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(16):2456-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16119/abstract-text/16651647/pubmed\" id=\"16651647\" target=\"_blank\">",
"        16651647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shen ZX, Chen GQ, Ni JH, et al, &ldquo;Use of Arsenic Trioxide (As2O3) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1997, 89(9):3354-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16119/abstract-text/9129042/pubmed\" id=\"9129042\" target=\"_blank\">",
"        9129042",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Soignet SL, Frankel SR, Douer D, et al, &ldquo;United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(18):3852-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16119/abstract-text/11559723/pubmed\" id=\"11559723\" target=\"_blank\">",
"        11559723",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tallman MS and Altman JK, &ldquo;How I Treat Acute Promyelocytic Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 114(25):5126-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16119/abstract-text/19797519/pubmed\" id=\"19797519\" target=\"_blank\">",
"        19797519",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vey N, Bosly A, Guerci A, et al, &ldquo;Arsenic Trioxide in Patients With Myelodysplastic Syndromes: A Phase II Multicenter Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(16):2465-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16119/abstract-text/16651646/pubmed\" id=\"16651646\" target=\"_blank\">",
"        16651646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Von Ehrenstein OS, Guha Mazumder DN, Hira-Smith M, et al,  &ldquo;Pregnancy Outcomes, Infant Mortality, and Arsenic in Drinking Water in West Bengal, India,&rdquo;",
"      <i>",
"       Am J Epidemiol",
"      </i>",
"      , 2006,163(7):662-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16119/abstract-text/16651647/pubmed\" id=\"16651647\" target=\"_blank\">",
"        16651647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yang CY, Chang CC, Tsai SS, et al, &ldquo;Arsenic in Drinking Water and Adverse Pregnancy Outcome in an Arseniasis-Endemic Area in Northeastern Taiwan,&rdquo;",
"      <i>",
"       Environ Res",
"      </i>",
"      , 2003, 91(1):29-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/47/16119/abstract-text/12550085/pubmed\" id=\"12550085\" target=\"_blank\">",
"        12550085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8977 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_47_16119=[""].join("\n");
var outline_f15_47_16119=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708626\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136731\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136750\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136733\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136746\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136735\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136736\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136716\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136702\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136718\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136717\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5132459\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401582\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136748\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136721\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136706\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298770\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136710\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136728\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136712\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136723\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136741\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5132460\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323000\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136714\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539820\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136705\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136720\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8977\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8977|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/32/25092?source=related_link\">",
"      Arsenic trioxide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/1/24598?source=related_link\">",
"      Arsenic trioxide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_47_16120="Approach to the adult with nausea and vomiting";
var content_f15_47_16120=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the adult with nausea and vomiting",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/47/16120/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/47/16120/contributors\">",
"     George F Longstreth, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/47/16120/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/47/16120/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/47/16120/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/47/16120/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/47/16120/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea, the unpleasant sensation of being about to vomit, can occur alone or can accompany vomiting (the forceful expulsion of gastric contents), dyspepsia, or other gastrointestinal symptoms. Retching differs from vomiting in the absence of expulsion of gastric content. In addition, patients may confuse vomiting with regurgitation, which is the return of esophageal contents to the hypopharynx with little effort [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommendations made in this topic are generally consistent with the American Gastroenterological Association (AGA) guidelines for nausea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/2\">",
"     2",
"    </a>",
"    ]. The pathophysiology of nausea and vomiting and the overall approach to the patient with these symptoms will be reviewed here. The prevention and treatment of chemotherapy-induced nausea and vomiting and characteristics of antiemetic drugs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19208?source=see_link\">",
"     \"Characteristics of antiemetic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal function of the upper gastrointestinal tract involves an interaction between the gut and the central nervous system. The motor function of the gut is controlled at three main levels: the parasympathetic and sympathetic nervous systems; enteric brain neurons; and smooth muscle cells (",
"    <a class=\"graphic graphic_figure graphicRef55162 \" href=\"UTD.htm?0/51/817\">",
"     figure 1",
"    </a>",
"    ). A discussion of the anatomy and physiology of gastric motor function is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14312?source=see_link\">",
"     \"Pathogenesis of delayed gastric emptying\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nausea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies that produce motion sickness in humans indicate how some of the physiologic interactions can cause nausea [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In one report, for example, gastric myoelectrical activity and endogenous neuroendocrine responses were compared in subjects with and without motion sickness elicited by vection (induced by rotating a drum with black and white vertical stripes around seated stationary subjects) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/3\">",
"     3",
"    </a>",
"    ]. Thirteen subjects developed tachygastria (an increase in gastric slow wave rhythm) and motion sickness during vection, while nine maintained normal gastric rhythms and remained symptom-free. Nausea followed within minutes of and was proportional to the degree of tachygastria. Anticipatory increases in plasma cortisol and beta endorphin occurred in subjects who developed nausea and gastric tachyarrhythmias; endogenous epinephrine and norepinephrine concentrations were also increased in these subjects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vomiting is a reflex that allows an animal to rid itself of ingested toxins or poisons. It can be activated by humoral or neuronal stimuli, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/5\">",
"     5",
"    </a>",
"    ]. Multiple afferent and efferent pathways exist which induce vomiting; the following are the major components of these pathways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The area postrema in the floor of the fourth ventricle which contains a \"chemoreceptor trigger zone\" that is sensitive to many humoral factors, including neurotransmitters, peptides, drugs, and toxins.",
"     </li>",
"     <li>",
"      An area in the medulla known as the nucleus tractus solitarius (NTS) which may serve as a central pattern generator for vomiting; information from humoral factors via the area postrema and visceral afferents via the vagus nerve may converge at this site [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The central pattern generator presumably projects to the various motor nuclei to elicit the sequential excitation and inhibition that controls the vomiting reflex.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vagal afferent nerves from the gastrointestinal tract synapse in the NTS. From there, some neurons extend to the area postrema; other neurons from the NTS ascend to the paraventricular nuclei of the hypothalamus and the limbic and cortical regions, where gastric electromechanical events are perceived as normal sensations or symptoms such as nausea or discomfort. Afferent sympathetic neurons mediating nociceptive stimuli synapse in the spinal cord and ascend to brainstem nuclei and the hypothalamus, where vasopressin (antidiuretic hormone) and corticotropin releasing factor can be released (",
"    <a class=\"graphic graphic_figure graphicRef52708 \" href=\"UTD.htm?17/3/17459\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Studies of vomiting in dogs reveal that gastric content is expelled as a result of gastric and lower esophageal sphincter relaxation, retrograde contraction in the proximal small bowel and antrum, abdominal muscle contraction, and initial cricopharyngeus contraction followed by relaxation seconds before vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/6\">",
"     6",
"    </a>",
"    ]. Retching occurs when the glottis closes and respiratory muscles counteract abdominal muscle contraction to prevent the expulsion of gastric content.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     APPROACH TO MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, the following three steps should be considered in patients with persistent nausea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The etiology should be sought, taking into account whether the patient has acute nausea and vomiting or chronic symptoms (at least one month in duration) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The consequences or complications of nausea and vomiting (eg, fluid depletion, hypokalemia, and metabolic alkalosis) should be identified and corrected.",
"     </li>",
"     <li>",
"      Targeted therapy should be provided, when possible (eg, surgery for bowel obstruction or malignancy). In other cases, the symptoms should be treated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558191189\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial careful history and physical examination should be performed. In most cases, the cause of the nausea and vomiting can be determined from the history and physical examination and additional testing is not required [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. If additional testing is needed, it should be guided by the symptom duration, frequency, and severity, as well as the characteristics of vomiting episodes and associated symptoms.",
"   </p>",
"   <p>",
"    The following clinical features are especially important:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal pain with vomiting often indicates an organic etiology (eg, cholelithiasis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abdominal distension and tenderness suggest bowel obstruction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=see_link\">",
"       \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/50/22311?source=see_link\">",
"       \"Acute colonic pseudo-obstruction (Ogilvie's syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vomiting of food eaten several hours earlier and a succussion splash detected on abdominal examination suggest gastric obstruction or gastroparesis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link\">",
"       \"Etiology and diagnosis of delayed gastric emptying\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44793?source=see_link\">",
"       \"Gastric outlet obstruction in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Heartburn with nausea often indicates gastroesophageal reflux disease (GERD), and GERD can present as chronic nausea without typical reflux symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=see_link\">",
"       \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Early morning vomiting is characteristic of pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=see_link\">",
"       \"Clinical manifestations and diagnosis of early pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Feculent vomiting suggests intestinal obstruction or a gastrocolic fistula. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=see_link\">",
"       \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/50/22311?source=see_link\">",
"       \"Acute colonic pseudo-obstruction (Ogilvie's syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vertigo and nystagmus are typical of vestibular neuritis and other causes of vertigo. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35062?source=see_link\">",
"       \"Vestibular neuritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17001?source=see_link\">",
"       \"Pathophysiology, etiology, and differential diagnosis of vertigo\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bulimia is associated with dental enamel erosion, parotid gland enlargement, lanugo-like hair, and calluses on the dorsal surface of the hand [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"       \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neurogenic vomiting may be positional, projectile, and is usually associated with other neurologic signs or symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link\">",
"       \"Clinical presentation and diagnosis of brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic dyspepsia often overlaps with nausea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/11\">",
"     11",
"    </a>",
"    ]. Most patients with chronic nausea and vomiting that is unexplained after routine evaluation should undergo esophagogastroduodenoscopy to identify disorders that should have specific therapy.",
"   </p>",
"   <p>",
"    However, endoscopy and other routine tests are often normal, suggesting an idiopathic (functional) etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=see_link\">",
"     \"Functional dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558191174\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders associated with nausea and vomiting are listed in following table (",
"    <a class=\"graphic graphic_table graphicRef78422 \" href=\"UTD.htm?42/41/43678\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SPECIFIC DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acute disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Acute gastroenteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute gastroenteritis is second only to the common cold as a cause of lost productivity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/12\">",
"     12",
"    </a>",
"    ]. Bacterial, viral, and parasitic pathogens cause this illness which is characterized by diarrhea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting. Vomiting is especially common with infections caused by rotaviruses, enteric adenovirus, and norovirus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6313?source=see_link\">",
"     \"Epidemiology of viral gastroenteritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory testing usually is unnecessary in adults with domestically acquired illness. In one study, there was no association between abnormal laboratory results and the requirement for intravenous hydration, antibiotic treatment for a positive stool culture, or hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/13\">",
"     13",
"    </a>",
"    ]. Stool cultures had higher yields in patients with fever or diarrhea of more than two days' duration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Postoperative nausea and vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;About one-third of surgical patients have nausea, vomiting or both after receiving general anesthesia. Risk factors include female sex, nonsmoker status, previous history of postoperative nausea and vomiting or motion sickness, and unanticipated use of postoperative opioids. Most research has been directed toward prevention rather than therapy of established symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/14\">",
"     14",
"    </a>",
"    ]. In a large trial, intravenous doses of 1.25 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    and 4 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    within 20 minutes after the start of anesthesia or 4 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    during the last 20 minutes of surgery each reduced postoperative nausea and vomiting by about 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/14\">",
"     14",
"    </a>",
"    ]. Combining drugs had an additive effect, and the combination of droperidol and dexamethasone was more beneficial than ondansetron.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Vestibular neuritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;This acute labyrinthine disorder is characterized by rapid onset of severe vertigo with nausea, vomiting and gait instability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35062?source=see_link\">",
"     \"Vestibular neuritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Patients receiving chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea and vomiting are common side effects of cancer chemotherapy. Anticipatory antiemetic therapy is indicated when highly emetogenic chemotherapy regimens are given. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple drugs are associated with nausea and thus a careful medication history is mandatory. The history should include non-prescription drugs. Use of marijuana has been associated with recurrent vomiting with features similar to cyclic vomiting syndrome. Compulsive bathing behavior may be a clue to identifying cannabinoid hyperemesis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34568?source=see_link\">",
"     \"Cyclic vomiting syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Chronic disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Nausea and vomiting of pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 70 to 85 percent of pregnant women suffer nausea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting; 50 percent have both nausea and vomiting, and 25 percent have nausea only. Risk factors include increased placental mass (eg, advanced molar gestation, multiple gestation), family history of hyperemesis gravidarum or a personal history of the disorder in a previous pregnancy, female fetus, and a history of motion sickness or migraine headaches.",
"   </p>",
"   <p>",
"    This disorder nearly always begins within the first nine weeks of pregnancy; onset after the initial nine weeks should direct especially careful evaluation for another cause within the differential diagnosis of nausea and vomiting in nonpregnant patients. The diagnosis of hyperemesis gravidarum is applied to the most severely affected patients, approximately 0.5 to 2 percent of pregnancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41207?source=see_link\">",
"     \"Clinical features and evaluation of nausea and vomiting of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Functional nausea and vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with functional gastroduodenal disorders have nausea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/11,17\">",
"     11,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=see_link\">",
"     \"Functional dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Gastroparesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea may be a feature of gastroparesis but there is a poor correlation among symptoms, gastric dysrhythmias, and gastric emptying rate. Gastric motor dysfunction can be identified by special tests (such as gastric scintigraphy) in a large proportion of these patients. A noninvasive method of recording gastric myoelectrical activity or slow waves from cutaneous leads placed over the stomach (electrogastrography) reveals abnormalities in some patients. There is no evidence that correction of these abnormalities improves symptoms; thus, the role of this procedure in management is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link\">",
"     \"Etiology and diagnosis of delayed gastric emptying\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link\">",
"     \"Treatment of delayed gastric emptying\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Gastroesophageal reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea can occasionally be the presenting symptom of gastroesophageal reflux disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Gastric outlet obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyloric stenosis can occur from malignancy or peptic ulcer disease. Inflammatory edema associated with ulcers may respond to acid suppression therapy and nasogastric suction. However, fibrotic strictures may persist after ulcer healing. Treatment of benign fibrotic strictures can be accomplished surgically or endoscopically. The endoscopic approach is the least invasive; however, there is a risk of perforation and recurrence is common after long-term follow-up if the natural history of the underlying ulcer disease is not altered. Conversely, one study revealed that all 23 patients whose obstruction related to peptic ulcer disease was treated with endoscopic dilation, removal of inciting factors, and gastric suppression, had long-term symptom remission [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/19\">",
"     19",
"    </a>",
"    ]. Endoscopic dilation may be most appropriate for patients at high risk for surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40282?source=see_link\">",
"     \"Overview of the complications of peptic ulcer disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44793?source=see_link\">",
"     \"Gastric outlet obstruction in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Eosinophilic gastroenteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign eosinophilic infiltration of the gut is uncommon, but its diagnosis is especially important as steroid therapy is usually effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=see_link\">",
"     \"Eosinophilic gastroenteritis\"",
"    </a>",
"    .) The disease can occur from the esophagus to the colon, and the symptoms depend upon the extent and layer(s) of bowel involved. Gastric mucosal disease is typically associated with nausea and vomiting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=see_link\">",
"     \"Eosinophilic gastroenteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Cyclic vomiting syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclic vomiting syndrome is characterized by repeated episodes of nausea and vomiting that last for hours to days and are separated by symptom-free periods of variable length [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/20\">",
"     20",
"    </a>",
"    ]. It has been most often described in children in whom symptoms often begin in the early school years and stop spontaneously at puberty. In adults, the disorder consists of episodes of nausea and vomiting lasting for three to six days in a patient-specific stereotypic pattern. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34568?source=see_link\">",
"     \"Cyclic vomiting syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Chronic idiopathic intestinal pseudo-obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic intestinal pseudo-obstruction is usually secondary to an underlying disorder affecting neuromuscular function that suggests mechanical bowel obstruction of the small or large bowel in the absence of an anatomic lesion that obstructs the flow of intestinal contents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/26/2474?source=see_link\">",
"     \"Chronic intestinal pseudo-obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Rumination syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rumination syndrome is a behavioral disorder that is most commonly identified among mentally-disadvantaged children, although it is increasingly recognized among adolescents and adults of normal mental capacity. The behavior consists of daily, effortless regurgitation of undigested food within minutes of starting or completing ingestion of a meal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link&amp;anchor=H12#H12\">",
"     \"Etiology and diagnosis of delayed gastric emptying\", section on 'Rumination syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various therapies, including drugs, gastric electrical stimulation, and surgery, have been used in the treatment of nausea and vomiting. Dietary interventions and the treatment of hypovolemia are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of delayed gastric emptying\", section on 'Dietary modifications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=see_link\">",
"     \"Maintenance and replacement fluid therapy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few high quality therapeutic trials have compared the efficacy of different drugs in specified types of nausea and vomiting. As a result, treatment is often based upon clinical experience, costs, and safety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558191836\">",
"    <span class=\"h3\">",
"     Antiemetics and prokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute or chronic nausea and vomiting can often be helped by antiemetic or prokinetic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/21\">",
"     21",
"    </a>",
"    ]. The antiemetic drug therapy generally recommended varies according to the etiology (",
"    <a class=\"graphic graphic_table graphicRef78749 \" href=\"UTD.htm?5/10/5292\">",
"     table 2",
"    </a>",
"    ). The efficacy of the available prokinetic drugs is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19208?source=see_link\">",
"     \"Characteristics of antiemetic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"       Prochlorperazine",
"      </a>",
"      is an antiemetic that often partially alleviates acute nausea and vomiting (eg, acute gastroenteritis), but is associated with risks of hypotension and extrapyramidal side effects. Prochlorperazine should usually be considered in such cases before trying serotonin receptor antagonists or prokinetic drugs.",
"     </li>",
"     <li>",
"      The dopamine receptor antagonist,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      , has combined antiemetic and prokinetic properties. However, it can be associated with extrapyramidal side effects. It can be given orally or intravenously. When given intravenously, using a slow infusion over 15 minutes is associated with a lower incidence of akathisia compared with bolus dosing, without a decrease in efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/22\">",
"       22",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Another dopamine antagonist,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"       domperidone",
"      </a>",
"      , penetrates the blood-brain barrier poorly. As a result, anxiety and dystonia are much less common than with metoclopramide. Domperidone is not approved for use in the United States. However, the Food and Drug Administration has encouraged \"physicians who would like to prescribe domperidone for their patients with severe gastrointestinal disorders that are refractory to standard therapy to open an Investigational New Drug Application.\" The FDA domperidone investigational new drug section can be contacted at DomperidoneIND@fda.hhs.gov. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of delayed gastric emptying\", section on 'Domperidone'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Agents with mainly prokinetic properties include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      (motilin receptor agonist) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25476?source=see_link\">",
"       bethanechol",
"      </a>",
"      (muscarinic receptor agonist).",
"      <br/>",
"      <br/>",
"      Erythromycin has a narrow therapeutic window, above which abdominal pain and nausea are common. Thus, it can improve gastric emptying without improving nausea. A systematic review of published clinical trials of oral erythromycin therapy for various types of gastroparesis revealed that all studies were methodologically weak and that improvement occurred in fewer than 50 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/23\">",
"       23",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The side effects of bethanechol are similar to those of erythromycin, and trial data are even more limited.",
"     </li>",
"     <li>",
"      The serotonin antagonists form the cornerstone of therapy for the control of acute emesis with chemotherapy agents and can also be used or other causes of nausea and vomiting (",
"      <a class=\"graphic graphic_table graphicRef78749 \" href=\"UTD.htm?5/10/5292\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19208?source=see_link&amp;anchor=H8#H8\">",
"       \"Characteristics of antiemetic drugs\", section on 'Serotonin receptor antagonists'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link&amp;anchor=H4#H4\">",
"       \"Prevention and treatment of chemotherapy-induced nausea and vomiting\", section on '5-HT3 receptor antagonists'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558191844\">",
"    <span class=\"h3\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients have chronic functional nausea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting that does not fit the pattern of cyclic vomiting syndrome or other disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/11,17\">",
"     11,17",
"    </a>",
"    ]. Antinausea drugs are usually ineffective in such patients. Particular attention should be directed to potential psychosocial factors, which should be addressed, if present. There are few data on psychotherapy or low-dose antidepressant therapy in these patients but a trial of such therapy can be considered based upon the efficacy of these approaches in patients with other functional gastrointestinal disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Gastric electrical stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric electrical stimulation via implanted electrodes has been applied to highly selected patients with gastroparesis that is refractory to conventional therapy. A device is available in the United States for humanitarian use, and open-label studies in patients with gastroparesis of various etiologies have found benefit. However, results of controlled trials are less convincing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31574?source=see_link\">",
"     \"Electrical stimulation for gastroparesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrostomy, jejunostomy, and gastrectomy have been performed in patients with postsurgical, diabetic, and idiopathic gastroparesis, but the reports were uncontrolled, unblinded, and retrospective, and the benefit was unconvincing, except possibly for completion gastrectomy in patients with postsurgical gastroparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16120/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=see_link\">",
"       \"Patient information: Nausea and vomiting in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       \"Patient information: Upper endoscopy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/42/30370?source=see_link\">",
"       \"Patient information: Motion sickness (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"       \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nausea, the unpleasant sensation of being about to vomit, can occur alone or can accompany vomiting (the forceful expulsion of gastric contents), dyspepsia, or other gastrointestinal symptoms. Retching differs from vomiting in the absence of expulsion of gastric content. In addition, patients may confuse vomiting with regurgitation, which is the return of esophageal contents to the hypopharynx with little effort. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The consequences or complications of nausea and vomiting (eg, fluid depletion, hypokalemia, and metabolic alkalosis) should be identified and corrected.",
"     </li>",
"     <li>",
"      The etiology should be sought. A variety of disorders can produce nausea with or without vomiting (",
"      <a class=\"graphic graphic_table graphicRef78422 \" href=\"UTD.htm?42/41/43678\">",
"       table 1",
"      </a>",
"      ). The diverse differential diagnosis of nausea and vomiting should be approached initially with a careful history and physical examination. In most cases, the cause of the nausea and vomiting can be determined from the history and physical examination and additional testing is not required (eg, in a patient with a history and examination suggestive of gastroenteritis). (See",
"      <a class=\"local\" href=\"#H558191189\">",
"       'History and physical examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H558191174\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Testing should be guided by the symptom duration, frequency, and severity, as well as the characteristics of vomiting episodes and associated symptoms. (See",
"      <a class=\"local\" href=\"#H558191189\">",
"       'History and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with chronic nausea and vomiting that is unexplained should undergo esophagogastroduodenoscopy to identify disorders that should have specific therapy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Endoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Targeted therapy should be provided, when possible (eg, surgery for bowel obstruction or malignancy). In other cases symptoms should be treated. Few high-quality therapeutic trials have compared the efficacy of different drugs in specified types of nausea and vomiting. However, acute or chronic nausea and vomiting may be helped by antiemetic or prokinetic drugs depending upon the underlying cause. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/1\">",
"      Hasler WL, Chey WD. Nausea and vomiting. Gastroenterology 2003; 125:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/2\">",
"      American Gastroenterological Association. American Gastroenterological Association medical position statement: nausea and vomiting. Gastroenterology 2001; 120:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/3\">",
"      Koch KL, Stern RM, Vasey MW, et al. Neuroendocrine and gastric myoelectrical responses to illusory self-motion in humans. Am J Physiol 1990; 258:E304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/4\">",
"      Xu LH, Koch KL, Summy-Long J, et al. Hypothalamic and gastric myoelectrical responses during vection-induced nausea in healthy Chinese subjects. Am J Physiol 1993; 265:E578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/5\">",
"      Carpenter DO. Neural mechanisms of emesis. Can J Physiol Pharmacol 1990; 68:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/6\">",
"      Lang IM, Sarna SK, Dodds WJ. Pharyngeal, esophageal, and proximal gastric responses associated with vomiting. Am J Physiol 1993; 265:G963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/7\">",
"      Metz A, Hebbard G. Nausea and vomiting in adults--a diagnostic approach. Aust Fam Physician 2007; 36:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/8\">",
"      Scorza K, Williams A, Phillips JD, Shaw J. Evaluation of nausea and vomiting. Am Fam Physician 2007; 76:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/9\">",
"      Brzana RJ, Koch KL. Gastroesophageal reflux disease presenting with intractable nausea. Ann Intern Med 1997; 126:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/10\">",
"      Carney CP, Andersen AE. Eating disorders. Guide to medical evaluation and complications. Psychiatr Clin North Am 1996; 19:657.",
"     </a>",
"    </li>",
"    <li>",
"     Tack J, Talley NJ, Camilleri M, et al. Functional gastrointestinal disorders. In: Rome III, The Functional Gastrointestinal Disorders, 3rd ed, Drossman DA, et al (Eds), Degnon Associates, McLean, VA 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/12\">",
"      Moffet HL. Common infections in ambulatory patients. Ann Intern Med 1978; 89:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/13\">",
"      Carmeli Y, Samore M, Shoshany O, et al. Utility of clinical symptoms versus laboratory tests for evaluation of acute gastroenteritis. Dig Dis Sci 1996; 41:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/14\">",
"      Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004; 350:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/15\">",
"      Sullivan S. Cannabinoid hyperemesis. Can J Gastroenterol 2010; 24:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/16\">",
"      Soriano-Co M, Batke M, Cappell MS. The cannabis hyperemesis syndrome characterized by persistent nausea and vomiting, abdominal pain, and compulsive bathing associated with chronic marijuana use: a report of eight cases in the United States. Dig Dis Sci 2010; 55:3113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/17\">",
"      Olden KW, Chepyala P. Functional nausea and vomiting. Nat Clin Pract Gastroenterol Hepatol 2008; 5:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/18\">",
"      Parkman HP, Hasler WL, Barnett JL, et al. Electrogastrography: a document prepared by the gastric section of the American Motility Society Clinical GI Motility Testing Task Force. Neurogastroenterol Motil 2003; 15:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/19\">",
"      Cherian PT, Cherian S, Singh P. Long-term follow-up of patients with gastric outlet obstruction related to peptic ulcer disease treated with endoscopic balloon dilatation and drug therapy. Gastrointest Endosc 2007; 66:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/20\">",
"      Hejazi RA, McCallum RW. Review article: cyclic vomiting syndrome in adults--rediscovering and redefining an old entity. Aliment Pharmacol Ther 2011; 34:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/21\">",
"      Flake ZA, Scalley RD, Bailey AG. Practical selection of antiemetics. Am Fam Physician 2004; 69:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/22\">",
"      Tura P, Erdur B, Aydin B, et al. Slow infusion metoclopramide does not affect the improvement rate of nausea while reducing akathisia and sedation incidence. Emerg Med J 2012; 29:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/23\">",
"      Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol 2003; 98:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16120/abstract/24\">",
"      Jones MP, Maganti K. A systematic review of surgical therapy for gastroparesis. Am J Gastroenterol 2003; 98:2122.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2537 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-E943584887-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_47_16120=[""].join("\n");
var outline_f15_47_16120=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nausea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      APPROACH TO MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H558191189\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H558191174\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SPECIFIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acute disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Acute gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Postoperative nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Vestibular neuritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Patients receiving chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Chronic disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Nausea and vomiting of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Functional nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Gastroparesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Gastroesophageal reflux",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Gastric outlet obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Eosinophilic gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Cyclic vomiting syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Chronic idiopathic intestinal pseudo-obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Rumination syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Drug therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H558191836\">",
"      - Antiemetics and prokinetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H558191844\">",
"      - Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Gastric electrical stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2537\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2537|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/51/817\" title=\"figure 1\">",
"      Control of gastric motility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/3/17459\" title=\"figure 2\">",
"      Neuromuscular disorders impairing gastric motor function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2537|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/41/43678\" title=\"table 1\">",
"      Differential dx of nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/10/5292\" title=\"table 2\">",
"      Antiemetics by etiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/50/22311?source=related_link\">",
"      Acute colonic pseudo-obstruction (Ogilvie's syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19208?source=related_link\">",
"      Characteristics of antiemetic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/26/2474?source=related_link\">",
"      Chronic intestinal pseudo-obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41207?source=related_link\">",
"      Clinical features and evaluation of nausea and vomiting of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=related_link\">",
"      Clinical manifestations and diagnosis of early pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34568?source=related_link\">",
"      Cyclic vomiting syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31574?source=related_link\">",
"      Electrical stimulation for gastroparesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=related_link\">",
"      Eosinophilic gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6313?source=related_link\">",
"      Epidemiology of viral gastroenteritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=related_link\">",
"      Etiology and diagnosis of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=related_link\">",
"      Functional dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44793?source=related_link\">",
"      Gastric outlet obstruction in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40282?source=related_link\">",
"      Overview of the complications of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14312?source=related_link\">",
"      Pathogenesis of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17001?source=related_link\">",
"      Pathophysiology, etiology, and differential diagnosis of vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/42/30370?source=related_link\">",
"      Patient information: Motion sickness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=related_link\">",
"      Patient information: Nausea and vomiting in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=related_link\">",
"      Small bowel obstruction: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=related_link\">",
"      Treatment of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35062?source=related_link\">",
"      Vestibular neuritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_47_16121="Treatment and outcome of bacterial meningitis in the neonate";
var content_f15_47_16121=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and outcome of bacterial meningitis in the neonate",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/47/16121/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/47/16121/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/47/16121/contributors\">",
"     Carol J Baker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/47/16121/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/47/16121/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/47/16121/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/47/16121/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/47/16121/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/47/16121/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial meningitis is more common in the first month than at any other time of life [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/1\">",
"     1",
"    </a>",
"    ]. Despite advances in infant intensive care, neonatal meningitis remains a devastating disease.",
"   </p>",
"   <p>",
"    The mortality rate has declined from almost 50 percent in the 1970s to contemporary rates of less than 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. However, morbidity from neonatal meningitis is relatively unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/6\">",
"     6",
"    </a>",
"    ]. Survivors remain at high risk for neurologic sequelae and lifelong impairment as a result of infectious insult to their developing brains [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment and outcome of bacterial meningitis in the neonate (age &lt;1 month) will be discussed here. The clinical features, diagnosis, and complications are discussed separately, as is bacterial meningitis in older children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7928?source=see_link\">",
"     \"Clinical features and diagnosis of bacterial meningitis in the neonate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in the neonate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=see_link\">",
"     \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31656?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial care for all neonates with meningitis should be provided in an intensive care setting. Although there are no data to quantify the impact, adequate oxygenation, prevention of hypoglycemia, effective anticonvulsant therapy, control of intracranial hypertension, and prevention of fluctuations in cerebral blood flow are considered crucial parts of the management of neonates with bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/7\">",
"     7",
"    </a>",
"    ]. Details of fluid management, electrolyte balance, administration of inotropic agents, maintenance of airway and ventilatory support, as well as control of seizure activity, are best undertaken in the neonatal intensive care unit. The treatment of neonatal seizures is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/13?source=see_link\">",
"     \"Treatment of neonatal seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate broad spectrum antimicrobial therapy with agents that have adequate cerebrospinal (CSF) penetration is indicated if the initial cerebrospinal fluid evaluation is suggestive of bacterial meningitis (eg, organism present on Gram-stained smear, increased CSF white blood cell count, increased CSF protein, decreased CSF glucose) and should be initiated as soon as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/8\">",
"     8",
"    </a>",
"    ]. Empirical therapy for nonbacterial infections also can be indicated for some neonates pending definitive evaluation (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"     acyclovir",
"    </a>",
"    for herpes simplex virus in neonates who have mucocutaneous vesicles or clinical or CSF findings suggesting herpes simplex virus). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7928?source=see_link\">",
"     \"Clinical features and diagnosis of bacterial meningitis in the neonate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=see_link&amp;anchor=H4#H4\">",
"     \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the results of the CSF and blood cultures, including antimicrobial susceptibilities, are available, antimicrobial therapy is adjusted as indicated. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Specific therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Empirical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial choice of antimicrobials for suspected bacterial meningitis in the neonate is based on the infant's age, likely pathogens, and the susceptibility patterns of gram-negative organisms causing late-onset infections in infants with continuous care in a particular nursery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7928?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of bacterial meningitis in the neonate\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In neonates zero through three days of age, the most common bacterial pathogens are group B streptococcus (GBS),",
"      <em>",
"       Escherichia coli",
"      </em>",
"      , other enteric bacilli, and",
"      <em>",
"       Listeria monocytogenes",
"      </em>",
"      . Uncommon pathogens include other streptococci, including groups A, C, or G, viridans streptococci and enterococci, non-typeable",
"      <em>",
"       Haemophilus influenzae",
"      </em>",
"      ,",
"      <em>",
"       Neisseria meningitidis",
"      </em>",
"      , and",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"      .",
"     </li>",
"     <li>",
"      In neonates four days of age or older, other gram-negative organisms must be considered in addition to GBS,",
"      <em>",
"       E. coli",
"      </em>",
"      , and other enterics, including",
"      <em>",
"       Serratia marcescens",
"      </em>",
"      ,",
"      <em>",
"       Pseudomonas aeruginosa",
"      </em>",
"      , and",
"      <em>",
"       Citrobacter koseri",
"      </em>",
"      , as well as",
"      <em>",
"       L. monocytogenes",
"      </em>",
"      .",
"     </li>",
"     <li>",
"      In continuously hospitalized neonates seven days of age or older, a wide range of potential gram-positive organisms must be considered in addition to antimicrobial-resistant gram-negative organisms, such as",
"      <em>",
"       Acinetobacter",
"      </em>",
"      ,",
"      <em>",
"       Stenotrophomonas",
"      </em>",
"      , multiple-drug-resistant",
"      <em>",
"       Klebsiella",
"      </em>",
"      , and other enterics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Early-onset",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial empirical therapy for suspected bacterial meningitis within the first three to six days of age is",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       ampicillin",
"      </a>",
"      and an aminoglycoside, usually",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      An alternative regimen of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       ampicillin",
"      </a>",
"      and an expanded spectrum third-generation cephalosporin (such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      ) can be used if",
"      <em>",
"       L. monocytogenes",
"      </em>",
"      or enterococci are unlikely. High rates of ampicillin resistance among",
"      <em>",
"       E. coli",
"      </em>",
"      isolates and a link between maternal intrapartum ampicillin and",
"      <em>",
"       E. coli",
"      </em>",
"      resistance have been reported, but only in very low-birth-weight (LBW) infants (birth weight &lt;1500 g) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/9\">",
"       9",
"      </a>",
"      ]. However, rapid emergence of cephalosporin-resistant strains, especially",
"      <em>",
"       Enterobacter cloacae",
"      </em>",
"      ,",
"      <em>",
"       Klebsiella pneumoniae",
"      </em>",
"      , and",
"      <em>",
"       Serratia",
"      </em>",
"      species, can occur when use of cefotaxime is routine [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When meningitis resulting from a gram-negative organism is strongly suspected, for example when the CSF Gram stain reveals gram-negative bacilli, the empirical regimen of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       ampicillin",
"      </a>",
"      and an aminoglycoside should be expanded to include",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Late-onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial empirical therapy for suspected bacterial meningitis after the first week of life depends upon the preliminary CSF findings (particularly the Gram stain) and whether the neonate remains hospitalized or has been discharged from the hospital.",
"   </p>",
"   <p>",
"    In the non-hospitalized neonate who has CSF findings consistent with bacterial meningitis, broad-spectrum therapy should be continued pending confirmation of the organism and susceptibility results, since Gram stain results are subject to observer misinterpretation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Specific therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the non-hospitalized neonate who is strongly suspected to have bacterial meningitis, but whose CSF parameters are not immediately available or not entirely consistent with bacterial meningitis (eg, negative Gram stain),",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    &nbsp;",
"    <strong>",
"     plus",
"    </strong>",
"    an aminoglycoside",
"    <strong>",
"     plus",
"    </strong>",
"    &nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    should be initiated. In one survey of febrile infants younger than 90 days who presented to an emergency center, nearly 80 percent of infants with meningitis had ampicillin-resistant pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/12\">",
"     12",
"    </a>",
"    ]. The authors recommended that the initial regimen contain ampicillin and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    plus a third-generation cephalosporin because of the risk of GBS and",
"    <em>",
"     L. monocytogenes",
"    </em>",
"    infection in this age group, as well as for treatment of cefotaxime-susceptible gram-negative enteric organisms.",
"   </p>",
"   <p>",
"    Late-onset sepsis",
"    <strong>",
"     without",
"    </strong>",
"    meningitis in neonates who remain hospitalized is treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    and an aminoglycoside. When lumbar puncture suggests meningitis,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    should be added to provide an extended spectrum for gram-negative enterics and for optimal activity in the CSF against pneumococci.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     Ampicillin",
"    </a>",
"    should be added to a vancomycin-aminoglycoside regimen if GBS or",
"    <em>",
"     L. monocytogenes",
"    </em>",
"    is suspected (eg, on the basis of the Gram stain), because vancomycin concentrations in the CSF are not bactericidal for these organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Specific therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the causative agent and its in vitro antimicrobial susceptibility pattern are known, empirical antimicrobial therapy should be altered accordingly. Guidelines for the treatment of the most common causative organisms of neonatal meningitis are provided below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Group B streptococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;GBS is uniformly susceptible to penicillin and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    . The combination of penicillin or ampicillin plus an aminoglycoside should be employed until sterility of the bloodstream and CSF has been documented. This recommendation is based on the improved in vitro synergy and in vivo efficacy in animal models of infection when these combinations are compared with penicillin or ampicillin alone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/14-20\">",
"     14-20",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/46/14054?source=see_link\">",
"     Penicillin G",
"    </a>",
"    monotherapy should be given when clinical and microbiologic responses have been documented to complete a 14- to 21-day course of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=see_link&amp;anchor=H27#H27\">",
"     \"Group B streptococcal infection in neonates and young infants\", section on 'Antimicrobial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose for penicillin varies depending upon the age of the neonate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants &le;7 days of age: 250,000 to 450,000",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      per day intravenously (IV) divided every eight hours",
"     </li>",
"     <li>",
"      Infants &gt;7 days of age: 450,000 to 500,000",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      per day IV divided every six hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dose for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    varies depending upon the age of the neonate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants &le;7 days: 200 to 300",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV divided every eight hours",
"     </li>",
"     <li>",
"      Infants &gt;7 days: 300 to 400",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV divided every six hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Gram-negative enteric bacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     Ampicillin",
"    </a>",
"    is the antimicrobial of choice for neonatal meningitis resulting from ampicillin-susceptible strains of",
"    <em>",
"     E. coli",
"    </em>",
"    .",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     Ampicillin",
"    </a>",
"    -resistant",
"    <em>",
"     E. coli",
"    </em>",
"    and other gram-negative organisms usually are treated with a combination of an expanded-spectrum cephalosporin, generally",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    (or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=see_link\">",
"     ceftazidime",
"    </a>",
"    in the case of",
"    <em>",
"     P. aeruginosa",
"    </em>",
"    ) in combination with an aminoglycoside, usually",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    . Once sterility of the CSF is documented, the combination is continued for 7 to 14 days. Thereafter, cefotaxime alone is used to complete a minimum of 21 days or 14 days of therapy after the CSF is sterile, whichever is longer.",
"   </p>",
"   <p>",
"    The prevalence of antimicrobial resistance among",
"    <em>",
"     K. pneumoniae",
"    </em>",
"    has increased markedly since the 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/21\">",
"     21",
"    </a>",
"    ]. The hospital microbiology laboratory should provide assistance for appropriate testing of gram-negative organisms for multidrug-resistant (MDR) patterns.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"     Meropenem",
"    </a>",
"    is recommended for treatment of infections caused by most MDR enteric organisms. Although there are limited data documenting the optimal dose and tolerance of meropenem in neonates, meropenem should be administered for the entire course of therapy for neonates with meningitis that is caused by MDR gram-negative organisms.",
"   </p>",
"   <p>",
"    For infants &gt;3 months of age, the dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"     meropenem",
"    </a>",
"    is 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 8 hours. Meropenem is not approved for use in infants &lt;3 months of age. However, when there are no other treatment options, we use a dose of 20 to 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 8 to 12 hours, with the lower dose for infants with renal impairment or immaturity of renal function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Listeria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    is more effective than ampicillin alone in vitro and in animal models of infection, and it is appropriate for initial therapy. When the CSF has been sterilized and the infant has improved clinically, a 14-day course of treatment can be completed with ampicillin monotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment, prognosis, and prevention of Listeria monocytogenes infection\", section on 'Antibiotic regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Coagulase-negative staphylococci",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     Vancomycin",
"    </a>",
"    is the antimicrobial of choice for proven meningitis caused by coagulase-negative staphylococci. These organisms rarely invade the meninges except as a complication of bacteremia accompanying intraventricular hemorrhage in very LBW infants (birth weight &lt;1500 g) or as a result of surgical manipulations or placement of a ventriculoperitoneal shunt. Such infections invariably are of late onset.",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    is 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose; the dosing interval varies depending upon gestational age as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &lt;30 weeks' gestation: every 18 hours",
"     </li>",
"     <li>",
"      30 to 37 weeks' gestation: every 12 hours",
"     </li>",
"     <li>",
"      &gt;37 weeks' gestation: every 8 hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sterilization of the CSF usually is achieved promptly after initiation of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    . If the CSF is persistently positive, consideration should be given to adding",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours) to vancomycin for synergy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Positive CSF culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antimicrobial therapy depends upon the causative organism and the clinical course:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 14-day course is sufficient for neonates with uncomplicated GBS meningitis and for meningitis caused by other gram-positive organisms, such as",
"      <em>",
"       L. monocytogenes",
"      </em>",
"      or",
"      <em>",
"       Enterococcus",
"      </em>",
"     </li>",
"     <li>",
"      A longer course of therapy is required for neonates with GBS meningitis who have a complicated course (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=see_link\">",
"       \"Neurologic complications of bacterial meningitis in the neonate\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A 21-day course is the",
"      <strong>",
"       minimum",
"      </strong>",
"      for neonates with meningitis resulting from",
"      <em>",
"       E. coli",
"      </em>",
"      or other gram-negative pathogens [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prolonged treatment, sometimes for as long as eight weeks, may be required for neonates with ventriculitis, abscesses, or multiple areas of infarction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=see_link\">",
"       \"Neurologic complications of bacterial meningitis in the neonate\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Negative CSF culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antibiotic therapy for neonates with negative cultures must be determined on an individual clinical basis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For neonates with suspected but unproven bacterial meningitis, we usually suggest discontinuation of antimicrobials after 48 to 72 hours of negative CSF culture",
"     </li>",
"     <li>",
"      For neonates with CSF pleocytosis and bacteremia, but a negative CSF culture, we usually continue meningeal doses of antimicrobial therapy for 10 days for gram-positive bacteremia (ie, GBS) and 14 days for gram-negative bacteremia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The administration of antibiotics for several hours or days before CSF evaluation may result in negative CSF culture, but other CSF parameters, such as the cell count and protein concentration, will be sufficiently abnormal to permit accurate diagnosis of meningitis if it is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7928?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical features and diagnosis of bacterial meningitis in the neonate\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For neonates in whom the CSF evaluation was delayed because of clinical instability, meningeal doses of antimicrobial therapy should be continued until the lumbar puncture can be safely performed. The total duration of therapy depends upon the CSF evaluation and blood culture result:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Those who have a CSF pleocytosis and positive blood culture are treated as described above",
"     </li>",
"     <li>",
"      For those who have a CSF pleocytosis and negative blood culture, we individualize the duration of meningitic doses of antimicrobial therapy based on clinical parameters and likelihood that there is a noninfectious explanation for the pleocytosis (such as intraventricular hemorrhage)",
"     </li>",
"     <li>",
"      For those who have a normal CSF profile, and negative blood and CSF culture, we usually discontinue antimicrobial therapy when these cultures are sterile after 48 to 72 hours of incubation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with infants whose mothers did not receive intrapartum antibiotic prophylaxis (IAP), infants whose mothers did receive IAP are more likely to be healthy-appearing, less likely to be critically ill, and less likely to be infected [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/23\">",
"       23",
"      </a>",
"      ]. Neonates whose mothers received IAP and have a clinical course that suggests neonatal sepsis or meningitis are treated in the same manner as infants with proven sepsis or meningitis.",
"     </li>",
"     <li>",
"      Neonates who are receiving prophylactic antibiotics at the time of CSF evaluation (eg, for vesicoureteral reflux) are treated in the same manner as infants in whom the CSF evaluation was delayed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence from experimental models that immune modulation may positively impact the outcome of neonatal meningitis. However, none of the modalities investigated thus far has been sufficiently characterized for their use to be included in the routine management of neonatal meningitis.",
"   </p>",
"   <p>",
"    The effect of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    to diminish the risk of neurologic sequelae in neonatal meningitis was evaluated in a small, randomized trial that did not have a placebo arm [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/24\">",
"     24",
"    </a>",
"    ]. The administration of dexamethasone did not significantly affect mortality or neurologic outcome at two years of age, and dexamethasone therapy is not currently recommended.",
"   </p>",
"   <p>",
"    Adjunctive therapies for neonatal sepsis, which is a prelude to neonatal meningitis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26200?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment and outcome of sepsis in term and late preterm infants\", section on 'Adjunctive therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MONITORING RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to antimicrobial and supportive therapy and the potential development of complications are monitored clinically through repeat neurologic evaluations, evaluation of the cerebrospinal fluid (CSF), and by neuroimaging. In bacteremic infants, a blood culture should be performed to document sterility of the blood stream. The follow-up blood culture is usually obtained when it is known that the initial blood culture is positive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Repeat lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar puncture should be repeated routinely at 24 to 48 hours after initiation of antimicrobial therapy to document CSF sterilization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/11,22\">",
"     11,22",
"    </a>",
"    ]. Gram-positive bacteria usually clear rapidly (within 24 to 48 hours) from the CSF after initiation of appropriate antimicrobial therapy, whereas gram-negative may persist for several days in severe cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reevaluation of the CSF 24 to 48 hours after initiation of antimicrobial therapy is important for several reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/22,27\">",
"     22,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delayed sterilization of the CSF is associated with an increased risk of developing neurologic sequelae [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/26,28,29\">",
"       26,28,29",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Prognostic factors'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      The persistent identification of organisms on a Gram-stained smear may be an early indication of inadequacy of antimicrobial therapy (eg, the organism is not susceptible to the concentration of antibiotic that is attained in the CSF) (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Coagulase-negative staphylococci'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Persistence of viable organisms more than 48 hours after initiation of antimicrobial therapy is an indication for diagnostic neuroimaging because it can indicate a purulent focus (eg, obstructive ventriculitis, multiple small vessel thrombi) that can require additional intervention or increased duration of antimicrobial therapy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=see_link\">",
"       \"Neurologic complications of bacterial meningitis in the neonate\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sterilization of the CSF is a criterion for discontinuing combination therapy for some pathogens (eg, GBS,",
"      <em>",
"       Listeria",
"      </em>",
"      ) (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Specific therapy'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In uncomplicated neonatal meningitis, the CSF culture obtained 24 to 48 hours after initiation of therapy is sterile. If there is just a colony or two, it is appropriate to obtain a third CSF culture when it is known that the second is positive (ie, after an additional 24 to 48 hours). However, as indicated above, a positive culture obtained 24 to 48 hours after initiation of therapy with more than one or two colonies raises a concern for ventriculitis. The additional evaluation and management of infants with possible ventriculitis is individualized and should be undertaken in consultation with specialists in pediatric infectious diseases and pediatric neurosurgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=see_link&amp;anchor=H3#H3\">",
"     \"Neurologic complications of bacterial meningitis in the neonate\", section on 'Ventriculitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging is indicated to assist in defining the potential complications of neonatal meningitis and typically is performed late in the course of therapy to provide the best prognostic information. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in the neonate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, it is our practice, even in neonates with an apparently uncomplicated course of neonatal bacterial meningitis, to obtain a neuroimaging study 48 to 72 hours before the anticipated end of therapy. Magnetic resonance imaging (MRI) or contrast-enhanced computed tomography (CT) is performed; MRI provides added detail compared with CT scan and optimizes assessment of injury to white matter [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/30\">",
"     30",
"    </a>",
"    ]. If there are focal findings that require extension of the course of antimicrobial therapy, treatment can be continued without interruption.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cranial sonography &ndash; Early in the course of infection, cranial sonography is the most useful and practical neuroimaging technique. It is most helpful for assessing ventricular size and the presence of intraventricular hemorrhage. Cranial sonography also can demonstrate ventriculitis, echogenic sulci, abnormal parenchymal echogenicities, and extracerebral fluid collections [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. In addition, because sonography can be performed at the bedside, it can be useful in defining the progression of complications in infants with prolonged seizure activity or focal neurologic deficits. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=see_link\">",
"       \"Neurologic complications of bacterial meningitis in the neonate\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Computed tomography or magnetic resonance imaging &ndash; Similar to ultrasonography, early in the treatment course, CT with contrast enhancement and MRI can demonstrate the degree of cerebral edema, obstruction to CSF flow, infarction, abscess, and subdural fluid collections [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/33\">",
"       33",
"      </a>",
"      ]. Later in the treatment course, contrast-enhanced CT or MRI is useful in detecting cerebral abscesses, persistent cerebritis, areas of infarct or encephalomalacia, and degree of cerebral cortical and white matter atrophy. These findings may influence duration of antimicrobial therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the need for early intervention services. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=see_link\">",
"       \"Neurologic complications of bacterial meningitis in the neonate\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Contrast-enhanced neuroimaging (CT or MRI) is integral to the care of all neonates with meningitis caused by organisms that have a propensity for formation of intracranial abscesses. These include",
"    <em>",
"     Citrobacter",
"    </em>",
"    species,",
"    <em>",
"     S. marcescens",
"    </em>",
"    ,",
"    <em>",
"     Proteus mirabilis",
"    </em>",
"    , and",
"    <em>",
"     Enterobacter sakazakii",
"    </em>",
"    (also known as",
"    <em>",
"     Cronobacter",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/34-40\">",
"     34-40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=see_link&amp;anchor=H5#H5\">",
"     \"Neurologic complications of bacterial meningitis in the neonate\", section on 'Brain abscess'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Overall",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal meningitis is a devastating disease. Advances in infant intensive care have helped to reduce mortality, which is approximately 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/2,3,5,41\">",
"     2,3,5,41",
"    </a>",
"    ], but survivors remain at high risk for neurologic sequelae and lifelong impairments, as illustrated below [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/3,5,41\">",
"     3,5,41",
"    </a>",
"    ]. Approximately 20 percent of survivors have severe disability and another 35 percent have mild to moderate disability.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a Canadian review of 101 infants with gestational age of 35 weeks or greater admitted to a tertiary-care center with a diagnosis of neonatal bacterial meningitis (established by culture of the pathogen from the CSF) between 1979 and 1998, 13 infants died [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/42\">",
"       42",
"      </a>",
"      ]. Mortality declined from 17.4 percent to 9 percent between 1979 and 1988, and 1989 and 1998. Among survivors, 17 had moderate or severe disability at one year of age. Moderate or severe disability was defined as severe CP (severe impairment of daily activities), moderate to severe developmental delay (Bayley score &lt;2 SD for age), blindness,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      deafness.",
"     </li>",
"     <li>",
"      In a survey comparing five-year outcome between a cohort of children born in England and Wales who had neonatal meningitis (bacterial, viral, or fungal) in 1996 to 1997 (15 percent had birth weight &lt;2000 g) with control groups of neonates hospitalized for other reasons and patients from general practice, more patients with neonatal meningitis had serious disability at five years than did hospital or general practice controls (23 percent, 7 percent, and 2 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/3\">",
"       3",
"      </a>",
"      ]. Between 1985 and 1996, mortality declined from 22 to 6.6 percent, but the incidence of serious disability was unchanged (25.5 percent and 23.5 percent in 1985 and 1996, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/3,43,44\">",
"       3,43,44",
"      </a>",
"      ]. Serious disability was defined by multiple impairments, intellectual impairment, moderate or severe sensorineural hearing loss or visual impairment, epilepsy, neuromotor disability hydrocephalus, or inability to attend mainstream school.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Gram-positive",
"    </span>",
"    &nbsp;&mdash;&nbsp;In case series from the late 1990s from Europe and early 2000s from the US, the mortality rates of group B streptococcal (GBS) meningitis were 22 and 6 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Long-term neurologic sequelae occur in as many as 40 percent of survivors of GBS meningitis. Among 43 survivors of GBS meningitis between 1998 and 2006 who underwent follow-up examination at age 3 through 12 years, 24 (56 percent) demonstrated age-appropriate development, eight (19 percent) had severe impairment (eg, cognitive skills &gt;2 standard deviations [SD] below the mean in at least one domain, severe neurologic or functional impairment), and 11 (25 percent) had mild-to-moderate impairment (eg, cognitive skills within 1 to 2 SD below the mean in any domain, academic underachievement, evidence of mild neurologic or functional impairment) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/47\">",
"     47",
"    </a>",
"    ]. These outcomes are little changed from those reported two decades earlier [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=see_link&amp;anchor=H37#H37\">",
"     \"Group B streptococcal infection in neonates and young infants\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Gram-negative",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one review of 72 neonates with gram-negative meningitis from 1969 to 1989, the mortality rate was 17 percent. Among the 44 survivors, 55 percent had central nervous system (CNS) sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/28\">",
"     28",
"    </a>",
"    ]. CNS sequelae included developmental delay in 32 percent, seizure disorder in 30 percent, cerebral palsy in 25 percent, and hearing loss in 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Low-birth-weight infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;One review compared clinical outcomes in 64 very low-birth-rate (LBW) infants (birth weight &lt;1500 g) who had neonatal meningitis (including Candidal meningitis) from 1977 through 1995 and very LBW infants without meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/49\">",
"     49",
"    </a>",
"    ]. After controlling for birth weight, intraventricular hemorrhage, chronic lung disease, and social risk factors, survivors of meningitis had an increased risk of major neurologic abnormality (odds ratio 2.27 [95% CI 1.02-5.05]). Major neurologic abnormality included cerebral palsy, hypertonia, hypotonia, shunt-dependent hydrocephalus (without other neurologic abnormality), blindness, deafness, and mental developmental index &lt;70 at 20 months of age.",
"   </p>",
"   <p>",
"    In a large cohort study of extremely LBW (birth weight &lt;1000 g) infants, those with neonatal meningitis were more likely than uninfected infants to have cerebral palsy, neurodevelopmental impairment, and low mental developmental index scores [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors predictive of death or serious sequelae from bacterial meningitis include LBW (birth weight &lt;2500 g) or preterm birth (&lt;37 weeks' gestation) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/4,51,52\">",
"     4,51,52",
"    </a>",
"    ], a history of symptoms for longer than 24 hours before hospitalization, leukopenia (WBC",
"    <span class=\"nowrap\">",
"     &lt;5000/microL)",
"    </span>",
"    and neutropenia at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/4,42,48\">",
"     4,42,48",
"    </a>",
"    ], seizures occurring more than 72 hours after hospitalization, focal neurologic deficits, requirement for mechanical ventilatory support or inotropes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/42,48,53\">",
"     42,48,53",
"    </a>",
"    ], and delayed sterilization of the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/26,28,29,54\">",
"     26,28,29,54",
"    </a>",
"    ]. In a retrospective study, 22 percent of survivors of GBS meningitis had neurologic sequelae evident at hospital discharge; the most common sequelae were persistent seizure disorder, followed by hypertonicity and dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/46\">",
"     46",
"    </a>",
"    ]. In multivariate analysis, only seizures that persisted after admission predicted sequelae at discharge. In another study, low voltage background pattern and electrographic seizure activity on amplitude integrated electroencephalogram were predictive of poor outcome in 13 survivors of GBS meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuroimaging findings of meningeal inflammation are not related to neurologic outcome, but the presence and size of parenchymal lesions (eg, thrombi, encephalomalacia) do have prognostic significance. In particular, abscess formation is associated with neurologic sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term follow-up for survivors of neonatal meningitis includes monitoring of hearing, visual acuity, and developmental status. Hearing should be evaluated by evoked response audiometry within four to six weeks of completion of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16121/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Survivors of neonatal meningitis are at risk for developmental delay and may be eligible to receive early intervention services in the United States (eligibility criteria vary by state). Appropriate referrals should be made as indicated. Developmental surveillance should continue throughout childhood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=see_link&amp;anchor=H18501566#H18501566\">",
"     \"Developmental-behavioral surveillance and screening in primary care\", section on 'When to perform developmental-behavioral screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial meningitis in the neonate is a devastating disease. Advances in infant intensive care have helped to reduce mortality, but survivors remain at high risk for neurologic sequelae and lifelong impairments. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neonates with bacterial meningitis should receive initial care in an intensive care unit. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antimicrobial therapy for neonatal meningitis is indicated if the results of the cerebrospinal fluid (CSF) evaluation are suggestive of bacterial meningitis. Appropriate broad spectrum antimicrobial therapy with agents that have adequate CSF penetration should be initiated as soon as possible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7928?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical features and diagnosis of bacterial meningitis in the neonate\", section on 'Laboratory features'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H3\">",
"       'Antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial choice of antimicrobials for suspected bacterial meningitis in the neonate is empirical, based on the infant's age, likely pathogens, and the susceptibility patterns of gram-negative organisms causing late-onset infections in infants with continuous care in a particular nursery. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Empirical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the causative agent and its in vitro antimicrobial susceptibility pattern are known, empirical antimicrobial therapy should be altered accordingly. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Specific therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of antimicrobial therapy depends upon the causative organism and the clinical course. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Duration'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=see_link\">",
"       \"Neurologic complications of bacterial meningitis in the neonate\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The response to antimicrobial and supportive therapy and the potential development of complications are monitored clinically, through repeat neurologic examinations, evaluation of the CSF, and by neuroimaging. Neurologic complications must be considered in the neonate with neonatal meningitis who fails to improve clinically after 24 to 48 hours of appropriate antibiotic therapy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Monitoring response to therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=see_link\">",
"       \"Neurologic complications of bacterial meningitis in the neonate\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest repeat lumbar puncture 24 to 48 hours after initiation of antimicrobial therapy to document sterilization of the CSF (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Repeat lumbar puncture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuroimaging is indicated in neonates with signs suggesting neurologic complications. In addition, we suggest contrast-enhanced neuroimaging for all neonates with bacterial meningitis, even those with an apparently uncomplicated course, 48 to 72 hours before the anticipated discontinuation of antimicrobial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mortality of neonatal bacterial meningitis is approximately 10 percent. Approximately 20 percent of survivors have severe disability and another 35 percent have mild to moderate disability. Long-term neurologic sequelae are somewhat more frequent after gram-negative neonatal meningitis than after group B streptococcal neonatal meningitis. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term follow-up for survivors of neonatal meningitis includes monitoring of hearing, visual acuity, and developmental status. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/1\">",
"      Wenger JD, Hightower AW, Facklam RR, et al. Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. The Bacterial Meningitis Study Group. J Infect Dis 1990; 162:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/2\">",
"      Harvey D, Holt DE, Bedford H. Bacterial meningitis in the newborn: a prospective study of mortality and morbidity. Semin Perinatol 1999; 23:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/3\">",
"      de Louvois J, Halket S, Harvey D. Neonatal meningitis in England and Wales: sequelae at 5 years of age. Eur J Pediatr 2005; 164:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/4\">",
"      Bortolussi R, Krishnan C, Armstrong D, Tovichayathamrong P. Prognosis for survival in neonatal meningitis: clinical and pathologic review of 52 cases. Can Med Assoc J 1978; 118:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/5\">",
"      Chang CJ, Chang WN, Huang LT, et al. Neonatal bacterial meningitis in southern Taiwan. Pediatr Neurol 2003; 29:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/6\">",
"      Polin RA, Harris MC. Neonatal bacterial meningitis. Semin Neonatol 2001; 6:157.",
"     </a>",
"    </li>",
"    <li>",
"     Saez-Llorens X, McCracken GH Jr. Krugman's Infectious Diseases of Children. In: Krugman's Infectious Diseases of Children, 11th ed, Greshon AA, Hotez PJ, Katz SL (Eds), Mosby, Philadelphia 2004. p.373.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/8\">",
"      Sarff LD, Platt LH, McCracken GH Jr. Cerebrospinal fluid evaluation in neonates: comparison of high-risk infants with and without meningitis. J Pediatr 1976; 88:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/9\">",
"      Alarcon A, Pe&ntilde;a P, Salas S, et al. Neonatal early onset Escherichia coli sepsis: trends in incidence and antimicrobial resistance in the era of intrapartum antimicrobial prophylaxis. Pediatr Infect Dis J 2004; 23:295.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Escherichia coli and other gram-negative bacilli (septicemia and meningitis in neonates). In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.321.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/11\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/12\">",
"      Byington CL, Rittichier KK, Bassett KE, et al. Serious bacterial infections in febrile infants younger than 90 days of age: the importance of ampicillin-resistant pathogens. Pediatrics 2003; 111:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/13\">",
"      Albanyan EA, Baker CJ. Is lumbar puncture necessary to exclude meningitis in neonates and young infants: lessons from the group B streptococcus cellulitis- adenitis syndrome. Pediatrics 1998; 102:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/14\">",
"      Schauf V, Deveikis A, Riff L, Serota A. Antibiotic-killing kinetics of group B streptococci. J Pediatr 1976; 89:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/15\">",
"      Deveikis A, Schauf V, Mizen M, Riff L. Antimicrobial therapy of experimental group B streptococcal infection in mice. Antimicrob Agents Chemother 1977; 11:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/16\">",
"      Cooper MD, Keeney RE, Lyons SF, Cheatle EL. Synergistic effects of ampicillin-aminoglycoside combinations on group B streptococci. Antimicrob Agents Chemother 1979; 15:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/17\">",
"      Overturf GD, Horowitz M, Wilkins J, et al. Bactericidal studies of penicillin-gentamicin combinations against group B streptococci. J Antibiot (Tokyo) 1977; 30:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/18\">",
"      Swingle HM, Bucciarelli RL, Ayoub EM. Synergy between penicillins and low concentrations of gentamicin in the killing of group B streptococci. J Infect Dis 1985; 152:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/19\">",
"      Backes RJ, Rouse MS, Henry NK, et al. Activity of penicillin combined with an aminoglycoside against group B streptococci in vitro and in experimental endocarditis. J Antimicrob Chemother 1986; 18:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/20\">",
"      Kim KS. Effect of antimicrobial therapy for experimental infections due to group B Streptococcus on mortality and clearance of bacteria. J Infect Dis 1987; 155:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/21\">",
"      Lautenbach E, Patel JB, Bilker WB, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/22\">",
"      Heath PT, Nik Yusoff NK, Baker CJ. Neonatal meningitis. Arch Dis Child Fetal Neonatal Ed 2003; 88:F173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/23\">",
"      Escobar GJ, Li DK, Armstrong MA, et al. Neonatal sepsis workups in infants &gt;/=2000 grams at birth: A population-based study. Pediatrics 2000; 106:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/24\">",
"      Daoud AS, Batieha A, Al-Sheyyab M, et al. Lack of effectiveness of dexamethasone in neonatal bacterial meningitis. Eur J Pediatr 1999; 158:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/25\">",
"      McCracken GH Jr. The rate of bacteriologic response to antimicrobial therapy in neonatal meningitis. Am J Dis Child 1972; 123:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/26\">",
"      Olson DA, Hoeprich PD, Nolan SM, Goldstein E. Successful treatment of gram-negative bacillary meningitis with moxalactam. Ann Intern Med 1981; 95:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/27\">",
"      Pong A, Bradley JS. Bacterial meningitis and the newborn infant. Infect Dis Clin North Am 1999; 13:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/28\">",
"      Unhanand M, Mustafa MM, McCracken GH Jr, Nelson JD. Gram-negative enteric bacillary meningitis: a twenty-one-year experience. J Pediatr 1993; 122:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/29\">",
"      Anderson SG, Gilbert GL. Neonatal gram negative meningitis: a 10-year review, with reference to outcome and relapse of infection. J Paediatr Child Health 1990; 26:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/30\">",
"      Shah DK, Daley AJ, Hunt RW, et al. Cerebral white matter injury in the newborn following Escherichia coli meningitis. Eur J Paediatr Neurol 2005; 9:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/31\">",
"      Raju VS, Rao MN, Rao VS. Cranial sonography in pyogenic meningitis in neonates and infants. J Trop Pediatr 1995; 41:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/32\">",
"      Yikilmaz A, Taylor GA. Sonographic findings in bacterial meningitis in neonates and young infants. Pediatr Radiol 2008; 38:129.",
"     </a>",
"    </li>",
"    <li>",
"     Volpe JJ. Bacterial and fungal intracranial infections. In: Neurology of the newborn, 4th ed, WB Saunders Company, Philadelphia 2001. p.774.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/34\">",
"      Campbell JR, Diacovo T, Baker CJ. Serratia marcescens meningitis in neonates. Pediatr Infect Dis J 1992; 11:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/35\">",
"      Kline MW, Kaplan SL. Citrobacter diversus and neonatal brain abscess. Pediatr Neurol 1987; 3:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/36\">",
"      Graham DR, Band JD. Citrobacter diversus brain abscess and meningitis in neonates. JAMA 1981; 245:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/37\">",
"      Willis J, Robinson JE. Enterobacter sakazakii meningitis in neonates. Pediatr Infect Dis J 1988; 7:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/38\">",
"      Renier D, Flandin C, Hirsch E, Hirsch JF. Brain abscesses in neonates. A study of 30 cases. J Neurosurg 1988; 69:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/39\">",
"      Iversen C, Lehner A, Mullane N, et al. Identification of \"Cronobacter\" spp. (Enterobacter sakazakii). J Clin Microbiol 2007; 45:3814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/40\">",
"      Phan H, Lehman D. Cerebral abscess complicating Proteus mirabilis meningitis in a newborn infant. J Child Neurol 2012; 27:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/41\">",
"      Holt DE, Halket S, de Louvois J, Harvey D. Neonatal meningitis in England and Wales: 10 years on. Arch Dis Child Fetal Neonatal Ed 2001; 84:F85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/42\">",
"      Klinger G, Chin CN, Beyene J, Perlman M. Predicting the outcome of neonatal bacterial meningitis. Pediatrics 2000; 106:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/43\">",
"      de Louvois J. Acute bacterial meningitis in the newborn. J Antimicrob Chemother 1994; 34 Suppl A:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/44\">",
"      Bedford H, de Louvois J, Halket S, et al. Meningitis in infancy in England and Wales: follow up at age 5 years. BMJ 2001; 323:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/45\">",
"      ter Horst HJ, van Olffen M, Remmelts HJ, et al. The prognostic value of amplitude integrated EEG in neonatal sepsis and/or meningitis. Acta Paediatr 2010; 99:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/46\">",
"      Levent F, Baker CJ, Rench MA, Edwards MS. Early outcomes of group B streptococcal meningitis in the 21st century. Pediatr Infect Dis J 2010; 29:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/47\">",
"      Libster R, Edwards KM, Levent F, et al. Long-term outcomes of group B streptococcal meningitis. Pediatrics 2012; 130:e8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/48\">",
"      Edwards MS, Rench MA, Haffar AA, et al. Long-term sequelae of group B streptococcal meningitis in infants. J Pediatr 1985; 106:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/49\">",
"      Doctor BA, Newman N, Minich NM, et al. Clinical outcomes of neonatal meningitis in very-low birth-weight infants. Clin Pediatr (Phila) 2001; 40:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/50\">",
"      Stoll BJ, Hansen NI, Adams-Chapman I, et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA 2004; 292:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/51\">",
"      Overall JC Jr. Neonatal bacterial meningitis. Analysis of predisposing factors and outcome compared with matched control subjects. J Pediatr 1970; 76:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/52\">",
"      May M, Daley AJ, Donath S, et al. Early onset neonatal meningitis in Australia and New Zealand, 1992-2002. Arch Dis Child Fetal Neonatal Ed 2005; 90:F324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/53\">",
"      Franco SM, Cornelius VE, Andrews BF. Long-term outcome of neonatal meningitis. Am J Dis Child 1992; 146:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16121/abstract/54\">",
"      Greenberg RG, Benjamin DK Jr, Cohen-Wolkowiez M, et al. Repeat lumbar punctures in infants with meningitis in the neonatal intensive care unit. J Perinatol 2011; 31:425.",
"     </a>",
"    </li>",
"    <li>",
"     Estripeaut D, Saez-Llorens X. Perinatal bacterial diseases. In: Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.979.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6016 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.124.11.8-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_47_16121=[""].join("\n");
var outline_f15_47_16121=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTIMICROBIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Empirical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Early-onset",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Late-onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Specific therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Group B streptococcus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Gram-negative enteric bacteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Listeria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Coagulase-negative staphylococci",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Positive CSF culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Negative CSF culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ADJUNCTIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MONITORING RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Repeat lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Overall",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Gram-positive",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Gram-negative",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Low-birth-weight infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7928?source=related_link\">",
"      Clinical features and diagnosis of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=related_link\">",
"      Developmental-behavioral surveillance and screening in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=related_link\">",
"      Group B streptococcal infection in neonates and young infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=related_link\">",
"      Neonatal herpes simplex virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31656?source=related_link\">",
"      Neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=related_link\">",
"      Neurologic complications of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26200?source=related_link\">",
"      Treatment and outcome of sepsis in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=related_link\">",
"      Treatment and prognosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/13?source=related_link\">",
"      Treatment of neonatal seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=related_link\">",
"      Treatment, prognosis, and prevention of Listeria monocytogenes infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_47_16122="Surgical management of severe obesity in adolescents";
var content_f15_47_16122=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical management of severe obesity in adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/47/16122/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/47/16122/contributors\">",
"     Stavra A Xanthakos, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/47/16122/contributors\">",
"     Thomas H Inge, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/47/16122/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/47/16122/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/47/16122/contributors\">",
"     Daniel Jones, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/47/16122/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/47/16122/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/47/16122/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the past few years, severe obesity has gained recognition as a significant health problem facing a large proportion of adults and children in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Due to a lack of nonsurgical options for extremely obese adolescents and a demonstrated safety and efficacy record in adults, there has been increasing interest in surgical procedures for weight loss (\"bariatric surgery\") for selected obese adolescents with severe obesity.",
"   </p>",
"   <p>",
"    The rationale, outcomes, and indications for weight loss surgery in adolescents will be reviewed here. The management and outcomes of weight loss surgery in adults and other aspects of obesity in children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=see_link\">",
"     \"Medical management of patients after bariatric surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=see_link\">",
"     \"Clinical evaluation of the obese child and adolescent\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37674?source=see_link\">",
"     \"Comorbidities and complications of obesity in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=see_link\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18378?source=see_link\">",
"     \"Management of childhood obesity in the primary care setting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents with severe obesity are at risk for important comorbidities, including obstructive sleep apnea, diabetes, hypertension, cardiac hypertrophy, and nonalcoholic steatohepatitis, as well as depression and impaired quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Therefore, treatment that is targeted at obesity may treat or prevent these problems and improve long-term health outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37674?source=see_link\">",
"     \"Comorbidities and complications of obesity in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History of weight loss surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the past 30 to 40 years, weight loss surgery has clearly been shown to produce significant and sustained reductions in BMI, diabetes, and hypertriglyceridemia in adults. It also reduces mortality, as highlighted in a 10-year follow-up of patients undergoing gastric bypass, banding, or vertical gastroplasty in the Swedish Obesity Study [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Weight loss surgery has been performed in small groups of adolescents since the late 1970s. An analysis of representative national hospital administrative data from the United States demonstrated that between 1996 and 2000, the annual number of surgical weight loss procedures in adolescents remained stable [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/9\">",
"     9",
"    </a>",
"    ]. However, between 2000 and 2003, the rate of surgical weight loss procedures in adolescents tripled to an estimated 771 procedures nationwide [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/9\">",
"     9",
"    </a>",
"    ]. In a survey of bariatric surgeons in the United States in 2005, 75 percent indicated they were planning to perform an adolescent procedure in the upcoming year, and 42 percent were in the process of developing a multidisciplinary adolescent weight loss surgery program in their community [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/10\">",
"     10",
"    </a>",
"    ]. Nonetheless, weight loss surgery for adolescents remains a small percentage of overall annual weight loss surgery procedures in the United States (0.7 percent), with the majority of these cases (90 percent) being gastric bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Defining severe obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;When evaluating the risks and benefits of surgery, an important step is to identify the group of patients that are most likely to benefit from the intervention. In adults, severe obesity is generally defined as a body mass index (BMI) &ge;40",
"    <span class=\"nowrap\">",
"     kg/m2.",
"    </span>",
"    This is also the BMI threshold for consideration of surgery as proposed by an NIH consensus panel; a threshold of 35",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    is used for adults with significant current comorbidities such as diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children, a BMI &ge;120 percent of the 95th percentile, or &ge;35",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    defines a group that is at high risk for medical complications of obesity in the long term [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/12\">",
"     12",
"    </a>",
"    ]. This threshold corresponds to approximately the 99th percentile (Z-score 2.33), but is preferred because the CDC growth standards are not sufficiently precise to use percentile curves at the extremes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/13\">",
"     13",
"    </a>",
"    ]. In the United States, approximately 4 percent of children 5 to 17 years of age are currently in this range [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/14\">",
"     14",
"    </a>",
"    ]. These children will almost always remain in the obese range as adults, and 65 percent will have Class III obesity as adults (BMI &ge;40) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. They have a significantly greater prevalence of cardiovascular risk factors as compared with children with lesser degrees of obesity, and will have more health complications and higher mortality as compared with those who developed obesity during adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/16-19\">",
"     16-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For boys, the 99th percentile for BMI is approximately 32",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    at 13 years of age and rises to 34 at 16 years of age. For girls, the 99th percentile for BMI is approximately 34 at 13 years of age, and rises to 36",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    at age 15, and 38 by age 16. Therefore, use of an absolute BMI &ge;35 will define a subgroup of patients with a degree of obesity that is even more severe than that defined by the 99th percentile for all adolescent boys, particularly for younger adolescents. For most but not all girls, a BMI of &ge;35",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    is also greater than the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile. A BMI &ge;40 will define a subgroup of patients with very severe obesity, and is above the 99th percentile for virtually all adolescents.",
"   </p>",
"   <p>",
"    Z-scores provide an alternative method of defining severe obesity in children and adolescents. Z-scores correspond directly to percentiles. As an example, the 95th percentile corresponds to a Z-score of 1.65, the 97th percentile to a Z-score of 1.89, and the 99th percentile to a Z-score of 2.33. However, Z-scores beyond the 97th percentile have been calculated using mathematical equations derived from population-based data between the 3rd and 97th percentile due to insufficient numbers of subjects with BMI values greater than the 97th percentile in national samples. For this reason, actual BMI values can vary widely at percentiles above the 99th percentile. BMI percentiles and Z-scores can be determined using a gender-specific calculator for boys (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?35/14/36070?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) or for girls (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?34/60/35782?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Further work is needed to correlate these different thresholds for defining severe obesity to current and future risks of clinical comorbidities and, thereby, to the potential benefits and risks of surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Alternatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the potential risks of surgical weight loss, noninvasive approaches should always be the first-line treatment for any child or adolescent with obesity. The best established approaches are multidisciplinary, using family-based behavioral techniques to support changes in diet and physical activity, with goals of reducing caloric intake, improving the quality of the food intake, and increasing energy expenditure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/12\">",
"     12",
"    </a>",
"    ]. Recommendations from an expert committee, endorsed by the American Academy of Pediatrics and other professional organizations, advocate a staged approach to weight management based on the child's degree of obesity and response to previous interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/12,20\">",
"     12,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, the limited data available suggest that dietary and behavioral interventions alone rarely achieve long-term success for individuals with severe obesity. In one study of 24 preadolescent children with severe obesity (mean BMI 34",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    ages 8 to 12) weight loss during a 12-week behavioral program was modest; children lost an average of 2.5 kg (3.2 percent) of their initial weight [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/21\">",
"     21",
"    </a>",
"    ]. At follow-up seven months later, all lost weight had been regained. In another study of 12 adolescents with BMI values &ge;40",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    (mean BMI 47",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    participating in a pediatric behavioral weight loss treatment program, the subjects had only a 3 percent reduction of BMI (mean 46",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    after one year [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/22\">",
"     22",
"    </a>",
"    ]. Finally, obese adolescents randomized to placebo and behavioral therapy (eg, controls in pharmaceutical studies for weight loss) have typically demonstrated &lt;3 percent weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. These studies suggest that dietary and behavioral interventions generally have poor success rates for adolescents with severe obesity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TYPES OF SURGERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7607783\">",
"    <span class=\"h2\">",
"     Roux-en-Y gastric bypass and adjustable gastric band",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently, the most widely performed procedures in adolescents and adults are the roux-en-Y gastric bypass (RYGB) (",
"    <a class=\"graphic graphic_figure graphicRef79256 \" href=\"UTD.htm?32/35/33329\">",
"     figure 1",
"    </a>",
"    ) and the adjustable gastric band (AGB) (",
"    <a class=\"graphic graphic_figure graphicRef57064 \" href=\"UTD.htm?2/38/2656\">",
"     figure 2",
"    </a>",
"    ). Details of these procedures and the experience in adults are discussed in a separate topic review (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link&amp;anchor=H16#H16\">",
"     \"Surgical management of severe obesity\", section on 'Bariatric surgical procedures'",
"    </a>",
"    ). Outcomes of these procedures and considerations specific to adolescents are discussed below. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Outcomes'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H16\">",
"     'Postoperative management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration (FDA) has approved two adjustable gastric band devices for use in adults in the United States, but these devices are not yet FDA-approved for adolescents younger than age 18. An industry-sponsored prospective study is in progress, and numerous retrospective studies of adolescents have been published with favorable results (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Outcomes'",
"    </a>",
"    below). Despite lack of FDA approval, a trend of increased use of AGB in adolescents has been reported in some areas of the United States. Between 2005 and 2007, 590 adolescents (aged 13 to 20 years) underwent bariatric surgery in 86 California hospitals. White adolescents accounted for 65 percent of the procedures. Rates of AGB increased 6.9-fold, whereas RYGB rates decreased from 3.8 to 2.7 per 100,000 population in this analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/25\">",
"     25",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7607762\">",
"    <span class=\"h2\">",
"     Vertical sleeve gastrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vertical sleeve gastrectomy (VSG) has gained increased interest as a type of weight loss surgery in adults and adolescents (",
"    <a class=\"graphic graphic_figure graphicRef54612 \" href=\"UTD.htm?35/40/36480\">",
"     figure 3",
"    </a>",
"    ). This procedure was originally performed as the first part of a two-stage weight loss procedure for high risk extremely obese patients. The sleeve gastrectomy was performed first to promote initial weight loss, and was followed at a later stage by the biliopancreatic diversion with duodenal switch",
"    <span class=\"nowrap\">",
"     (BPD/DS)",
"    </span>",
"    or roux-en-Y gastric bypass (RYGB) as the final weight loss procedure. However, accumulating short term data in adults suggest that similar degrees of weight loss and comorbidity resolution occur within one to three years after small-caliber sleeve gastrectomy alone, prompting increasing use of this procedure as a standalone weight loss surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/26\">",
"     26",
"    </a>",
"    ]. Data on long-term outcomes is pending. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link&amp;anchor=H23#H23\">",
"     \"Surgical management of severe obesity\", section on 'Sleeve gastrectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because the sleeve gastrectomy is less complex and has a lower risk of micronutrient deficiencies as compared to malabsorptive procedures, it is an attractive option. Additionally, if long-term weight regain occurs, the option of converting to a RYGB or",
"    <span class=\"nowrap\">",
"     BPD/DS",
"    </span>",
"    remains. A small case series of four adolescents undergoing sleeve gastrectomy has been reported with good safety and efficacy outcomes at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/27\">",
"     27",
"    </a>",
"    ]. Subsequently, a retrospective series of 108 pediatric patients undergoing VSG was reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/28\">",
"     28",
"    </a>",
"    ]. The mean age was 14 years and the series included seven patients with Prader-Willi syndrome, two with Bardet-Biedl syndrome, three with mental retardation, and one with Down syndrome. The mean preoperative BMI of 47",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    declined by 37 percent at one year in a total of 41 eligible for one-year follow-up; no further weight loss or gain was seen in eight patients at two years&rsquo; time. There were no deaths and no major complications. This study represents the largest adolescent experience to date with VSG. Another study of 51 adolescents who underwent VSG with one-year follow-up confirmed these weight loss and safety findings [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/29\">",
"     29",
"    </a>",
"    ]. Thus, accumulating adolescent data suggests that VSG may prove to be a safe alternative to RYGB with fewer nutritional risks; in addition, the lack of foreign body&ndash;related complications as seen with banding makes this procedure of particular interest for use in younger patients. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7607776\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, the range of surgical weight loss procedures performed on adults and a few adolescents included jejunoileal bypass (a procedure associated with a high rate of malabsorptive complications), vertical banded gastroplasty, and banded gastric bypass. Due to unsatisfactory safety profiles",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    efficacy, these procedures are no longer recommended. Other procedures that cause malabsorption, such as biliopancreatic diversion, are occasionally performed on adults but are generally not recommended for adolescents due to lack of safety data in this age group and concerns about long-term nutritional complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MECHANISMS OF WEIGHT LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduction of caloric intake plays an important role in the dramatic weight loss produced by bariatric surgery. However, this may not be purely due to reduced capacity of the stomach or pouch. Many patients report a subjective decrease in appetite and increase in postprandial satiety after surgery, which helps them maintain lower intake of food. This experience suggests that the effects of bariatric surgery on weight loss and comorbidities may have neuroendocrine mechanisms, and are not due to mechanical restriction of food intake or of malabsorption.",
"   </p>",
"   <p>",
"    Emerging data suggest that alterations in neuroenteric hormones that regulate appetite and energy expenditure could contribute to changes in satiety after surgery. Several studies have demonstrated an increase in postprandial total peptide YY (both PYY and PYY3-36) after roux-en-Y gastric bypass compared with lean or obese nonoperative controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. This postprandial increase in PYY is not reported after an adjustable gastric band [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. However, a single series of 12 patients undergoing the vertical banded gastroplasty (also purely restrictive) reported an increase in fasting and postprandial PYY after surgery to levels comparable to those measured in lean controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dramatic improvements in insulin resistance and diabetes occur after gastric bypass, even prior to any significant weight loss. These changes may in part be due to increased secretion of incretins, such as glucagon-like-peptide-1 (GLP-1) by intestinal endocrine cells after surgery. After gastric bypass, postprandial GLP-1 plasma levels rise dramatically as compared to levels in lean and obese controls, and as compared to patients undergoing adjustable gastric banding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/33\">",
"     33",
"    </a>",
"    ]. Further research is needed to elucidate the mechanisms through which bariatric surgery causes this abrupt enhancement of insulin sensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all studies reporting outcomes of weight loss surgery in adolescents have utilized a retrospective design and report short- to intermediate-term outcomes (outcomes measured from 1 to 6.3 years after surgery). A few studies have reported small numbers of patients 10 or more years after their procedure. In most of these long-term studies, a substantial number of subjects were lost to follow-up, which could bias findings.",
"   </p>",
"   <p>",
"    Despite these limitations, the existing retrospective data clearly demonstrate that both gastric bypass and banding in adolescents lead to clinically important and durable decreases in weight and BMI in the majority of patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastric bypass &ndash; The largest retrospective series of adolescents after gastric bypass reported a 37 percent overall reduction in BMI at one year postoperatively [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/22\">",
"       22",
"      </a>",
"      ]. In a meta-analysis, the summary statistic for weight loss in adolescents after gastric bypass ranged from 17.8 to 22.3",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      in studies with one to six years of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/35\">",
"       35",
"      </a>",
"      ]. Weight loss outcomes in adult cohorts are often reported as percentage of excess weight loss (EWL). Several series have reported 56 to 62 percent EWL after roux-en-Y gastric bypass in pediatric cohorts [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The nadir postoperative BMI tends to be lower in patients with less severe obesity preoperatively as compared to those with more severe obesity, although the percent BMI change is similar. In a large series of patients from a single center, the mean nadir postoperative BMI was 31, 38, and 47",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      for patients with starting BMIs between 40 to 54, 55 to 65, and &gt;65",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adjustable banding &ndash; Comparable results have been reported after adjustable gastric banding (AGB) in adolescents. In two studies of adolescents undergoing AGB, mean weight loss after ranged from 52 to 60 percent EWL at one- and two-years follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/39-41\">",
"       39-41",
"      </a>",
"      ]. In a meta-a",
"      <sup>",
"       n",
"      </sup>",
"      alysis, the summary statistic for weight loss in adolescents after AGB ranged from 10.6 to 13.7",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      in studies with one to three years of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/35\">",
"       35",
"      </a>",
"      ]. The rate of weight loss",
"      <sup>",
"      </sup>",
"      appears to be more gradual after AGB as compared with gastric bypass, wit",
"      <sup>",
"       h",
"      </sup>",
"      maximal weight los",
"      <sup>",
"       s",
"      </sup>",
"      in AGB achieved at 12 or more months after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. One study reported 70 percent EWL (range 37 to 101 percent) in 18 patients followed for three years after AGB [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/42\">",
"       42",
"      </a>",
"      ]. The relatively high EWL in this group might be explained by the fa",
"      <sup>",
"       c",
"      </sup>",
"      t that participants",
"      <sup>",
"       h",
"      </sup>",
"      ad relatively mild obesity prior to surgery (mean BMI 42) as compared to other series. A prospective series reported somewhat less weight loss (34 percent EWL at 12 months and 41 percent EWL at 18 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/43\">",
"       43",
"      </a>",
"      ]. This study was limited by a 20 percent dropout rate (5 of 25 patients were unavailable for data collection).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A randomized trial of 50 adolescents compared AGB to a supervised lifestyle intervention, with two-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/44\">",
"     44",
"    </a>",
"    ]. The patients in the AGB group lost an average of 34.6 kg or 79 percent EWL, as compared with 3.0 kg or 13 percent EWL in the lifestyle group. The study was limited by a 28 percent dropout rate in the lifestyle group (18 of 25 patients completed the study). Of note, almost 30 percent of the patients undergoing AGB required revisional procedures. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Long-term complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Weight loss after surgery is accompanied by a significant reduction in body fat (from 51 percent to 37 percent in one series) with a relative preservation of lean body mass [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/45\">",
"     45",
"    </a>",
"    ]. Not surprisingly, given the improvement in adiposity, obesity-related diseases usually improve or resolve after surgically induced weight loss in adolescents. The most dramatic improvements have been seen in insulin resistance, triglyceride levels, diabetes, obstructive sleep apnea, as well as depression and quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/4,22,42,46,47\">",
"     4,22,42,46,47",
"    </a>",
"    ]. One study also showed improvements in obesity-associated cardiac abnormalities, including concentric left ventricular hypertrophy and diastolic function, as measured by echocardiogram performed before and 10 &plusmn; 3 months after gastric bypass surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not clear to what degree weight loss will be sustained in adolescents and whether comorbid conditions will recur if significant weight is regained in long-term follow-up. Two studies with 4 to 10 years of follow-up suggest that 10 to 15 percent of patients regain significant weight after gastric bypass procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/36,49\">",
"     36,49",
"    </a>",
"    ]. A substantial number of patients also regain some or all of their lost weight after adjustable gastric banding. In one retrospective series of 24 adolescents, maximal EWL (52 percent) occurred at one year after adjustable gastric banding with a regression to 42 percent EWL at two and three years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/40\">",
"     40",
"    </a>",
"    ]. Specific predictors of weight regain after surgical weight loss procedures are unknown for adults and adolescents. There is still insufficient information to directly compare the long-term weight loss outcomes of roux-en-Y gastric bypass to those for adjustable gastric banding or sleeve gastrectomy in adolescents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Short-term complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative complications (&lt;30 days) are generally similar to those in adults. Among 590 adolescent cases in California, the rate of minor in-hospital complications was 5.6 percent, major in-hospital complications 1 percent, and there were no deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/25\">",
"     25",
"    </a>",
"    ]. Complications after gastric bypass include intestinal leakage at anastomotic sites, wound infections, pulmonary embolus, gastrojejunal strictures requiring endoscopic dilatation, small bowel obstruction, gastrogastric fistula formation, and symptomatic cholelithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/37\">",
"     37",
"    </a>",
"    ]. Complications of AGB procedures in adolescents and adults include band slippage requiring repositioning, gastric obstruction, and esophageal or gastric pouch dilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications requiring reoperation appear to be higher for patients undergoing AGB as compared to those undergoing gastric bypass. In the series from California cited above, 4.7 percent of patients undergoing AGB had band revision or removal, compared to a 2.9 percent reoperation rate for patients undergoing gastric bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/25\">",
"     25",
"    </a>",
"    ]. In a randomized controlled trial of adolescents undergoing AGB, 33 percent underwent reoperation, due to symmetric pouch dilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tubing puncture during access [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/44\">",
"     44",
"    </a>",
"    ]. In the meta-analysis cited above, complications requiring reoperation occurred in 8 percent of adolescent patients undergoing AGB [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/35\">",
"     35",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link\">",
"     \"Complications of bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies performed in the United States suggest weight loss surgery may be somewhat safer in adolescents as compared with adults. The reason for this is unknown, but the observation may reflect a better state of health among individuals undergoing surgery at a young age.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A national analysis of weight loss surgery using utilization codes revealed no perioperative mortality and a significantly shorter length of stay in adolescents as compared with adults [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/9\">",
"       9",
"      </a>",
"      ]. Five percent of adolescent patients had major complications, but the majority (78.3 percent) was respiratory in nature.",
"     </li>",
"     <li>",
"      A large study comparing the perioperative outcomes of weight loss surgery between 309 adolescents and 55,192 adults (&gt;18 years) found that the overall 30-day complication rate was significantly lower in adolescents (5.5 percent) as compared to adults (9.8 percent). There was no difference in",
"      <span class=\"nowrap\">",
"       observed/expected",
"      </span>",
"      mortality ratios. The 30-day morbidity and mortality rates for adolescents following restrictive procedures (adjustable gastric banding and gastroplasty) were nil, in comparison with the morbidity rate of 4.3 percent for laparoscopic gastric bypass, and 7.6 percent for open gastric bypass [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Long-term complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term complications of weight loss surgery in adolescents are primarily nutritional. In particular, patients are at risk for deficiency of iron, vitamin B12, vitamin D, and thiamine. For this reason, lifelong vitamin and mineral supplementation is imperative. However, adherence to supplementation regimens among adolescents may be poor; one study reported that only 13 percent of adolescents were adherent to all prescribed nutritional supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/36,49\">",
"     36,49",
"    </a>",
"    ]. The specific recommendations are outlined below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Nutritional supplements'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Gastric bypass is associated with reduced bone mass in adults and is probably caused by a combination of reduced mechanical load, changes in adipogenic hormones, and nutritional deficiencies. In adolescents, reduced bone mass has been noted two years after weight loss surgery, but remains appropriate for age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/51\">",
"     51",
"    </a>",
"    ]. As in adults, long-term studies are lacking, and the clinical implications of these changes are unclear. However, these findings underscore the importance of supplementing and monitoring vitamin D and calcium after weight loss surgery. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Nutritional supplements'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'Nutritional monitoring'",
"    </a>",
"    below.) &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Some adult patients have developed severe postprandial hypoglycemia after gastric bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. The exact cause of these hypoglycemic episodes is not known but may result in part from increased incretin secretion after surgery, pancreatic islet cell hyperplasia, and inappropriate postprandial hyperinsulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/54\">",
"     54",
"    </a>",
"    ]. Although a similar syndrome in adolescents after gastric bypass has not yet been reported in the literature, at least one adolescent patient in the authors' weight loss surgery program developed severe postprandial hyperinsulinemia after gastric bypass. Dietary management by providing small meals with relatively low content of carbohydrates was successful in controlling symptoms. Therefore, it is important to query adolescents seen in follow-up about symptoms that may suggest postprandial hypoglycemia.",
"   </p>",
"   <p>",
"    Long-term follow-up of adjustable gastric banding (AGB) in adult patients indicates that reoperations due to complications, including slippage, erosion, or device failure, occurs in 10 to 32 percent of adults [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. One prospective evaluation of adults undergoing AGB in Sweden indicated that one-third of the 196 patients experienced a major reoperation: 18 percent had a band replacement and 14 percent had removal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/56\">",
"     56",
"    </a>",
"    ]. Late complications included band migration, leakage, slippage, and pouch dilatation, as well as device-related problems, such as tube replacement and port-related complications.",
"   </p>",
"   <p>",
"    There is a substantial risk that patients undergoing AGB will require reoperation during the first few years after the initial procedure; rates of adverse events over longer follow up periods are not yet available. During the randomized trial of AGB in 25 adolescent patients cited above, eight reoperations (33 percent) were required in a total of seven patients during the two year follow-up period [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/44\">",
"     44",
"    </a>",
"    ]. Six of the procedures were for pouch dilation, and two were for tubing injuries. Other adverse events reported among the 25 patients with AGB in this trial were cholelithiasis requiring cholecystectomy (one patient), unplanned pregnancy (two patients), and depression requiring hospital admission (one patient). These rates were similar to those in the lifestyle group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION AND SCREENING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommended screening prior to surgical weight loss procedures includes evaluation for the presence and severity of coexisting diseases, as well as assessment of the patient's and family's understanding and readiness for a life-changing and often permanent procedure. The table highlights the recommended screening tests and evaluations that should be completed during the evaluation (",
"    <a class=\"graphic graphic_table graphicRef55342 \" href=\"UTD.htm?43/24/44427\">",
"     table 1",
"    </a>",
"    ). The final decision on whether to proceed with surgery must be made by the multidisciplinary team, taking into consideration both objective and subjective assessments of the patient's severity of obesity and related diseases, risk of future health problems, failure to lose weight through more conventional means, psychosocial status and support, and patient and family readiness for surgery.",
"   </p>",
"   <p>",
"    A multidisciplinary approach is recommended when offering weight loss surgery to extremely obese adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. At a minimum, the team evaluating and caring for the candidate should include an experienced bariatric surgeon, pediatric obesity specialist, nurse, dietician, and pediatric psychologist or psychiatrist. One of these providers or an additional team member should have responsibility for coordinating each patient's care and ensuring follow-up and adherence to the prescribed medical regimen. The program also must have ready access to relevant pediatric subspecialties, including endocrinology, cardiology, gastroenterology, pulmonology, gynecology, and orthopedics for further evaluation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    management of specific comorbidities as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, the threshold for consideration of weight loss surgery is a BMI &ge;40",
"    <span class=\"nowrap\">",
"     kg/m2;",
"    </span>",
"    a threshold of 35",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    is used for individuals with significant current comorbidities, such as diabetes. For adjustable banding, the threshold for adults with significant comorbidities is a BMI&gt;30",
"    <span class=\"nowrap\">",
"     kg/m2.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adolescents, BMI percentile curves increase with age and vary by gender. This creates some difficulty using a flat threshold for BMI during a period of continued linear growth and applied to both genders. The use of a flat BMI cutpoint as a minimum threshold for consideration of weight loss surgery has the advantage of being more conservative at younger ages (ie, corresponding to a higher BMI percentile or Z-score). However, it also underestimates the severity of obesity in younger male adolescents (ages 13 to 17) in whom a BMI of 40 corresponds to a BMI percentile significantly greatly than the 99th percentile. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Defining severe obesity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because of mounting evidence of the adverse long-term consequences of severe adolescent obesity, and favorable safety outcomes of surgery in adolescents, a panel of experts in pediatric obesity and bariatric surgery has recommended the following criteria for use when selecting adolescent patients for bariatric surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BMI &ge;35",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      and a severe comorbidity that has significant short-term effects on health (eg, moderate to severe obstructive sleep apnea [AHI &gt;15], type 2 diabetes mellitus, pseudotumor cerebri, or severe and progressive steatohepatitis), OR BMI&ge;40 with more minor comorbidities. These are similar to the BMI thresholds used to select adults for bariatric surgery. Note that use of these fixed BMI thresholds is naturally more conservative for younger patients, as compared to use of BMI percentile thresholds. Even more conservative thresholds were used in the past [",
"      <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/57,59,62\">",
"       57,59,62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Physical maturity, defined as completing 95 percent of predicted adult stature based on bone age or reaching Tanner stage IV. This criterion is based on theoretical concerns that rapid weight loss after gastric bypass might inhibit statural growth if an adolescent has not reached near adult height. It may not be necessary for adjustable gastric banding procedures because weight loss is usually more gradual. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link&amp;anchor=H4#H4\">",
"       \"Normal puberty\", section on 'Sexual maturity rating (Tanner stages)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10073?source=see_link&amp;anchor=H4#H4\">",
"       \"The child with tall stature or abnormally rapid growth\", section on 'Bone age and prediction of height potential'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      History of sustained efforts to lose weight through changes in diet and physical activity. There is no evidence that prolonged preoperative weight management programs enhance selection of patients for weight loss surgery. However, consistent attendance in such a treatment program may be a valuable indicator of the patient's ability to understand and adhere to medical and nutritional recommendations postoperatively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These guidelines rest primarily on expert opinion and retrospectively evaluated outcomes data. There is only one randomized controlled trial in adolescents that demonstrates superiority of surgical weight loss as compared to conventional medical therapy for the severe comorbidities listed above. However, randomized controlled trials in adults with type 2 diabetes mellitus have demonstrated that bariatric surgery (including RYGB, AGB, and VSG) is significantly more effective than conventional or intensive medical therapy in resolution of type 2 diabetes mellitus at one and two years postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be recognized that the above criteria alone are not sufficient to select the patients who are most likely to benefit from weight loss surgery during adolescence. We recommend that the multidisciplinary team consider carefully whether the patient and family have the ability and motivation to adhere to recommended treatments pre- and postoperatively, including consistent use of micronutrient supplements. Evidence may include a history of reliable attendance at office visits for weight management and compliance with other medical needs. In addition, the team should consider whether the adolescent shows evidence of mature decision-making, with appropriate understanding of the risks and benefits of surgery, and has support but not coercion from family members.",
"   </p>",
"   <p>",
"    Contraindications for surgical weight loss procedures in adolescents include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Medically correctable cause of obesity",
"     </li>",
"     <li>",
"      An ongoing substance abuse problem (within the preceding year)",
"     </li>",
"     <li>",
"      A medical, psychiatric, psychosocial, or cognitive condition that prevents adherence to postoperative dietary and medication regimens or impairs decisional capacity",
"     </li>",
"     <li>",
"      Current or planned pregnancy within 12 to 18 months of the procedure",
"     </li>",
"     <li>",
"      Inability on the part of the patient or parent to comprehend the risks and benefits of the surgical procedure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risks and benefits of weight loss surgery for individuals with syndromic obesity (eg, Prader-Willi syndrome) have not been adequately explored, and more investigation is required before use of surgery can be widely recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/65\">",
"     65",
"    </a>",
"    ]. It is unclear whether weight loss surgery is effective for these individuals, and they may have increased risks for complications, such as gastric rupture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PERIOPERATIVE SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;To provide for optimum safety of the patient while hospitalized, it is important to ensure that the program also has access to pediatric anesthesiology and radiology consultants who have experience caring for individuals with severe obesity. Specialized equipment, such as CT, MRI, and DEXA scanners, often have weight limitations, which may preclude their use for these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/66\">",
"     66",
"    </a>",
"    ]. Further, basic equipment such as operating tables, stretchers, scales, beds, and toilets that can support extreme weight ranges must be available to ensure safety of the patient and caretakers.",
"   </p>",
"   <p>",
"    To prevent the development of venous thromboembolism, we recommend the use of compression boots until the patient is ambulatory. Patients at increased risk for deep vein thrombosis and thromboembolism (eg, those with severely impaired mobility or a hypercoagulable state) are often treated with low-molecular weight",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    in the perioperative period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link&amp;anchor=H22#H22\">",
"     \"Complications of bariatric surgery\", section on 'Pulmonary embolism and deep venous thrombosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32810?source=see_link&amp;anchor=H26#H26\">",
"     \"Postoperative management of the critically ill obese patient\", section on 'Venous thromboembolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Weight loss surgery frequently leads to an abrupt resolution of hypertension and hyperglycemia. Antihypertensive or hypoglycemic medications that were given preoperatively usually can be discontinued after surgery, and the patient should be monitored for his or her response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=see_link&amp;anchor=H16#H16\">",
"     \"Medical management of patients after bariatric surgery\", section on 'Medication management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Average inpatient stays range from three to four days for laparoscopic roux-en-y gastric bypass (RYGB) and from one to two days for laparoscopic adjustable gastric banding (AGB). Postoperative management for patients includes strict measurement of intake and output, monitoring of drain output (after RYGB) to evaluate for potential leak, and gradual advancement of diet from NPO to clear liquids to a high-protein liquid diet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=see_link&amp;anchor=H3#H3\">",
"     \"Medical management of patients after bariatric surgery\", section on 'Nutritional management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary management after discharge varies with the type of surgery. After RYGB, the patient advances through several stages, from high-protein shakes to gradual introduction of greater volumes and more textured and solid foods [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/67\">",
"     67",
"    </a>",
"    ]. The advancement to regular foods is slow, occurring over the first six months after surgery. For best results, the patient is encouraged to eat three to four small, high-protein meals per day and to avoid high-fat and carbohydrate foods, as these may provoke malabsorptive or dumping side effects. Supplemental fluids are encouraged to avoid dehydration (64 to 92 ounces per day of sugar-free, noncarbonated beverages). Drinks should be sugar-free to avoid dumping syndrome and weight regain through overconsumption of liquid calories. Patients also are advised to avoid drinking during meals to avoid nausea and vomiting.",
"   </p>",
"   <p>",
"    Dietary management after vertical sleeve gastrectomy (VSG) is very similar to that after bypass, but the introduction of thicker and more solid foods may be delayed by an additional two weeks at each stage of advancement. Some patients also experience greater degrees of nausea in the first postoperative month, requiring addition of anti-emetics and antinausea medications. Typically, however, this resolves over time.",
"   </p>",
"   <p>",
"    After AGB, patients are able to return to a regular diet more quickly [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/67\">",
"     67",
"    </a>",
"    ]. The tightness of the band is sequentially adjusted (every four to six weeks during the first one to two years) to maintain satiety and restrict food intake. If large volumes of food are eaten quickly, vomiting may result, which may provide an additional incentive to limit intake. Three to four small meals are recommended, again with high-protein content, to maintain lean body mass during the weight loss. The patient gradually learns to feel sated with smaller volumes of meals and to chew more slowly. Excessive tightening of the band may result in recurrent vomiting, which in turn can lead to nutritional deficiencies, such as beriberi or long-term maladaptive eating behaviors.",
"   </p>",
"   <p>",
"    Follow-up visits for RYGB and VSG patients are typically performed at two weeks postoperatively, then 1, 3, 6, 9, and 12 months after surgery. After that, annual follow-up is recommended for monitoring of anthropometric measurements, nutritional status, residual comorbidities, and general health. Follow-up for AGB patients typically is more frequent due to the need for band adjustments. Some patients require visits every four to six weeks during the first one to two years.",
"   </p>",
"   <p>",
"    General recommendations for long-term weight maintenance include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Drinking 8 to 12 eight-ounce servings of sugar-free liquids per day",
"     </li>",
"     <li>",
"      Exercising 30 to 60 minutes daily",
"     </li>",
"     <li>",
"      Eating protein first at each meal (1",
"      <span class=\"nowrap\">",
"       gm/kg",
"      </span>",
"      of ideal body weight)",
"     </li>",
"     <li>",
"      Three to four portion-controlled meals per day, with minimal snacking between meals",
"     </li>",
"     <li>",
"      Taking daily vitamin and mineral supplementation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These guidelines may need to be tailored to meet an individual patient's needs if significant weight regain or too much weight loss has occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Nutritional supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;After RYGB or AGB procedures, lifelong supplementation with vitamins and minerals is recommended to avoid development of nutritional complications secondary to reduced intake",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mild malabsorption. Although VSG may be associated with reduced risk, long-term data on nutritional outcomes are still lacking. We therefore prescribe the same supplementation for both RYGB and VSG patients. As long-term data on outcomes of VSG in adolescents are collected, these initial recommendations may be modified.",
"   </p>",
"   <p>",
"    After RYGB, patients should conscientiously adhere to a supplementation regimen because of risks for malabsorption of micronutrients; the recommended doses and preparations vary somewhat among practices and may be adjusted based on laboratory measures.",
"   </p>",
"   <p>",
"    We prescribe the following supplements for all patients (",
"    <a class=\"graphic graphic_table graphicRef80913 \" href=\"UTD.htm?15/27/15803\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Standard multivitamin with folate and iron, or prenatal vitamin if female (once or twice daily)",
"     </li>",
"     <li>",
"      Vitamin B12, 500 micrograms orally daily",
"     </li>",
"     <li>",
"      Calcium, 1200 to 1500 mg daily (measured as elemental calcium), with 800 to 1000 international units of vitamin D",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional supplementation may be necessary during pregnancy or as indicated by laboratory testing. If postoperative vomiting is severe, vitamin B1 (thiamine) deficiency also can rapidly develop. Vitamin B1 is particularly important to recognize early, as lasting neurologic sequelae can result if rapid replenishment of vitamin B1 is not initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/68\">",
"     68",
"    </a>",
"    ]. In the author's program, vitamin B1 supplementation (50 mg orally daily) is provided during the first six months after surgery as a prophylactic measure.",
"   </p>",
"   <p>",
"    After adjustable gastric banding, a routine multivitamin may suffice if a well-balanced, healthy diet is consumed. However, menstruating females may require additional iron supplementation, and all patients should have routine monitoring for deficiencies as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Nutritional monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;After bariatric surgery, lifelong monitoring of nutritional status is recommended. In our practice, we measure the following parameters annually:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood cell count with differential",
"     </li>",
"     <li>",
"      Serum iron and ferritin",
"     </li>",
"     <li>",
"      Red blood cell folate, serum vitamin B12, and serum homocysteine",
"     </li>",
"     <li>",
"      Serum thiamine (vitamin B1)",
"     </li>",
"     <li>",
"      Albumin and total protein",
"     </li>",
"     <li>",
"      Alkaline phosphatase, calcium, 25-hydroxy vitamin D, and parathyroid hormone",
"     </li>",
"     <li>",
"      DEXA to monitor lean and fat-free mass, and bone density (this test is optional and may not be needed annually or for patients with good nutritional status)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adjustments in nutritional supplements may need to be made if specific deficiencies emerge over time, particularly because many adolescents may be nonadherent or only partially adherent to recommended supplementation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=see_link&amp;anchor=H13#H13\">",
"     \"Medical management of patients after bariatric surgery\", section on 'Micronutrient deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pregnancy prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe obesity can lead to irregular menstruation, anovulation, and infertility. Conversely, surgically induced weight loss leads to resumption of ovulation and renewed fertility for some women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/69\">",
"     69",
"    </a>",
"    ]. The effects of bariatric surgery on menstrual irregularities and anovulation in adolescents has not been established. However, in a series of 47 adolescent females who had undergone bariatric surgery during adolescence, a higher-than-expected rate of pregnancy was observed (seven pregnancies, six of which occurred between 10 and 22 months postoperatively) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/70\">",
"     70",
"    </a>",
"    ]. Although the medical and psychosocial factors contributing to this high rate could not be addressed in this retrospective report, the high rate of pregnancy highlights the importance of addressing contraception and pregnancy prevention in all female adolescents undergoing bariatric surgery.",
"   </p>",
"   <p>",
"    Pregnancy should absolutely be avoided for at least 12 to 18 months after surgery due to the rapid weight loss and potential micronutrient deficiencies, which may have adverse effects on the mother and fetus. However, long-term effects of bariatric surgery on fertility and pregnancy outcomes are generally good. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=see_link&amp;anchor=H44#H44\">",
"     \"Medical management of patients after bariatric surgery\", section on 'Pregnancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27945?source=see_link\">",
"     \"Fertility and pregnancy after bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of oral contraceptives or transdermal contraceptive patches may be compromised in patients with obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. This is a significant concern both pre- and postoperatively, as many adolescent patients may still have a postoperative BMI",
"    <span class=\"nowrap\">",
"     &gt;30kg/m2",
"    </span>",
"    despite significant weight loss after surgery. The American College of Obstetricians and Gynecologists (ACOG) recommends using non-oral forms of hormonal contraception in women who have undergone malabsorptive bariatric surgery and desire hormonal contraception. Further, use of oral contraception is associated with an increased risk of thromboembolism, which may compound the higher risk associated with obesity.",
"   </p>",
"   <p>",
"    Depot",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/49/36631?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    is effective in overweight or obese women but has been reported to cause significant weight gain (mean of 4 to 9 kg) in overweight or obese adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. In contrast, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    intrauterine system (Mirena, Bayer Schering Pharma, Berlin, Germany) does not cause weight gain and remains effective in",
"    <span class=\"nowrap\">",
"     overweight/obese",
"    </span>",
"    women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/76\">",
"     76",
"    </a>",
"    ]. It has several notable advantages that make it an optimal choice for adolescent females after bariatric surgery, including five-year efficacy, promotion of amenorrhea (which could help reduce risk of iron deficiency anemia after surgery), and option for placement at time of bariatric surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/77\">",
"     77",
"    </a>",
"    ]. Therefore, we consider it a particularly valuable choice for adolescents who have undergone gastric bypass. However, as with all forms of hormonal contraception, adolescents should be counseled to use additional barrier protection against sexually transmitted diseases. These and other considerations about contraceptive choice are discussed separately (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27945?source=see_link\">",
"     \"Fertility and pregnancy after bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adolescent females who become pregnant after weight loss surgery should be counseled about adequate macro- and micronutrient intake. At a minimum, a prenatal vitamin with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    and iron, 1200 to 1500 mg of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/2/29733?source=see_link\">",
"     calcium citrate",
"    </a>",
"    with 800 IU vitamin D, and 500 mcg of oral vitamin B12 daily should be prescribed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/47/16122/abstract/78\">",
"     78",
"    </a>",
"    ]. Additional iron supplementation may be necessary in pregnant women after gastric bypass. Iron, folate, and vitamin B12 levels should be monitored during pregnancy and additional supplementation prescribed as indicated by results. Protein intake of at least 1",
"    <span class=\"nowrap\">",
"     gm/kg",
"    </span>",
"    of ideal body weight (typically 60 to 80 grams) per day is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical weight loss is an appropriate consideration for adolescents with severe obesity and with medical comorbidities who have failed to lose weight through conventional dietary interventions and behavioral modification.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most widely performed procedures in adolescents and adults are the roux-en-Y gastric bypass (RYGB) and adjustable gastric banding (AGB). Vertical sleeve gastrectomy (VSG) is increasing in use as well in adolescents, but there are no published data yet on the frequency of this procedure in the adolescent age group. Other procedures that cause significant malabsorption are generally not recommended for adolescents due to lack of safety data in this age group and concerns about long-term nutritional complications. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Types of surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Efficacy and complications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There appear to be substantial clinical benefits of weight loss surgery for selected adolescents with severe obesity and medical comorbidities. This statement is based on retrospective studies with outcomes measured less than 10 years postoperatively, and the characteristics of patients included in these studies vary widely. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reported weight loss for adolescents undergoing weight loss surgery ranges from 52 to 70 percent of excess body weight. In most cases, there are associated improvements in adiposity, insulin resistance, triglyceride levels, diabetes, obstructive sleep apnea, depression, and impaired quality of life. These outcomes are comparable to those reported for adults undergoing weight loss surgery. The rate of weight loss appears to be more gradual after adjustable gastric banding as compared to gastric bypass. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Weight loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perioperative complications in adolescents undergoing weight loss surgery are generally similar to those in adults but occur somewhat less frequently. Long-term complications are primarily nutritional and include deficiencies of iron, vitamin B12, vitamin D, and thiamine. Lifelong vitamin and mineral supplementation is imperative. However, adherence to supplementation regimens among adolescents may be poor. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight loss surgery for adolescents should be performed in the context of a multidisciplinary program with specific expertise in adolescent medicine and extensive expertise in bariatric surgery. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest using a BMI of &ge;35",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      as a minimum threshold for consideration of weight loss surgery in an adolescent with significant medical comorbidities (ie, those that carry a high risk of morbidity over the short-term) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This is a lower BMI threshold than that proposed in earlier guidelines because emerging data show potential advantages of earlier surgery and good safety outcomes as compared to adults. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other important criteria for patient selection include physical maturity, lack of medically correctable causes of obesity, and adequate emotional maturity and stability to ensure competent decision-making and good adherence to medical follow-up (",
"      <a class=\"graphic graphic_table graphicRef55342 \" href=\"UTD.htm?43/24/44427\">",
"       table 1",
"      </a>",
"      ). In addition, most authorities agree that the patient should have failed organized and sustained attempts to lose weight through lifestyle intervention. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perioperative and postoperative management is similar to that for adults undergoing weight loss surgery. Diet recommendations vary depending on the type of procedure and vary slightly among centers. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Perioperative safety'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Diet'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients who have undergone RYGB and VSG, we suggest treatment with a daily multivitamin, with additional supplements of calcium, vitamin B12, and vitamin D&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef80913 \" href=\"UTD.htm?15/27/15803\">",
"       table 2",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We perform laboratory monitoring for micronutrient deficiencies at least once annually thereafter. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Nutritional supplements'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Nutritional monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend avoidance of pregnancy for 12 to 18 months after surgical weight loss procedures (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Because adolescent girls appear to be at high risk for pregnancy after gastric bypass surgery as compared to others in their age group, all girls should have counseling about pregnancy avoidance and assurance of adequate contraception as part of the preparation and follow up after weight loss surgery. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Pregnancy prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/1\">",
"      Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/2\">",
"      Sturm R. Increases in clinically severe obesity in the United States, 1986-2000. Arch Intern Med 2003; 163:2146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/3\">",
"      Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350:2362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/4\">",
"      Kalra M, Inge T, Garcia V, et al. Obstructive sleep apnea in extremely overweight adolescents undergoing bariatric surgery. Obes Res 2005; 13:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/5\">",
"      Xanthakos S, Miles L, Bucuvalas J, et al. Histologic spectrum of nonalcoholic fatty liver disease in morbidly obese adolescents. Clin Gastroenterol Hepatol 2006; 4:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/6\">",
"      Zeller MH, Roehrig HR, Modi AC, et al. Health-related quality of life and depressive symptoms in adolescents with extreme obesity presenting for bariatric surgery. Pediatrics 2006; 117:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/7\">",
"      Sj&ouml;str&ouml;m L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351:2683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/8\">",
"      Sj&ouml;str&ouml;m L, Narbro K, Sj&ouml;str&ouml;m CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/9\">",
"      Tsai WS, Inge TH, Burd RS. Bariatric surgery in adolescents: recent national trends in use and in-hospital outcome. Arch Pediatr Adolesc Med 2007; 161:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/10\">",
"      Allen SR, Lawson L, Garcia V, Inge TH. Attitudes of bariatric surgeons concerning adolescent bariatric surgery (ABS). Obes Surg 2005; 15:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/11\">",
"      NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med 1991; 115:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/12\">",
"      Barlow SE, Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007; 120 Suppl 4:S164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/13\">",
"      Flegal KM, Wei R, Ogden CL, et al. Characterizing extreme values of body mass index-for-age by using the 2000 Centers for Disease Control and Prevention growth charts. Am J Clin Nutr 2009; 90:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/14\">",
"      Freedman DS, Mei Z, Srinivasan SR, et al. Cardiovascular risk factors and excess adiposity among overweight children and adolescents: the Bogalusa Heart Study. J Pediatr 2007; 150:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/15\">",
"      Skelton JA, Cook SR, Auinger P, et al. Prevalence and trends of severe obesity among US children and adolescents. Acad Pediatr 2009; 9:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/16\">",
"      Bibbins-Domingo K, Coxson P, Pletcher MJ, et al. Adolescent overweight and future adult coronary heart disease. N Engl J Med 2007; 357:2371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/17\">",
"      Must A, Jacques PF, Dallal GE, et al. Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med 1992; 327:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/18\">",
"      Baker JL, Olsen LW, S&oslash;rensen TI. Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med 2007; 357:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/19\">",
"      Must A, Phillips SM, Naumova EN. Occurrence and timing of childhood overweight and mortality: findings from the Third Harvard Growth Study. J Pediatr 2012; 160:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/20\">",
"      Spear BA, Barlow SE, Ervin C, et al. Recommendations for treatment of child and adolescent overweight and obesity. Pediatrics 2007; 120 Suppl 4:S254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/21\">",
"      Levine MD, Ringham RM, Kalarchian MA, et al. Is family-based behavioral weight control appropriate for severe pediatric obesity? Int J Eat Disord 2001; 30:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/22\">",
"      Lawson ML, Kirk S, Mitchell T, et al. One-year outcomes of Roux-en-Y gastric bypass for morbidly obese adolescents: a multicenter study from the Pediatric Bariatric Study Group. J Pediatr Surg 2006; 41:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/23\">",
"      Berkowitz RI, Fujioka K, Daniels SR, et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 2006; 145:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/24\">",
"      Chanoine JP, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005; 293:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/25\">",
"      Jen HC, Rickard DG, Shew SB, et al. Trends and outcomes of adolescent bariatric surgery in California, 2005-2007. Pediatrics 2010; 126:e746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/26\">",
"      Clinical Issues Committee of the American Society for Metabolic and Bariatric Surgery. Updated position statement on sleeve gastrectomy as a bariatric procedure. Surg Obes Relat Dis 2010; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/27\">",
"      Till H, Bl&uuml;her S, Hirsch W, Kiess W. Efficacy of laparoscopic sleeve gastrectomy (LSG) as a stand-alone technique for children with morbid obesity. Obes Surg 2008; 18:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/28\">",
"      Alqahtani AR, Antonisamy B, Alamri H, et al. Laparoscopic sleeve gastrectomy in 108 obese children and adolescents aged 5 to 21 years. Ann Surg 2012; 256:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/29\">",
"      Boza C, Viscido G, Salinas J, et al. Laparoscopic sleeve gastrectomy in obese adolescents: results in 51 patients. Surg Obes Relat Dis 2012; 8:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/30\">",
"      Chan JL, Mun EC, Stoyneva V, et al. Peptide YY levels are elevated after gastric bypass surgery. Obesity (Silver Spring) 2006; 14:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/31\">",
"      Korner J, Bessler M, Cirilo LJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005; 90:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/32\">",
"      Korner J, Inabnet W, Conwell IM, et al. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 2006; 14:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/33\">",
"      le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/34\">",
"      Alvarez Bartolom&eacute; M, Borque M, Martinez-Sarmiento J, et al. Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes Surg 2002; 12:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/35\">",
"      Treadwell JR, Sun F, Schoelles K. Systematic review and meta-analysis of bariatric surgery for pediatric obesity. Ann Surg 2008; 248:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/36\">",
"      Strauss RS, Bradley LJ, Brolin RE. Gastric bypass surgery in adolescents with morbid obesity. J Pediatr 2001; 138:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/37\">",
"      Sugerman HJ, Sugerman EL, DeMaria EJ, et al. Bariatric surgery for severely obese adolescents. J Gastrointest Surg 2003; 7:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/38\">",
"      Inge TH, Jenkins TM, Zeller M, et al. Baseline BMI is a strong predictor of nadir BMI after adolescent gastric bypass. J Pediatr 2010; 156:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/39\">",
"      Al-Qahtani AR. Laparoscopic adjustable gastric banding in adolescent: safety and efficacy. J Pediatr Surg 2007; 42:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/40\">",
"      Dillard BE 3rd, Gorodner V, Galvani C, et al. Initial experience with the adjustable gastric band in morbidly obese US adolescents and recommendations for further investigation. J Pediatr Gastroenterol Nutr 2007; 45:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/41\">",
"      Nadler EP, Youn HA, Ren CJ, Fielding GA. An update on 73 US obese pediatric patients treated with laparoscopic adjustable gastric banding: comorbidity resolution and compliance data. J Pediatr Surg 2008; 43:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/42\">",
"      Fielding GA, Duncombe JE. Laparoscopic adjustable gastric banding in severely obese adolescents. Surg Obes Relat Dis 2005; 1:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/43\">",
"      Holterman AX, Browne A, Tussing L, et al. A prospective trial for laparoscopic adjustable gastric banding in morbidly obese adolescents: an interim report of weight loss, metabolic and quality of life outcomes. J Pediatr Surg 2010; 45:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/44\">",
"      O'Brien PE, Sawyer SM, Laurie C, et al. Laparoscopic adjustable gastric banding in severely obese adolescents: a randomized trial. JAMA 2010; 303:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/45\">",
"      Inge T, Wilson KA, Gamm K, et al. Preferential loss of central (trunk) adiposity in adolescents and young adults after laparoscopic gastric bypass. Surg Obes Relat Dis 2007; 3:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/46\">",
"      Loux TJ, Haricharan RN, Clements RH, et al. Health-related quality of life before and after bariatric surgery in adolescents. J Pediatr Surg 2008; 43:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/47\">",
"      Inge TH, Miyano G, Bean J, et al. Reversal of type 2 diabetes mellitus and improvements in cardiovascular risk factors after surgical weight loss in adolescents. Pediatrics 2009; 123:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/48\">",
"      Ippisch HM, Inge TH, Daniels SR, et al. Reversibility of cardiac abnormalities in morbidly obese adolescents. J Am Coll Cardiol 2008; 51:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/49\">",
"      Rand CS, Macgregor AM. Adolescents having obesity surgery: a 6-year follow-up. South Med J 1994; 87:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/50\">",
"      Varela JE, Hinojosa MW, Nguyen NT. Perioperative outcomes of bariatric surgery in adolescents compared with adults at academic medical centers. Surg Obes Relat Dis 2007; 3:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/51\">",
"      Kaulfers AM, Bean JA, Inge TH, et al. Bone loss in adolescents after bariatric surgery. Pediatrics 2011; 127:e956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/52\">",
"      Patti ME, McMahon G, Mun EC, et al. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 2005; 48:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/53\">",
"      Service GJ, Thompson GB, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/54\">",
"      Goldfine AB, Mun EC, Devine E, et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab 2007; 92:4678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/55\">",
"      Lyass S, Cunneen SA, Hagiike M, et al. Device-related reoperations after laparoscopic adjustable gastric banding. Am Surg 2005; 71:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/56\">",
"      Balsiger BM, Ernst D, Giachino D, et al. Prospective evaluation and 7-year follow-up of Swedish adjustable gastric banding in adults with extreme obesity. J Gastrointest Surg 2007; 11:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/57\">",
"      Inge TH, Krebs NF, Garcia VF, et al. Bariatric surgery for severely overweight adolescents: concerns and recommendations. Pediatrics 2004; 114:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/58\">",
"      Apovian CM, Baker C, Ludwig DS, et al. Best practice guidelines in pediatric/adolescent weight loss surgery. Obes Res 2005; 13:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/59\">",
"      August GP, Caprio S, Fennoy I, et al. Prevention and treatment of pediatric obesity: an endocrine society clinical practice guideline based on expert opinion. J Clin Endocrinol Metab 2008; 93:4576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/60\">",
"      Pratt JS, Lenders CM, Dionne EA, et al. Best practice updates for pediatric/adolescent weight loss surgery. Obesity (Silver Spring) 2009; 17:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/61\">",
"      Michalsky M, Reichard K, Inge T, et al. ASMBS pediatric committee best practice guidelines. Surg Obes Relat Dis 2012; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/62\">",
"      Roberge JN, Brubaker PL. Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients. Endocrinology 1991; 128:3169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/63\">",
"      Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/64\">",
"      Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/65\">",
"      Scheimann AO, Butler MG, Gourash L, et al. Critical analysis of bariatric procedures in Prader-Willi syndrome. J Pediatr Gastroenterol Nutr 2008; 46:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/66\">",
"      Inge TH, Donnelly LF, Vierra M, et al. Managing bariatric patients in a children's hospital: radiologic considerations and limitations. J Pediatr Surg 2005; 40:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/67\">",
"      Fullmer MA, Abrams SH, Hrovat K, et al. Nutritional strategy for adolescents undergoing bariatric surgery: report of a working group of the Nutrition Committee of NASPGHAN/NACHRI. J Pediatr Gastroenterol Nutr 2012; 54:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/68\">",
"      Towbin A, Inge TH, Garcia VF, et al. Beriberi after gastric bypass surgery in adolescence. J Pediatr 2004; 145:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/69\">",
"      Teitelman M, Grotegut CA, Williams NN, Lewis JD. The impact of bariatric surgery on menstrual patterns. Obes Surg 2006; 16:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/70\">",
"      Roehrig HR, Xanthakos SA, Sweeney J, et al. Pregnancy after gastric bypass surgery in adolescents. Obes Surg 2007; 17:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/71\">",
"      Holt VL, Cushing-Haugen KL, Daling JR. Body weight and risk of oral contraceptive failure. Obstet Gynecol 2002; 99:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/72\">",
"      Holt VL, Scholes D, Wicklund KG, et al. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 2005; 105:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/73\">",
"      Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002; 77:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/74\">",
"      Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol 2002; 15:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/75\">",
"      Bonny AE, Ziegler J, Harvey R, et al. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Arch Pediatr Adolesc Med 2006; 160:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/76\">",
"      Luukkainen T, L&auml;hteenm&auml;ki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med 1990; 22:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/77\">",
"      Miller RJ, Xanthakos SA, Hillard PJ, Inge TH. Bariatric surgery and adolescent gynecology. Curr Opin Obstet Gynecol 2007; 19:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/47/16122/abstract/78\">",
"      Woodard CB. Pregnancy following bariatric surgery. J Perinat Neonatal Nurs 2004; 18:329.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5880 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-23AA9155C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_47_16122=[""].join("\n");
var outline_f15_47_16122=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History of weight loss surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Defining severe obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Alternatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TYPES OF SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7607783\">",
"      Roux-en-Y gastric bypass and adjustable gastric band",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7607762\">",
"      Vertical sleeve gastrectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7607776\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MECHANISMS OF WEIGHT LOSS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Short-term complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Long-term complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PREOPERATIVE EVALUATION AND SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PERIOPERATIVE SAFETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Nutritional supplements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Nutritional monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pregnancy prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Efficacy and complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5880\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5880|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/35/33329\" title=\"figure 1\">",
"      Roux en Y gastric bypass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/38/2656\" title=\"figure 2\">",
"      Lap adjustable gastric band",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/40/36480\" title=\"figure 3\">",
"      Sleeve gastrectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5880|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/24/44427\" title=\"table 1\">",
"      Eval adolescent WLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/27/15803\" title=\"table 2\">",
"      Recommended nutritional supplementation after bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/13/12506\" title=\"table 3\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?35/14/36070?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body Mass Index (BMI) percentiles for boys (2 to 20 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?34/60/35782?source=related_link\" title=\"calculator 2\">",
"      Calculator: Body Mass Index (BMI) percentiles for girls (2 to 20 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=related_link\">",
"      Clinical evaluation of the obese child and adolescent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37674?source=related_link\">",
"      Comorbidities and complications of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=related_link\">",
"      Complications of bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=related_link\">",
"      Definition; epidemiology; and etiology of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27945?source=related_link\">",
"      Fertility and pregnancy after bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18378?source=related_link\">",
"      Management of childhood obesity in the primary care setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=related_link\">",
"      Medical management of patients after bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32810?source=related_link\">",
"      Postoperative management of the critically ill obese patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10073?source=related_link\">",
"      The child with tall stature or abnormally rapid growth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_47_16123="Poor prognostic features after cardiac arrest";
var content_f15_47_16123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical parameters associated with an unfavorable prognosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical parameters",
"       </td>",
"       <td class=\"subtitle1\">",
"        Unfavorable prognosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration of anoxia",
"       </td>",
"       <td>",
"        &gt;8-10 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration of CPR",
"       </td>",
"       <td>",
"        &gt;30 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pupillary light reaction",
"       </td>",
"       <td>",
"        Absent on day 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Motor response to pain",
"       </td>",
"       <td>",
"        Absent on day 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brainstem reflexes",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood glucose on admission",
"       </td>",
"       <td>",
"        &gt;300 mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glascow coma score on day 3",
"       </td>",
"       <td>",
"        &lt;5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GPCS on day 3",
"       </td>",
"       <td>",
"        &lt;22",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_47_16123=[""].join("\n");
var outline_f15_47_16123=null;
var title_f15_47_16124="Eval risk factor CHD DM II";
var content_f15_47_16124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of predisposing risk factors in patients with diabetes mellitus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"1\" rowspan=\"1\">",
"        Body weight and fat distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         History:",
"        </strong>",
"        Assess history of body weight, age at onset of overweight, history of weight loss and",
"weight gain; assess eating and exercise habits, social and occupational",
"factors affecting body weight, family support, history of body weights",
"in family members in childhood and adulthood, attitudes and motivation",
"for weight control.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Physical examination:",
"        </strong>",
"        Measure body weight (kg) and height (m); calculate body mass index (BMI) (kg/m2); categorize body weight (BMI 25 to 29.9 = overweight; &ge;30 = obesity); measure waist circumference (abdominal obesity &ge;40 in [102 cm] in men or &ge;36 in [88 cm] in women; borderline abdominal obesity in men, 88 to 102 cm).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physical activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         History:",
"        </strong>",
"        Assess past and current levels of",
"physical activity; ascertain activity on the job, participation in",
"sports, regular walking, jogging, or swimming. In women, ask about",
"activity in housework, child care; determine opportunities and",
"available facilities for regular exercise.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Physical examination:",
"        </strong>",
"        Assess level of cardiovascular fitness in cardiac rehabilitation facilities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Family history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         History:",
"        </strong>",
"        Assess family history for",
"cardiovascular disease (CVD) or sudden death. (Family history is",
"positive if CVD or sudden death occurred in first-degree male relatives",
"before age 55 years or first-degree female relatives before age 65",
"years.) Determine presence or absence of other risk factors - high",
"serum cholesterol values, cigarette smoking, hypertension, diabetes -",
"in first-degree relatives (biological parents, siblings, offspring). If",
"possible, expand family tree to second-degree relatives (grandparents,",
"uncles, aunts). Create a simple family tree.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Laboratory:",
"        </strong>",
"        Measure blood glucose and serum lipids (cholesterol, triglycerides, and HDL cholesterol) in first-degree relatives.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Grundy, SM, Benjamin, IJ, Burke, GL, et al. Circulation 1999; 100:1134.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_47_16124=[""].join("\n");
var outline_f15_47_16124=null;
var title_f15_47_16125="Genetic disorders surfactant dysfunction";
var content_f15_47_16125=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genetic disorders causing surfactant dysfunction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        SFTPB",
"       </td>",
"       <td class=\"subtitle1\">",
"        SFTPC",
"       </td>",
"       <td class=\"subtitle1\">",
"        ABCA3",
"       </td>",
"       <td class=\"subtitle1\">",
"        NKX2.1&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Mode of inheritance",
"        </strong>",
"       </td>",
"       <td>",
"        Autosomal recessive",
"       </td>",
"       <td>",
"        Autosomal dominant,",
"        <em>",
"         de novo",
"        </em>",
"       </td>",
"       <td>",
"        Autosomal recessive",
"       </td>",
"       <td>",
"        Autosomal dominant,",
"        <em>",
"         de novo",
"        </em>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Pulmonary presentations",
"        </strong>",
"       </td>",
"       <td>",
"        Neonatal respiratory distress syndrome",
"       </td>",
"       <td>",
"        <p>",
"         Childhood interstitial lung disease",
"        </p>",
"        <p>",
"         Adult interstitial lung disease",
"        </p>",
"        <p>",
"         Neonatal respiratory distress syndrome",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Neonatal respiratory distress syndrome",
"        </p>",
"        <p>",
"         Childhood interstitial lung disease",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Neonatal respiratory distress syndrome",
"        </p>",
"        <p>",
"         Childhood interstitial lung disease",
"        </p>",
"        <p>",
"         Recurrent infection",
"        </p>",
"        <p>",
"         No pulmonary involvement",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Course",
"        </strong>",
"       </td>",
"       <td>",
"        Neonatal lethal",
"       </td>",
"       <td>",
"        <p>",
"         Highly variable",
"        </p>",
"        <p>",
"         Survival until 6th decade reported",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Neonatal lethal",
"        </p>",
"        <p>",
"         Variable severity in childhood",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Neonatal lethal",
"        </p>",
"        <p>",
"         Variable severity in childhood",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Treatment options described in literature",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Supportive",
"        </p>",
"        <p>",
"         Lung transplant",
"         <sup>",
"          [1,2]",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Supportive",
"        </p>",
"        <p>",
"         Corticosteroids",
"         <sup>",
"          [3,4]",
"         </sup>",
"        </p>",
"        <p>",
"         Hydroxychloroquine",
"         <sup>",
"          [3,4]",
"         </sup>",
"        </p>",
"        <p>",
"         Azithromycin",
"         <sup>",
"          [3]",
"         </sup>",
"        </p>",
"        <p>",
"         Lung transplant",
"         <sup>",
"          [2]",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Supportive",
"        </p>",
"        <p>",
"         Corticosteroids",
"         <sup>",
"          [5]",
"         </sup>",
"        </p>",
"        <p>",
"         Hydroxychloroquine",
"         <sup>",
"          [5]",
"         </sup>",
"        </p>",
"        <p>",
"         Lung transplant",
"         <sup>",
"          [6,7]",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        Supportive",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Comparative features of inheritance, timing of presentation, outcomes, and treatment options described in the literature for the four main causes of genetic surfactant dysfunction. \"Supportive\" care indicates measures for respiratory, nutritional, and anti-infective care.",
"    <div class=\"footnotes\">",
"     SFTPB: gene encoding the surfactant protein B; SFTPC: gene encoding surfactant protein C; ABCA3: gene encoding the member A3 of the ATP Binding Cassette family of proteins; NKX2.1: also called thyroid transcription factor 1, or TTF-1.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Hamvas A, Nogee LM, Mallory GB Jr, et al. Lung transplantation for treatment of infants with surfactant protein B deficiency. J Pediatr 1997; 130:231.",
"       </li>",
"       <li>",
"        Palomar LM, Nogee LM, Sweet SC, et al. Long-term outcomes after infant lung transplantation for surfactant protein B deficiency related to other causes of respiratory failure. J Pediatr 2006; 149:548.",
"       </li>",
"       <li>",
"        Abou Taam R, Jaubert F, Emond S, et al. Familial intestinal disease with I73T mutation: A mid- and long-term study. Pediatr Pulmonol 2009; 44:167.",
"       </li>",
"       <li>",
"        Thouvenin G, Abou Taam R, Flamein F, et al. Characteristics of disorders associated with genetic mutations of surfactant protein C. Arch Dis Child 2010; 95:449.",
"       </li>",
"       <li>",
"        Doan ML, Guillerman RP, Dishop MK, et al. Clinical, radiological and pathological features of ABCA3 mutations in children. Thorax 2008; 63: 366.",
"       </li>",
"       <li>",
"        Hamvas A, Nogee LM, Wegner DJ, et al. Inherited surfactant deficiency caused by uniparental disomy of rare mutations in the surfactant protein-B and ATP binding cassette, subfamily a, member 3 genes. J Pediatr 2009; 155:854.",
"       </li>",
"       <li>",
"        Faro A, Hamvas A. Lung transplantation for inherited disorders of surfactant metabolism. NeoReviews 2008; 9:e468.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_47_16125=[""].join("\n");
var outline_f15_47_16125=null;
var title_f15_47_16126="Rx nonfalcip malaria";
var content_f15_47_16126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of uncomplicated non-falciparum malaria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Adult dosing",
"      </td>",
"      <td class=\"subtitle1\">",
"       Pediatric dosing",
"      </td>",
"      <td class=\"subtitle1\">",
"       Pregnancy*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        <strong>",
"         P. vivax",
"        </strong>",
"       </p>",
"       <p>",
"        <strong>",
"         P. ovale",
"        </strong>",
"       </p>",
"       <p>",
"        (chloroquine-sensitive)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         Chloroquine",
"        </strong>",
"       </p>",
"       <p>",
"        OR",
"       </p>",
"       <p>",
"        <strong>",
"         Hydroxy-chloroquine",
"        </strong>",
"        &bull;",
"       </p>",
"       <p>",
"        PLUS",
"       </p>",
"       <p>",
"        <strong>",
"         Primaquine",
"        </strong>",
"        &Delta;",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         Chloroquine",
"        </strong>",
"        600 mg base (=1000 mg salt) orally immediately, followed by 300 mg base (=500 mg salt) orally at 6, 24, and 48 hours. Total dose: 1500 mg base (=2500 mg salt)",
"       </p>",
"       <p>",
"        <strong>",
"         Hydroxychloroquine",
"        </strong>",
"        620 mg base (=800 mg salt) orally immediately, followed by 310 mg base (=400 mg salt) orally at 6, 24 and 48 hours. Total dose: 1550 mg base (=2000 mg salt)",
"       </p>",
"       <p>",
"        <strong>",
"         Primaquine",
"        </strong>",
"        &Delta;&loz; 30 mg base orally once daily for 14 days",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         Chloroquine",
"        </strong>",
"        10 mg base/kg orally immediately, followed by 5 mg base/kg orally at 6, 24, and 48 hours. Total dose: 25 mg base/kg",
"       </p>",
"       <p>",
"        <strong>",
"         Hydroxychloroquine",
"        </strong>",
"        10 mg base/kg orally immediately, followed by 5 mg base/kg orally at 6, 24 and 48 hours. Total dose: 25 mg base/kg",
"       </p>",
"       <p>",
"        <strong>",
"         Primaquine",
"        </strong>",
"        &Delta;&loz; 30 mg base orally once daily for 14 days",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         Chloroquine",
"        </strong>",
"       </p>",
"       <p>",
"        OR",
"       </p>",
"       <p>",
"        <strong>",
"         Hydroxy-chloroquine",
"        </strong>",
"        &bull;",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       <p>",
"        <strong>",
"         Chloroquine-resistant P. vivax",
"        </strong>",
"        &sect;",
"       </p>",
"       <p>",
"        (Papua New Guinea and Indonesia)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         A. Mefloquine",
"        </strong>",
"       </p>",
"       <p>",
"        OR",
"       </p>",
"       <p>",
"        <strong>",
"         Atovaquone-proguanil (Malarone)",
"        </strong>",
"       </p>",
"       <p>",
"        PLUS",
"       </p>",
"       <p>",
"        <strong>",
"         Primaquine",
"        </strong>",
"        &Delta;",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         A. Mefloquine",
"        </strong>",
"        648 mg base (=750 mg salt) orally as initial dose, followed by 456 mg base (=500 mg salt) orally given 6-12 hours after initial dose (total dose = 1250 mg salt)",
"       </p>",
"       <p>",
"        <strong>",
"         Atovaquone-proguanil (Malarone)",
"        </strong>",
"        Adult tab = 250 mg atovaquone / 100 mg proguanil.",
"       </p>",
"       <p>",
"        4 adult tabs orally once daily for 3 days",
"       </p>",
"       <p>",
"        <strong>",
"         Primaquine",
"        </strong>",
"        (as above)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         A. Mefloquine",
"        </strong>",
"        13.7 mg base/kg (=15 mg salt/kg) orally as initial dose, followed by 9.1 mg base/kg (=10 mg salt//kg) orally given 6-12 hours after initial dose (total dose = 25 mg salt/kg)",
"       </p>",
"       <p>",
"        <strong>",
"         Atovaquone-proguanil (Malarone)",
"        </strong>",
"        Peds tab=62.5 mg atovaquone/ 25 mg proguanil.",
"       </p>",
"       <p>",
"        All doses administered orally once daily for 3 days: 5-8 kg: 2 peds tabs; 9-10 kg: 3 peds tabs; 11-20 kg: 1 adult tab; 21-30 kg: 2 adult tabs; 31-40 kg: 3 adult tabs; &gt;40kg: 4 adult tabs",
"       </p>",
"       <p>",
"        <strong>",
"         Primaquine",
"        </strong>",
"        (as above)",
"       </p>",
"      </td>",
"      <td>",
"       <strong>",
"        A. Mefloquine",
"       </strong>",
"       (only)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        <strong>",
"         B. Quinine",
"        </strong>",
"       </p>",
"       <p>",
"        PLUS one of the following:",
"       </p>",
"       <p>",
"        <strong>",
"         Doxycycline",
"        </strong>",
"       </p>",
"       <p>",
"        <strong>",
"         Tetracycline",
"        </strong>",
"       </p>",
"       <p>",
"        PLUS",
"       </p>",
"       <p>",
"        <strong>",
"         Primaquine",
"        </strong>",
"        &Delta;",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         B. Quinine",
"        </strong>",
"        &yen; 542 mg base (=650 mg salt) orally three times daily x 3 to 7 days",
"       </p>",
"       <p>",
"        <strong>",
"         Doxycycline",
"        </strong>",
"        100 mg orally twice daily x 7 days",
"       </p>",
"       <p>",
"        <strong>",
"         Tetracycline",
"        </strong>",
"        250 mg orally four times daily x 7 days",
"       </p>",
"       <p>",
"        <strong>",
"         Primaquine",
"        </strong>",
"        (as above)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         B. Quinine",
"        </strong>",
"        &yen; 8.3 mg base/kg (=10 mg salt/kg) orally three times daily x 3 to 7 days",
"       </p>",
"       <p>",
"        <strong>",
"         Doxycycline",
"        </strong>",
"        &Dagger; 2.2 mg/kg orally twice daily x 7 days",
"       </p>",
"       <p>",
"        <strong>",
"         Tetracycline",
"        </strong>",
"        &Dagger; 25 mg/kg/day orally divided four times daily x 7 days",
"       </p>",
"       <p>",
"        <strong>",
"         Primaquine",
"        </strong>",
"        (as above)",
"       </p>",
"      </td>",
"      <td>",
"       <strong>",
"        B. Quinine",
"       </strong>",
"       (only)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        <strong>",
"         P. malariae",
"        </strong>",
"       </p>",
"       <p>",
"        <strong>",
"         P. knowlesii",
"        </strong>",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         Chloroquine",
"        </strong>",
"       </p>",
"       <p>",
"        OR",
"       </p>",
"       <p>",
"        <strong>",
"         Hydroxy-chloroquine",
"        </strong>",
"        &bull;",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         Chloroquine",
"        </strong>",
"        (as above)",
"       </p>",
"       <p>",
"        <strong>",
"         Hydroxychloroquine",
"        </strong>",
"        (as above)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         Chloroquine",
"        </strong>",
"        (as above)",
"       </p>",
"       <p>",
"        <strong>",
"         Hydroxychloroquine",
"        </strong>",
"        (as above)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         Chloroquine",
"        </strong>",
"       </p>",
"       <p>",
"        OR",
"       </p>",
"       <p>",
"        <strong>",
"         Hydroxy-chloroquine",
"        </strong>",
"        &bull;",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Dosing as for adults. Primaquine, doxycycline, and tetracycle are contraindicated in pregnancy.",
"     <br>",
"      &bull; Hydroxychloroquine is a second line alternative to chloroquine.",
"      <br>",
"       &Delta; Primaquine is used to prevent P. vivax and P. ovale relapse by eradicating hypnozoite forms that may remain dormant in the liver. Because primaquine can cause hemolytic anemia in persons with G6PD deficiency, screening for G6PD deficiency is required prior to starting treatment with primaquine. Primaquine is contraindicated in pregnancy given uncertain neonatal G6PD status.",
"       <br>",
"        &loz; To prevent relapse of P. vivax, primaquine should be dosed 30 mg/day for 14 days. To prevent relapse of P. ovale, primaquine should be dosed 15 mg base/day for 14 days. Primaquine therapy should begin on the same day of treatment with chloroquine.",
"        <br>",
"         &sect; For treatment of uncomplicated malaria due to chloroquine-resistant P. vivax there are two options (A or B) that are equally recommended. Individuals with P. vivax infection acquired outside of Papua New Guinea or Indonesia should be started on chloroquine; if the patient does not respond, the treatment should be changed to a chloroquine-resistant P. vivax regimen.",
"         <br>",
"          &yen; For infections acquired in Southeast Asia, quinine treatment should continue for 7 days. For infections acquired in Africa and South America, quinine treatment should continue for 3 days. In the US quinine is encapsulated in a 324 mg dose; therefore, for adult dosing 2 capsules are sufficient. For pediatric dosing, if non-capsule forms are not available, atovaquone-proguanil or mefloquine may be used. Dosing for atovaquone-proguanil is outlined separately (see \"Treatment of malaria\").",
"          <br>",
"           &Dagger; Doxycycline and tetracycline are not indicated for use in children &lt;8 years. For children &lt;8 years with chloroquine-resistant P. vivax, quinine (given alone for 7 days) or mefloquine may be used. If these options are not available or not tolerated and if treatment benefits outweigh the risks, doxycycline or tetracycline may be given to children &lt;8 years.",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_47_16126=[""].join("\n");
var outline_f15_47_16126=null;
var title_f15_47_16127="Plantar fasciitis inject PI";
var content_f15_47_16127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F55689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F55689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Injection technique for plantar fasciitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intralesional injections are performed in the areas of point tenderness noted on physical examination. Injections should begin distally, and move toward the heel if multiple sites are affected. Prepare the area with soap and alcohol. A one inch No. 23 or No. 25 needle is inserted 1/4 to 1/2 inch deep into the plantar fascia, injecting a mixture of corticosteroid and local anesthetic (1 mL of 1 percent lidocaine hydrochloride, and 20 to 40 mg methylprednisolone or equivalent; no more than 40 mg methylprednisolone or equivalent for each foot). The mixture will flocculate within the syringe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_47_16127=[""].join("\n");
var outline_f15_47_16127=null;
